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X SUMMARY 
The  immune  mechanisms  leading  to  acquisition  of  immunity  against  blood  stages  of 
malaria  parasites  include  both  cell-mediated  and  humoral  responses.  Resistance  to 
blood  stages  of  Plasmodium  chabaudi  chabaudi  AS  is  largely  CD4+  T  lymphocytes 
dependent.  Both  TH1  and  TH2  cell  subsets  produce  soluble  mediators  that  have  been 
associated  with  protection  or  susceptibility.  These  include  the  cytokines  Interferon- 
gamma  (IFNy),  Tumour  Necrosis  Factor-alpha  (TNFa),  Transforming  Growth 
Factor-beta  (TGF3)  and  Interleukin-4  (IL-4).  The  use  of  a  live  system  for  the  delivery 
of  cytokines  in  vivo  constitutes  an  alternative  to  injection  of  recombinant  cytokines, 
as  a  method  of  examining  their  role  in  induction,  development  and/or  implementation 
of  immunity  against  blood  forms  of  P.  c.  chabaudi  AS.  Attenuated  S.  typhimurium 
expressing  the  genes  for  IFNy  (S.  typhimurium/IFNy),  TNFa  (S, 
typhimurium/TNFa),  TGFJ3  (S.  typhimurium/TGFI3)  or  IL-4  (S.  typhimurium/IL-4) 
were  used  in  mice  to  deliver  these  cytokines  in  vivo.  The  cytokines  are  secreted  in 
organs  colonised  by  the  bacteria,  i.  e.  mesenteric  lymph  nodes,  liver,  and  spleen. 
The  role  of  IFNy  in  acquisition  of  immunity  against  erythrocytic  forms  of 
P.  c.  chabaudi  AS  was  studied.  Inbred  NIH  mice  given  the  construct  7  days  before  the 
malaria  infection,  showed  a  significant  delay  in  the  onset  and  in  the  level  of  the 
recrudescent  parasitaemia  when  compared  with  controls.  Administration  of  the 
construct  8  days  before  malaria  infection  resulted  usually  in  a  significantly  decreased 
primary  parasitaemia  in  comparison  with  controls.  No  differences,  however,  were 
observed  in  the  recrudescent  parasitaemia  between  the  groups.  NIH  mice  infected 
with  malaria  3  days  after  or  on  the  same  day  as  the  administration  of  the  IFNy 
construct,  showed  a  primary  peak  of  infection  similar  to  controls,  but  the  resolution 
of  this  patent  parasitaemia  occurred  1  or  2  days  earlier  in  the  experimental  mice  when 
compared  with  controls.  In  the  same  experiment,  mice  given  the  construct  10  days 
before  malaria  infection  had  a  similar  course  of  infection  as  controls.  Simultaneous 
inoculation  with  two  S.  typhimurium  constructs:  IFNy  and  TNFa,  8  days  before 
malaria  infection  resulted  in  a  course  of  parasitaemia  similar  to  that  observed  in  mice 
given  the  IFNy  construct  alone.  On  the  other  hand,  inoculation  of  'susceptible'  inbred 
A/J  mice  with  S.  typhimurium/IFNy  3  days  or  8  days  before  malaria  infection  had  no 
effect  on  the  course  of  the  parasitaemia  when  compared  with  controls.  The  immune 
mechanisms  involved  in  the  better  control  of  the  malaria  infection  in  NIH  mice  given 
S.  typhimurium/IFNy,  seem  to  be  independent  of  nitric  oxide  (NO)  production,  since 
increased  levels  of  the  molecule  were  demonstrable  around  the  peak  of  the  primary 
xi parasitaemia  in  control  groups  but  not  in  experimental  mice.  In  the  latter  basal  levels 
of  serum  NO  were  observed  from  the  period  after  the  S.  typhimurium/IFNy 
inoculation  until  up  to  three  days  after  the  peak  of  the  parasitaemia.  The  role  of 
macrophages  on  the  enhanced  control  of  the  malaria  infection  in  S.  typhimurium/IFNy 
recipient  mice  remains  unexplored. 
To  assess  further  the  role  of  TNFa  in  acquisition  of  immunity  against  P.  c.  chabaudi 
AS,  'resistant'  NIH  and  'susceptible'  A/J  mice  were  given  TNFa  using  the  S. 
typhimurium  delivery  system.  NIH  mice  inoculated  orally  with  the  TNFa  construct  5 
and  3  days  before,  or  simultaneously  with  the  malaria  infection,  had  a  course  of 
infection  similar  to  controls.  However,  A/J  mice  given  the  construct  3  or  5  days 
before  the  malaria  infection  showed  a  significantly  decreased  peak  parasitaemia  when 
compared  with  controls. 
Other  S.  typhimurium  constructs  were  available  and  their  effect  on  the  course  of 
P.  c.  chabaudi  AS  infection  was  studied.  Preliminary  experiments  with  a  TGFß 
construct  included  its  inoculation  into  NIH  mice  4  and  7  days  before  malaria 
infection.  No  significant  differences  were  observed  in  the  course  of  parasitaemia  of 
experimental  mice  in  comparison  with  control  groups.  Similarly,  inoculation  of  this 
construct  into  A/J  mice  3  days  before  malaria  infection  had  no  effect  on  the  course  of 
parasitaemia. 
A  S.  typhimurium-IL-4  construct  was  given  to  NIH  mice  4  or  7  days  before  malaria 
infection.  This  resulted  in  a  similar  course  of  infection  in  experimental  and  control 
mice.  A/J  mice  infected  with  malaria  3  days  after  administration  of  the  IL-4  construct 
showed  a  course  of  parasitaemia  which  was  not  significantly  different  from  controls. 
A  role  for  NO  in  the  control  the  infection  with  P.  c.  chabaudi  AS,  has  been 
suggested  by  other  authors.  To  investigate  this  further,  inducible  NO  synthase  (iNOS) 
deficient  mice  were  infected  with  the  parasite  and  the  course  of  parasitaemia  was 
followed.  The  mice  had  an  increased  peak  parasitaemia  when  compared  with  controls. 
However,  the  significance  of  these  results  was  dependent  on  inclusion  in  the 
experiments  of  a  high  number  of  mice  in  the  experimental  and  control  groups.  In  vitro 
proliferation  of  spleen  cells  taken  6  days  after  malaria  infection  and  stimulated  with 
ConA,  showed  a  significantly  increased  response  of  cells  from  iNOS  depleted  mice  in 
comparison  with  controls.  However,  proliferation  of  spleen  cells  from  iNOS  depleted 
mice  obtained  at  days  0,10,14,  and  18  was  no  different  from  controls.  The 
supernatants  from  the  spleen  cell  cultures  showed  that  iNOS  depleted  mice  had  a 
higher  production  of  IFNy  than  controls,  when  cells  were  obtained  at  day  6  p.  i.,  but 
not  at  day  10,14  or  18  p.  i.  The  pattern  and  degree  of  sequestration  of  pRBC 
observed  at  around  the  peak  of  infection,  evaluated  by  taking  peripheral  blood 
smears,  was  the  same  in  iNOS  depleted  and  control  mice.  Furthermore,  other 
Xll parameters  such  as  anaemia  and  reticulocytaemia  did  not  differ  in  the  iNOS  deficient 
mice  in  comparison  with  controls. 
The  work  with  the  iNOS  depleted  model  confirms  that  although  not  essential  for  the 
resolution  of  parasitaemia,  NO  probably  exerts  cytostatic  and  cytotoxic  effects 
against  blood  forms  of  P.  c.  chabaudi  AS  which  contribute  with  the  control  of  the 
infection  around  peak  parasitaemia.  A  scheme  to  indicate  immune  interactions  in  mice 
injected  with  P.  c.  chabaudi  is  drawn  up. 
The  results  using  S.  typhimurium/IFNy  and  S.  typhimurium/TNFa  confirm  that  these 
two  cytokines  have  a  role  in  the  control  of  P.  c.  chabaudi  AS  blood  forms  during 
early  stages  of  infection,  and  that  the  degree  of  their  effect  depends  on  the  strain  of 
mice  used.  IFNy  seems  to  dominate  immunity  during  early  stages  of  infection  in  NIH 
'resistant'  mice,  while  TNFa  is  important  in  acquisition  of  immunity  by  A/J 
'susceptible'  mice.  Furthermore,  the  work  reported  here  suggests  the  feasibility  of 
using  S.  typhimurium  mutants  to  deliver  cytokines  in  vivo  in  mice.  The  next  step 
includes  the  use  of  these  S.  typhimurium  mutants  to  study  synergistic  effects  of 
cytokines  and  malarial  antigens.  This  could  be  achieved  by  either  creating  a  co- 
expression  system  to  deliver  cytokines  and  malarial  antigens  in  vivo  or  by 
immunisation  with  malarial  antigens  of  mice  inoculated  with  S.  typhimurium 
expressing  cytokine  genes. 
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1.1.  Historical  outline 
Malaria  is  an  ancient  disease.  For  centuries  it  was  attributed  to  the  inhalation  of 
noxious  vapours,  or  miasms,  from  marshes,  and  hence  the  derivation  of  the  word 
malaria  from  the  Italian  "Mala  Aria"  (bad  air).  Earliest  references  to  the  disease 
seem  to  come  from  inscriptions  found  at  the  temple  of  Denderah  (Tentyra,  upper 
Egypt)  where  accounts  of  an  annually  recurrent  febrile  disease  have  been  found 
(Boyd,  1949).  The  Orphic  poems  written  three  thousand  years  ago  talk  about  tertian 
and  quartan  fevers  (Hoops,  1934  as  cited  by  Boyd,  1949).  Hippocrates  (400  BC.  ) 
made  a  very  satisfactory  description  of  malaria  (Jones,  1923  as  cited  by  Boyd,  1949). 
In  his  writings  he  seemed  familiar  with  the  intermittent  and  periodic  fevers  of  a 
disease  he  considered  to  be  related  to  living  in  proximity  to  marshes.  Later,  Celsius 
(circa  50)  and  Galen  (second  century)  contributed  to  characterise  further  clinical 
aspects  of  the  disease  (Hoops,  1934  as  cited  by  Boyd,  1949). 
It  was  not  until  the  seventeenth  century  when  research  on  malaria  was  extended 
further.  Sydenham  (1624-1689)  studied  the  differences  in  the  periodicity  of  the  fever 
and  made  a  clinical  characterisation  of  complicated  malaria  (Boyd,  1949). 
No  important  contributions  were  made  towards  the  control  of  malaria  until  the  middle 
of  the  seventeenth  century,  when  the  Peruvian  Bark  known  by  natives  as  "Quina- 
quina"  was  introduced  to  Europe.  The  earliest  mention  in  Europe  of  the  bark  is  by 
Heyden  in  1643.  It  was  first  brought  to  England  around  1660.  Sydenham  and 
Morton  (1637-1698)  experimented  with  it  and  confirmed  the  efficacy  against  malaria 
fevers.  This  bark  was  later  called  Cinchona  by  Carl  von  Linne  (Linnaeus)  who 
classified  it  as  a  new  genus. 
Meckel  in  1847,  discovered  the  presence  of  black  granules  in  the  blood  of  a  patient 
dying  from  malaria.  In  1880  Alphonse  Laveran  observed  exflagellation  and  produced 
the  theory  that  a  parasite  was  the  cause  of  the  infection.  Almost  simultaneously 
Gerhardt  reported  successful  inoculation  of  healthy  persons  with  blood  from  infected 
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patients.  Together  these  observations  were  responsible  for  discrediting  the  doctrine  of 
miasms. 
As  early  as  1883,  American  physicians  implicated  mosquitoes  in  the  transmission  of 
malaria  (King,  1883).  Manson  in  1894  suggested  that  when  the  malaria  parasites 
were  ingested  by  a  mosquito  they  underwent  further  development  within  it.  Later, 
Ronald  Ross  started  studies  in  India  which  allowed  him  to  confirm  Manson  theory  by 
infecting  Culex  and  Aedes  with  blood  of  infected  individuals  and  observed  maturation 
of  gametocytes  in  the  mosquito  stomach,  but  they  did  not  develop  further.  He  then 
(1897)  carried  on  to  demonstrate  oocysts  on  the  stomach  of  Anopheles  that  were  fed 
on  a  crescent  carrier.  However,  all  developmental  stages  were  demonstrated  in  Culex 
when  studying  malaria  in  birds  (Ross,  1898  as  cited  by  Boyd,  1949).  Late  in  1898 
Grassi  was  the  first  to  verify  the  life  cycle  of  P.  falciparum  in  anophelines 
completely. 
The  first  demonstration  of  a  cycle  development  outside  the  red  blood  cell  was  made 
in  avian  species  of  Plasmodium.  James  &  Tate  described  in  1937,  the  exo- 
erythrocytic  schizogony  of  P.  gallinaceum  in  the  reticulo-endothelial  cells  of 
chickens.  However,  a  tissue  phase  for  malaria  in  mammals  was  not  described  until 
after  World  War  II.  Shortt  &  Garnharn  (1948a)  observed  pre-erythrocytic  forms  of  P. 
cynomolgi  in  the  liver  of  rhesus  monkeys,  soon  similar  forms  were  found  in  the  livers 
of  human  volunteers  infected  with  P.  vivax  and  P.  falciparum  (Shortt  &  Garnham, 
1948b;  Shortt,  1948) 
1.2.  Taxonomy 
Malaria  parasites  are  protozoans  with  the  ability  to  form  spores  and  therefore  they  fall 
into  the  Phylum  Sporozoa  (  or  Apicomplexa,  due  to  the  presence  of  a  characteristic 
apical  complex)  (Cox,  1993).  Since  the  spores,  which  develop  at  the  end  of  a  trophic 
cycle,  lack  polar  capsules  or  filaments,  they  have  been  classified  into  the  class 
Telosporea.  Their  zygotes  are  motile  and  their  sporozoites  devoid  of  resistant 
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membranes.  The  mature  trophozoites  are  small  and  intracellular  and  are  therefore 
assigned  to  the  Sub-class  Coccidia.  Within  this  Sub-class  the  Order  Eucoccidia 
comprises  those  which  undergo  sexual  reproduction  (sporogony)  as  well  as  asexual 
reproduction  (schizogony).  Being  unable  to  pass  any  part  of  their  life  cycle  outside 
the  body  of  their  host,  they  are  in  the  Sub-order  Haemosporina  in  which  they 
constitute  the  Family  Plasmodiidae.  This  Family  includes  parasites  that  undergo 
schizogony  in  the  vertebrate  host  and  sporogony  in  the  mosquito.  The  Family 
contains  a  single  Genus,  Plasmodium  (Baker  as  cited  by  Phillips,  1983). 
There  are  about  120  species  of  Plasmodium,  22  of  them  infect  primates  and  19 
rodents,  bats  and  other  mammals.  Four  species  naturally  infect  humans:  P. 
falciparum,  P.  malariae,  P.  ovale  and  P.  vivax.  Of  these  P.  falciparum  is  the  most 
important  in  public  health  as  it  is  the  parasite  responsible  for  the  high  mortality 
observed  in  malaria. 
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1.3.  Life  cycle 
For  mammalian  malaria  parasites  infection  of  the  host  is  initiated  by  the  bite  of  an 
infected  female  anopheline  mosquito.  During  a  blood  meal,  motile  sporozoites 
contained  in  the  mosquito's  saliva  are  inoculated  into  the  host's  bloodstream.  A  mean 
of  15  sporozoites  are  inoculated  (Rosenberg  et  al.,  1990).  Sporozoites  remain  in  the 
circulation  for  15  to  60  minutes  (Fairley,  1947;  Sinden  &  Smith,  1982)  before 
entering  the  hepatocytes  where  they  undergo  asexual  division  (pre-erythrocytic  or 
exo-erythrocytic  schizogony)  to  develop  into  exo-erythrocytic  schizonts  (Garnham, 
1966).  The  mature  schizonts  disrupt  the  hepatic  cell  and  thousands  of  haploid 
merozoites  are  discharged  into  the  bloodstream.  In  human  malaria  this  exo- 
erythrocytic  schizogony  takes  between  5.5  and  15  days,  depending  on  the  species, 
and  is  thought  to  occur  only  once  in  the  case  of  mammalian  malaria  parasites. 
In  P.  falciparum  and  P.  malariae,  all  sporozoites  immediately  undergo  tissue 
schizogony,  while  in  P.  vivax  and,  probably,  P.  ovale  infections,  a  proportion  of 
sporozoites  develop  into  latent  forms  known  as  hypnozoites  which  resume 
development  some  time  later.  The  presence  of  hypnozoites  explains  the  relapses  seen 
in  P.  vivax  (Krotoski  et  al.,  1982). 
In  avian  malaria,  the  exo-erythrocytic  development  of  the  parasite  occurs  in  the  fixed 
cells  of  the  reticulo-endothelial  system  rather  then  in  the  liver.  In  addition,  merozoites 
coming  from  exo-erythrocytic  and  erythrocytic  schizont  can  originate  further  cycles 
of  secondary  exo-erythrocytic  schizogony  (Phillips,  1983). 
Once  released  into  the  circulation,  the  merozoites  rapidly  invade  the  red  blood  cells 
where  they  begin  the  part  of  the  cycle  known  as  erythrocytic  schizogony.  The 
invasion  of  red  blood  cells  is  probably  due  to  the  presence  of  a  species-specific 
receptor  in/on  the  erythrocyte  membrane  which  enables  the  union  of  the  cell 
membrane  with  the  apical  complex  of  the  merozoite.  For  the  human  malarias  P.  vivax 
and  P.  falciparum,  these  receptors  are  known  to  be  associated  with  the  Duffy  blood 
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group  antigen  (Miller  et  al.,  1975b)  and  glycophorin  (Miller  et  al.,  1977a;  Perkins, 
1981)  respectively.  This  complex  contains  factors  that  cause  invagination  of  the 
erythrocyte  membrane  adjacent  to  the  merozoite  and  the  parasite  is  enclosed  in  a 
parasitophorous  vacuole  (Dvorak  et  al.,  1975,  Aikawa  et  al.,  1978).  It  has  been 
known  for  many  years  that  some  species  of  malaria  preferentially  parasitise  young 
erythrocytes  (reviewed  by  Bray  &  Garnham,  1982).  In  vivo  studies  showed  that  P. 
berghei  preferentially  infects  reticulocytes.  Similarly  P.  vivax  has  a  preference  for 
young  red  cells  (reviewed  by  Phillips,  1983).  On  the  other  hand,  P.  knowlesi,  for 
instance  shows  no  preference  for  reticulocytes,  while  P.  malariae  prefer  mature  red 
cells.  Increased  susceptibility  of  younger  erythrocytes  could  be  related  to  differences 
in  cell  surface  antigens  affecting  attachment  and  penetration  (Pasvol  et  al.,  1980). 
Within  the  red  blood  cell,  the  merozoite  develops  into  ring  and  trophozoite  stages  and 
undergoes  asexual  multiplication  to  form  a  schizont  containing  between  8-32 
merozoites.  Schizogony  occurs  by  a  process  of  budding  which  occurs  just  below  the 
surface  of  the  schizont  (reviewed  by  Phillips,  1983).  Finally,  the  erythrocytic  schizont 
bursts  releasing  merozoites  which  invade  further  red  blood  cells  (Dvorak  et  al., 
1975). 
The  erythrocytic  schizogony  takes  48  hours  in  P.  vivax,  P.  falciparum  and  P.  ovale, 
while  in  P.  malariae  it  lasts  72  hours.  This  cycle  is  relatively  synchronous  in  the 
natural  host  thus  explaining  the  clinical  symptoms  of  alternating  fever  and  chills 
characteristic  of  the  disease  (Hawking  et  al.,  1968).  The  periodicity  of  the  paroxysms 
depends  upon  the  time  of  occurrence  of  the  schizogony,  and  fever  coincides  with  the 
bursting  of  infected  red  blood  cells  and  reinvasion'  of  new  red  blood  cells  by  the 
merozoites. 
Most  of  the  merozoites  released  after  schizogony  invade  red  blood  cells  and  undergo 
asexual  replication,  but  a  small  proportion  may  differentiate  into  sexual  forms  or 
gametocytes.  The  stimulus  which  makes  a  merozoite  transform  into  macrogametocyte 
(female)  or microgametocyte  (male)  is  unknown.  However,  in  vitro  gametogony  of  P. 
falciparum  has  been  induced  by  the  addition  of  antimalarial  antibodies,  hypoxanthine, 
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lymphocytes  and  serum  from  infected  children,  corticosteroids  or  N- 
acetylglucosamine  (reviewed  by  Cornelissen  &  Waliker,  1985)  Gametocytes  complete 
their  sexual  cycle  in  the  female  mosquito  after  being  taken  up  from  the  circulation  in 
a  blood  meal.  Once  in  the  midgut  of  the  vector,  the  microgametocyte  undergoes  a 
process  of  mitotic  division  and  exflagellation  before  fertilisation  of  the  macrogamete. 
The  resultant  diploid  zygote  undergoes  meiotic  division  and  transforms  into  a  motile 
ookinete,  crosses  the  gut  wall  and  develops  into  a  haploid  oocyst  between  the  basal 
lamina  and  the  epithelial  layer  (Sinden  &  Strong,  1978).  During  the  next  10-16  days 
the  oocyst  divides  and  liberates  up  to  10,000  motile  sporozoites  into  the  mosquito's 
haemocoel  (reviewed  by  Russell  et  al.,  1963).  The  sporozoites  migrate  to  the 
mosquito's  salivary  gland  ready  to  be  injected  into  the  host  during  the  next  blood  meal 
(Vanderberg,  1975)  (Figure  1). 
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1.4.  Clinical  aspects 
Malarial  illness  may  take  a  variety  of  clinical  forms  differing  in  pattern  and  severity. 
Some  infections  are  symptomless,  others  are  fatal.  The  reason  for  such  a  spectrum  of 
disease  is  only  partially  understood.  One  important  factor  known  to  affect  the  clinical 
picture  of  the  infection  is  the  parasite  species,  P.  falciparum  being  the  most  likely 
cause  of  complicated  and  fatal  malaria.  Innate  or  acquired  resistance  of  the  host  can 
influence  the  severity  of  symptoms  or  prevent  them  entirely.  Similarly,  the  use  of 
antimalarial  drugs  and  the  susceptibility  of  the  parasites  to  them  do  affect  the  clinical 
presentation  of  the  disease  (Molyneux,  1995). 
The  classical  picture  of  malaria  in  humans  consists  of  alternate  episodes  of  chills  and 
fever.  Anaemia  and  splenomegaly  may  develop  with  heavy  infections  by  any  species 
of  Plasmodium.  Febrile  periods  last  for  6-8  hours  and  recur  every  2-3  days  depending 
on  the  parasite  species  and  the  synchrony  of  the  cycles.  Fever  in  P.  falciparum,  P. 
vivax  and  P.  ovale  recurs  each  third  day,  while  in  P.  malariae  is  present  each  fourth 
day.  The  periodicity  of  the  fever  is  always  related  to  the  rupture  of  an  important 
number  of  mature  schizonts  with  the  discharge  of  merozoites  and  antigenic  material 
into  the  bloodstream. 
Other  associated  symptoms  of  malaria  are  headache,  myalgias,  sweating,  vomit  and 
occasionally,  diarrhoea.  Most  of  the  fatalities  occur  during  the  acute  P.  falciparum 
malaria.  Some,  however,  are  secondary  to  immune  sequelae  due  to  chronic  infection. 
Such  is  the  case  of  P.  malariae  which  can  result  in  nephrosis  and  chronic 
splenomegaly. 
A  proportion  of  cases  of  P.  falciparum  malaria,  progress  from  mild  illness  to  severe 
or  complicated  disease.  In  areas  of  intense  transmission  children  are  most  affected. 
The  definition  of  "severe"  disease  is  difficult  to  establish  in  a  condition  with  a 
continuous  spectrum  of  clinical  forms.  However,  in  general,  malaria  is  considered  as 
being  severe  when  it  is life-threatening.  WHO  (1990)  recommended  some  criteria  to 
help  classify  a  malaria  infection  as  severe.  These  criteria  include  the  presence  of  the 
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following  complications:  coma,  renal  failure,  severe  anaemia,  acidosis,  respiratory 
distress  syndrome,  hypoglycaemia,  bleeding,  shock,  intravascular  haemolysis,  altered 
consciousness,  prostration,  convulsions,  jaundice  and  hyperparasitaemia. 
During  pregnancy,  the  clinical  impact  of  malaria  differs  according  to  the  level  of 
endemicity.  In  holoendemic  areas  of  P.  falciparum  infection,  pregnant  women  are 
more  likely  to  be  parasitaemic  and  at  higher  levels  than  non-pregnant  women. 
However,  there  is  no  convincing  evidence  that  pregnant  women  suffer  more 
symptomatic  malaria  that  non-pregnant  women.  Maternal  and  placental  malaria  are 
associated  with  low  birth  weight  in  the  case  of  primigravidae  (Brabin,  1983; 
McGregor  et  al.,  1983).  In  areas  of  low  or  unstable  transmission,  pregnant  women 
suffer  more  severe  disease  than  non-pregnant  women  when  infected  with  P. 
falciparum  (Subramanian  et  al.,  1992;  Nosten  et  al.,  1994).  In  these,  there  is  an 
increased  risk  of  foetal  loss,  intrauterine  or  neonatal  death,  and  increased  maternal 
mortality  (Molyneux,  1995).  Congenital  cases  of  malaria  in  holoendemic  areas  are 
rare,  but  in  areas  of  low  transmission,  malaria  in  the  mother  at  term  may  be  followed 
by  congenital  malaria.  Symptoms  begin  to  appear  between  2  weeks  and  2  months  and 
include  fever,  anorexia,  hepatosplenomegaly  and  anaemia  (Molyneux,  1995). 
Chronic  complications  can  develop  in  populations  subjected  to  intense  transmission  of 
malaria.  Although  rare,  some  individuals  may  develop  a  hyperactive  splenomegaly, 
nephrotic  syndrome  (secondary  to  P.  malariae  infection)  or,  when  co-infection  with 
Epstein-Barr  virus  exists,  Burkitt's  lymphoma  (Molyneux,  1995). 
1.5.  Diagnostic  methods 
The  cornerstone  of  diagnosis  and  still  the  basis  of  clinical  practice  is  the  stained 
peripheral  blood  film.  Morphological  examination  of  the  parasite  can  be  done  through 
evaluation  of  thin  blood  films.  A  thick  blood  film  is  a  more  appropriate  screening  test 
as  it  allows  diagnosis  of  low-density  parasitaemias. 
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A  dipstick  antigen  detection  test  constitutes  an  attractive  alternative  for  the  diagnosis 
of  the  infection  in  field,  where  staining  and  microscopy  equipment  are  not  easily 
available.  Sensitivity  and  specificity  of  this  method  for  the  diagnosis  of  P.  falciparum 
infection,  are  between  80%  and  100%  when  compared  with  blood  films  (Shiff  et  al., 
1994). 
Other  methods  for  the  detection  of  malaria  parasites  include  the  quantitative  buffy 
coat  method,  which  uses  acridine  orange  (Spielman  &  Perrone,  1989)  and  polymerase 
chain  reaction  (PCR)  (Snounou  et  al.,  1993).  The  latter  detects  low  numbers  of 
parasites  in  small  sample  volumes  and  has  been  reported  of  particular  utility  in 
epidemiological  studies  as  it  allows  genotyping  of  different  P.  falciparum  isolates 
(Viriyakosol  et  al,  1995).  Although  these  methods  have  high  sensitivity  and 
specificity,  they  are  impractical  for  field  work. 
1.6.  Chemotherapy 
For  nearly  two  centuries  following  its  introduction,  cinchona  was  largely  dispensed  as 
a  powder  prepared  from  the  bark  of  the  tree.  By  1810  Gomez,  a  Portuguese  chemist, 
had  extracted  an  impure  alkaloid  called  cinchoquine,  which  did  not  come  into  wide 
use.  In  1820  the  French  chemists  Pelletier  and  Caventou,  found  two  alkaloids  which 
were  named  quinine  and  cinchonine  (Scott,  1939  as  cited  by  Boyd,  1949).  Quinine 
was  soon  found  to  be  a  more  reliable  therapeutic  agent  than  the  bark  (Kremers,  1931 
as  cited  by  Boyd,  1949).  By  the  middle  of  this  century,  Ledger  collected  a  species  of 
cinchona  which  was  found  to  have  a  high  quinine  content.  This  was  subsequently 
named  Cinchona  ledgeriana  and  soon  constituted  the  main  source  of  quinine.  In  all 
more  than  twenty  crystallizable  and  amorphous  alkaloids  have  been  isolated  from 
cinchona.  Quinine  remained  the  standard  treatment  for  malaria  until  synthetic 
substitutes  were  developed.  Schuleman  (1927),  synthesised  plasmochin  and  atabrine 
(Boyd,  1949).  During  the  1930s-1940s,  quinine  was  largely  replaced  by  less  toxic  and 
more  efficacious  synthetic  compounds  (Geary  &  Jensen,  1983). 
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Chloroquine  is  the  prototype  of  4-aminoquinolines,  which  also  includes  amodiaquine 
(reviewed  by  McChesney,  1983).  They  are  rapid  blood  schizonticides  which  by 
binding  to  DNA,  block  synthesis  of  nucleic  acid  (reviewed  by  Cox,  1993). 
Primaquine,  an  8-aminoquinoline,  is  useful  in  the  control  of  tissue  schizonts.  In 
addition,  it  is  effective  against  sexual  forms  of  P.  falciparum.  Primaquine  is 
metabolised  to  a  quinoline  diquinone  structure  which  blocks  electron  transport 
(reviewed  by  Cox,  1993)  disrupting  the  parasite's  energy  metabolism. 
Antifolates  drugs  include  pyrimethamine  and  sulphadoxine.  They  act  by  blocking 
synthesis  of  tetrahydrofolate,  an  important  cofactor  in  the  parasite's  metabolism. 
Pyrimethamine  is  a  competitive  inhibitor  of  dihydrofolate  reductase,  while 
sulphadoxine  blocks  dihydropteroate  synthetase  (reviewed  by  Cox,  1993).  They  are 
useful  blood  schizonticides  and  are  used  in  combination  in  the  case  of  chloroquine 
resistant  P.  falciparum  infections.  Another  antifolate,  proguanil,  is  a  biguanide  which 
has  a  similar  mechanism  of  action  as  pyrimethamine,  and  is  effective  as  a  blood 
schizonticide.  A  biguanide,  chlorproguanil,  in  combination  with  dapsone  (an  anti- 
leprosy  compound),  have  been  used  as  an  alternative  treatment  in  cases  of  non-severe 
P.  falciparum  malaria  (reviewed  by  Watkins,  1995) 
. 
Mefloquine  and  halofantrine,  both  arylaminoalcohol  compounds  have  potent  action 
against  blood  schizonts  and  are  highly  effective  in  the  treatment  of  acute  malaria. 
Artemisin  (Quinghaosu),  a  sesquiterpenelactone,  is  the  antimalarial  principle  isolated 
from  Artemisia  annua.  Artemether,  artesunate  and  dihydroartemisin  have  been 
produced  from  artemisin.  They  all  have  a  more  potent  malarial  activity  than  the  parent 
compound  and  appear  to  be  the  most  rapidly  acting  of  all  the  antimalarials  developed 
so  far.  Their  action  is  mainly  against  schizonts  but  their  mechanism  of  action  is  not 
completely  understood. 
Pyronaridine  and  atovaquone  are  two  new  antimalarials.  The  former  exhibits  a 
marked  blood  schizonticidal  activity  and  it  may  have  potential  as  replacement  for  oral 
formulations  of  chloroquine.  Atovaquone,  a  hydroxynaphthoquinone,  has  a  broad- 
spectrum  antiprotozoan  activity.  It  has  a  novel  mode  of  action  by  inhibiting  electron 
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transport  with  a  high  intrinsic  activity  in  vitro  against  erythrocytic  stages  of  P. 
falciparum 
. 
It  has  also  been  found  effective  against  the  liver  stages  (reviewed  by 
Olliaro  &  Trigg,  1995). 
Finally,  benflumetol,  a  fluoromethanol,  is  an  active  blood  schizonticide.  In  preclinical 
studies  synergy  between  this  and  artemether  has  been  observed  (reviewed  by  Olliaro 
&Trigg,  1995). 
Drug  resistant  strains  may  arise  as  a  result  of  mutation  which  are  selected  after 
frequent  use  of  the  drug  or  incomplete  treatments.  Dissemination  of  resistance  results 
after  genetic  recombination  between  strains  (reviewed  by  Phillips,  1983).  Increasing 
drug  resistance  is  particularly  observed  in  countries  where  P.  falciparum  is  endemic. 
The  parasite  has  developed  resistance  to  chloroquine,  sulpha/pyrimethamine 
combinations  and,  to  some  extent,  quinine.  Chloroquine  resistance  is  widespread  in 
Africa,  particularly  in  eastern  Africa.  Multidrug  resistance  of  P.  falciparum  is  has 
been  observed  in  certain  countries  of  East  Asia  and  Western  Pacific  and  constitutes  a 
serious  problem  as  it  may  spread  to  African  countries  (reviewed  by  Olliaro  &  Trigg, 
1995). 
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1.7.  Host  resistance  to  malaria 
1.7.1.  Innate  resistance 
Innate  resistance  is  observed  in  some  hosts  that  have  not  been  exposed  to  the 
parasite.  Some  of  the  mechanisms  so  far  identified  involved  in  this  type  of  resistance 
are  genetically  controlled  whilst  others  may  simply  be  incidental,  reflecting  changing 
environmental  factors. 
Incompatibility  between  the  conditions  found  within  the  host  and  the  biochemical  or 
physiological  requirements  of  the  parasite  may  affect  survival  and/or  reproduction. 
Biochemical  incompatibility  can  take  different  forms.  For  instance,  this  may  exist 
when  essential  molecular  structures,  such  as  those  mediating  attachment  to  and 
penetration  of  the  parasite  into  cells,  are  missing  or  altered.  Physiological 
incompatibility  may  occur  when  parameters  such  as  pH,  oxygen  tension  or  the 
concentration  of  various  metabolites  are  unfavourable  for  parasite  survival. 
Furthermore,  a  host  which  could  offer  an  acceptable  biochemical  environment  to  the 
parasite  may  be  resistant  to  infection  due  to  the  occurrence  of  natural  immune 
mechanisms  different  from  those  evoked  secondary  to  infection. 
Malaria  merozoites  have  to  invade  red  blood  cells  as  an  integral  part  of  the  life  cycle. 
In  order  to  invade  these  cells,  malaria  parasites  must  make  specific  attachment 
through  specific  ligands  to  chemical  groupings  (receptors)  present  on  the  cell.  In  P. 
knowlesi,  specific  attachment  leading  to  invasion  does  not  occur  when  receptors  on 
the  erythrocyte  surface  are  removed  with  chymotrypsin  (Miller  et  al.,  1975a).  Miller 
et  al.,  (1975b)  provided  evidence  that  the  Duffy  antigen  on  human  erythrocytes  was 
the  receptor  for  P.  knowlesi 
. 
Their  in  vitro  studies  showed  that  P.  knowlesi  failed  to 
invade  Duffy-negative  red  blood  cells.  This  was  later  suggested  in  P.  vivax  infection 
(Miller  et  al.,  1976).  Duffy-negative  homozygous  enjoy  almost  complete  protection 
whereas  heterozygous  are  susceptible. 
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Red  blood  cell  surface  glycophorins  have  also  been  implicated  as  major  determinants 
of  invasion  by  merozoites  (Pasvol  et  al.,  1982).  Glycophorins  are  sialic  acid-rich 
glycoproteins  comprising  four  subgroups  (a,  b,  c  and  d).  Cells  lacking  glycophorin  a 
(En(a-)-  cells)  or  b  (S-s-U-cells)  are  significantly  resistant  to  P.  falciparum  merozoite 
invasion  (reviewed  by  Cox,  1993). 
The  susceptibility  of  the  erythrocytes  to  invasion  by  malaria  parasites  is  dependent 
upon  the  age  of  the  cell  (reviewed  by  Bray  &  Garnham,  1982).  Of  the  human 
malarias,  P.  vivax  and  P.  ovale  are  predominantly  found  in  either  reticulocytes  or 
slightly  older  normocytes.  P.  falciparum  is  thought  to  have  a  preference  for 
metabolically  young  red  blood  cells  (Phillips,  1983).  In  murine  malarias,  P.  berghei 
has  shown  preference  for  invasion  of  reticulocytes. 
Ring  forms  of  the  parasite  feed  on  host  cell  cytoplasm,  mainly  haemoglobin.  Thus 
growth  of  the  parasite  is  dependent  on  the  catabolism  of  haemoglobin.  Mutations  in 
or  near  the  globin  genes  which  alter  the  structure  (amino  acid  sequence)  of  or  the  rate 
of  synthesis  of  a  particular  globin  chain,  have  been  associated  with  protection  against 
malaria.  Most  of  the  pathologic  genetic  variants  result  from  a  single  amino  acid 
substitution  in  one  of  the  normal  globin  chains  (HbA).  The  most  representative  of 
these  haemoglobinopathies  is  sickle-cell  anaemia,  where  a  single  gene  mutation 
determines  that  the  sixth  amino  acid  from  the  N-terminal  end  of  the  13-globin  chain 
substitutes  valine  for  glutamic  acid.  As  a  result  the  abnormal  haemoglobin  (HbS) 
causes  the  erythrocyte  to  adopt  the  shape  of  a  sickle  when  oxygen  tension  is  low. 
Innate  resistance  to  P.  falciparum  infection  in  individuals  with  HbS  has  long  been 
recognised  (Allison,  1954;  Luzzato,  1979).  In  vitro  experiments  have  shown  that 
potassium  loss  and  not  the  HbS  related  sickling  is  responsible  for  killing  of  the 
parasite,  since  abrogation  of  potassium  loss  prevents  parasitic  death  even  in  sickled 
HbAS  cells.  In  addition,  HbS  polymer  has  being  shown  to  impair  parasite  growth  in 
spite  of  aerobic  conditions.  In  the  case  of  homozygous  cells  (HbSS)  needle-like 
aggregates  of  deoxyhaemoglobin  formed  when  the  cell  is  under  low  oxygen  tension, 
disrupt  the  parasite  (reviewed  by  Phillips,  1983). 
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Other  haemoglobins  have  also  been  associated  with  protection  against  malaria  these 
include:  a  and  ß  thalassaemias;  C,  E  and  foetal  haemoglobin. 
Glucose  6-phosphate  dehydrogenase  (G-6-PD)  is  another  red  blood  cell  defect  which 
has  been  suggested  to  give  some  protection  against  P.  falciparum  malaria  (reviewed 
by  Weatherall,  1987;  Martin,  1994).  Although  questionable,  oxidative  stress  is  the 
most  plausible  explanation  for  reduced  susceptibility  observed  in  female  heterozygous 
(Roth  et  al.,  1988).  Support  for  this  theory  comes  from  the  fact  that  isouramil,  an 
oxidant  isolated  from  fava  beans,  has  been  found  to  be  more  damaging  to  parasites  in 
G-6-PD-deficient  cells  (Golenser  et  al.,  1983). 
Structural  membrane  defects  of  the  red  blood  cell  seem  to  exert  a  protective  effect 
against  infection.  Individuals  with  ovalocytosis  have  a  lower  parasitaemia  than  normal 
when  infected  with  P.  falciparum,  P.  vivax,  or  P.  malariae  (Serjeantson  et  al.,  1977). 
Similarly,  eliptocytosis  has  been  reported  to  promote  resistance  to  invasion  by  both  P. 
knowlesi  and  P.  falciparum  (Hadley  &  Miller,  1988). 
Diet  has  been  shown  to  affect  the  course  of  malaria  infection.  Erythrocytic  stages, 
and  probably  pre-erythrocytic,  of  the  parasite  appear  to  be  suppressed  by  a  diet  with 
low  para-amino  benzoic  acid  (PABA)  (Hawking,  1954;  Gilks,  1988).  Similarly,  low 
protein  intake  has  been  reported  to  depress  rodent  P.  berghei  (Gilks  et  al.,  1989) 
infections.  This  may  in  part  explain  why  famine  relief  in  humans  is  sometimes 
accompanied  by  outbreaks  of  malaria  (Murray  et  al.,  1981). 
The  genetic  background  of  the  host  has  also  been  shown  to  affect  predisposition  to 
infection.  An  association  between  certain  HLA  class  I  and  II  haplotypes  and 
protection  from  severe  malaria  has  been  observed  in  the  Gambia  (Hill  et  al.,  1991). 
Molecular  analysis  of  the  HLA  B53  association  has  been  studied  by  sequencing  of 
peptides  eluted  from  the  B53  molecule  followed  by  screening  of  canditate  epitopes 
from  pre-erythrocytic  stage  antigens  of  P.  falciparum  (Hill  et  al.,  1992).  Among 
malaria-immune  Africans,  HLA-B53-restricted  cytotoxic  T  lymphocytes  recognised  a 
conserved  peptide  from  liver-stage-specific  antigen-1  (LSA-1). 
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In  the  rodent  model  of  malaria,  P.  chabaudi  in  inbred  mice,  which  is  used  in  this 
study,  susceptibility  to  infection  seems  to  be  under  genetic  control  by  a  single 
dominant,  autosomal,  non  H-2-linked  gene  (Stevenson  et  al.,  1989).  Susceptible 
mouse  strains,  such  as  A/J,  develop  a  fulminating  parasitaemia  and  succumb  to 
infection.  Resistant  hosts,  such  as  C57BL/6  and  NIH  mice,  develop  a  moderate  level 
of  peak  parasitaemia,  eliminate  the  acute  infection  in  five  weeks  and  are  immune  to 
reinfection.  The  ability  to  produce  high  amounts  of  NO  early  during  P.  chabaudi 
infection  has  been  correlated  with  resistance  to  infection 
. 
Resistant  C57BL/6  mice 
had  an  increased  expression  of  iNOS  mRNA  during  early  stages  of  the  infection  when 
compared  with  susceptible  A/J  mice  (Jacobs  et  al.,  1995).  Furthermore,  high  levels  of 
nitrate,  an  oxidised  form  of  NO,  have  been  observed  in  infected  mice.  during  primary 
parasitaemia  and  a  sharp  peak  of  nitrate  production  has  been  associated  with  the  peak 
of  infection  (Taylor-Robinson  et  al.,  1993).  Others  have  demonstrated  increased 
levels  of  nitrate  in  plasma  of  individuals  infected  with  P.  falciparum  or  P.  vivax  (Cot 
et  al.,  1994;  Nüssler  et  al.,  1994).  The  mechanisms  mediating  the  NO-dependent 
control  of  the  blood  forms  of  the  malaria  parasites  are  not  clear.  In  P.  falciparum  a 
direct  cytostatic  effect  has  been  observed  in  vitro  in  cultures  treated  with  SNAP  (an 
NO  producer)  (Balmer  et  al.,  1995),  while  NO  derivatives  had  a  cytostatic  effect  in 
vitro,  on  the  parasite. 
The  cytokines  IFNy  and  TNFa  are  critical  in  the  regulation  of  the  production  of  NO. 
Resistant  C57BL/6  mice  treated  with  anti-IFNy  and  anti-TNFa  mAb  had  a  reduction 
of  both  iNOS  mRNA  in  the  spleen  and  serum  NO3-  and  an  increased  peak 
parasitaemia  during  infection  with  blood  forms  of  P.  chabaudi  (Jacobs  et  al., 
1996a).  IFNy  production  peaks  in  resistant  mice  2-3  days  before  the  peak  of  infection 
with  P.  chabaudi  AS  (Slade  &  Langhorne,  1989).  In  vitro  production  of  the 
cytokine  by  spleen  cells  from  resistant  mice  has  been  observed  1-2  days  before  peak 
parasitaemia  (Stevenson  et  al.,  1990a,  Taylor-Robinson  &  Phillips,  1994a). 
Furthermore,  neutralisation  of  IFNy  in  vivo  results  in  exacerbation  of  infection  and 
injection  of  rIFNy  depress  parasitaemia  (Stevenson  et  al.,  1990a).  Tsuji  et  al.  (1995) 
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have  reported  a  slight  delay  (2-3  days)  in  the  clearance  of  a  blood  infection  with  P. 
chabaudi  adami  in  IFNy-receptor  ß-chain  deficient  mice  in  comparison  with 
controls.  Infection  of  IFNy-deficient  mice  with  blood  forms  of  P.  chabaudi  adami, 
resulted  in  a  higher  peak  parasitaemia  and  prolonged  infection  when  compared  with 
controls  (van  der  Heyde  et  al.,  1997). 
Stevenson  &  Ghadirian  (1989)  showed  that  treatment  of  resistant  C57BL/6  mice  with 
human  recombinant  TNFa  has  no  effect  on  the  course  or  outcome  of  P.  chabaudi  AS 
infection.  On  the  other  hand,  similar  treatment  of  susceptible  A/J  mice  resulted  in 
survival  from  a  P.  chabaudi  AS  infection  and  a  significant  decrease  in  the  peak 
parasitaemia  (Stevenson  &  Ghadirian,  1989)  compared  with  controls.  More  recent 
work  into  the  role  of  TNFa  in  the  genetically  dependent  resistant  to  P.  chabaudi 
infection  has  shown  that  resistant  C57BL/6  mice  have  higher  levels  of  TNFa 
messenger  RNA  (mRNA)  in  spleen  and  liver,  than  susceptible  mice  (Jacobs  et  al., 
1996b).  Furthermore,  increased  levels  of  TNFa  in  serum  and  of  TNFa  mRNA  in  liver 
later  during  infection,  were  found  in  susceptible  A/J  mice.  This  suggests  that  TNFa 
has  a  protective  role  during  a  P.  chabaudi  infection  when  it  is  produced  in  the  spleen 
and  the  liver  early  during  infection  and  has  a  deleterious  effect  when  it  is  found  in 
high  levels  only  in  the  liver.  Jacobs  et  al.  (1996b)  proposed  that  the  paradoxical  role 
of  protection  (or  resistance)  versus  pathology  (or  susceptibility)  of  TNFa  in  malaria 
infection  may  be  dependent  on  the  amount  of  TNFa  released  and  the  timing  and  site 
of  its  expression.  In  humans,  a  genetic  propensity  of  the  host  to  produce  high  levels 
of  TNFa  during  P.  falciparum  infections  has  been  observed  (McGuire  et  al.,  1994), 
as  a  result  of  changes  in  the  TNFa  gene  promoter  region.  Therefore,  children  who 
are  homozygous  for  the  TNF-2  allele  have  a  significantly  increased  risk  of  suffer 
neurological  sequelae  due  to  cerebral  malaria. 
18 INTRODUCTION 
1.7.2.  Immunity  to  malaria 
1.7.2.1.  Innate  immunity 
Non-specific  acquisition  of  resistance  against  malaria  has  been  observed  after 
administration  of  unrelated  agents.  In  murine  malarias  previous  exposure  to 
Mycobacterium  bovis  (BCG)  resulted  in  resistance  to  infection  (Clark  et  al.,  1976, 
Murphy,  1981),  Similarly,  inoculation  with  killed  Propionibacterium  acnes  (formerly 
known  as  Corynebacterium  parvum)  have  conferred  a  degree  of  protection  against 
subsequent  challenge  with  P.  chabaudi  (Clark  et  al.,  1977),  P.  vinckei  (Lucia  & 
Nussenzweig,  1969;  Cottrell  et  al.,  1977)  and  P.  berghei  (Nussenzweig,  1967; 
Murphy,  1981). 
Exposure  to  a  range  of  products  can  result  in  protection  against  malaria.  These 
include  Concavalin  A  (ConA),  lipopolysaccharide  (LPS)  (Cottrell  et  al.,  1977), 
Coxiella  burnetti  extract  (Clark,  1979),  freeze-thawed  Toxoplasma  gondii 
tachyzoites  (Omata  et  al.,  1981),  endotoxin  (Martin  et  al.,  1967),  and  magnesium 
silicate  in  calcium  phosphate  gel  (Michel  et  al.,  1982). 
The  mechanisms  which  mediate  such  non-specific  immune  response  to  malaria  have 
not  been  completely  elucidated.  These  may  include,  amongst  others,  macrophage 
activation  (Nussenzweig,  1967)  (with  or  without  the  production  of  macrophage 
autocrine  factor,  TNFct),  and  increase  of  natural  killer  (NK)  cells  levels.  In  separate 
observations  TNFct  was  implicated  in  parasite  death  through  the  release  of  nitric 
oxide  (Green  et  al.,  1990)  and  superoxide  ions  (Allison  &  Eugui,  1982). 
Endogenous  environmental  factors  such  as  hormones  play  an  important  role  in  the 
modulation  of  the  immune  response  (reviewed  by  Schuurs  &  Verheul,  1990).  In 
murine  infection  with  P.  chabaudi,  a  spleen-dependent  mechanism  has  been 
implicated  in  the  suppression  of  acquisition  of  immunity  to  blood  forms  of  the 
parasite  (Benten  et  al.,  1991). 
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The  processes  involved  in  naturally  acquired  immunity  to  malaria  are  not  well 
understood.  The  fact  that  many  different  antigens  are  presented  to  the  host's  immune 
system  throughout  a  malaria  infection,  results  in  a  complex  immune  response  to  the 
disease.  As  a  result  the  immune  responses  generated  tend  to  be  stage  specific  as  well 
as  species  and  strain  specific. 
The  development  of  malarial  immunity  is  related  to  the  level  of  endemicity  (Bjorkman 
et  al.,  1986).  Evidence  of  acquired  immunity  to  malaria  infection  in  humans  starts  to 
appear  at  the  beginning  of  the  second  week  of  patent  parasitaemia  and  is  manifested 
as  a  reduction  in  the  parasite's  reproduction  rate  and  in  the  number  of  pRBC  in  the 
blood.  After  a  variable  period,  the  immunity  decreases  the  parasitaemia  to  low  or 
undetectable  levels  (McGregor,  1956).  The  immune  response  can  diminish  the  clinical 
symptoms  of  infection.  However,  there  is  no  direct  correlation  between  parasitaemia 
and  the  presence  of  symptoms.  "Anti-disease"  immunity,  results  after  development  of 
an  immune  response  against  certain  parasite  antigens,  probably  different  form  those 
conferring  anti-parasite  immunity  (reviewed  by  Playfair,  1991).  As  acquired 
immunity  is  short-lasting,  constant  exposure  to  the  parasite  is  required  in  order  to  be 
maintained.  The  presence  of  sterile  immunity  has  been  described  in  rodents  infected 
with  P.  berghei  (Cox,  1962),  but  epidemiological  studies  indicate  that  it  does  not 
exist  in  humans. 
Infants  born  to  P.  falciparum  immune  mothers  are  protected  from  infection  up  to  the 
age  of  6  months.  This  protection  might  be  explained  by  the  effect  of  maternal 
antibodies  and  the  less  favourable  intracellular  environment  created  by  the  presence  of 
foetal  haemoglobin  (reviewed  by  Bruce-Chwatt,  1979),  in  addition  to  PABA  deficit 
(milk  is  deficient  in  PABA)  (Hawking,  1954).  During  the  following  2  years  of  age, 
they  suffer  from  severe  infections,  after  which  high  parasite  densities  persist,  but  less 
pronounced  illness  is  observed  ((Wilson  et  al.,  1950;  McGregor,  1960,  Playfair, 
1990). 
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1.7.2.2.  Acquired  immunity  against  asexual  erythrocytic  stages 
Although  asexual  forms  of  Plasmodium  are  not  the  initial  stage  of  the  parasite  to  be 
encountered  by  the  host,  they  are  responsible  for  essentially  all  of  the  pathology 
associated  with  malaria.  In  natural  infection,  the  synchronous  rupture  of  infected 
erythrocytes  allows  massive  antigen  release.  Subsequently,  on  invasion  of  new  RBC, 
different  antigens  are  expressed  on  the  surface  of  the  cell.  Therefore,  most  of  the 
parasite  antigens  that  are  exposed  to  the  immune  system  derived  from  the  asexual 
blood  stage.  However,  elucidation  of  the  nature  of  the  effector  immune  mechanisms 
to  the  asexual  blood  stages  have  been  difficult,  with  many  host  as  well  as  parasite 
factors  affecting  the  outcome  (Hviid  et  al.,  1992). 
a).  Humoral  immunity 
In  human  malaria,  in  vivo  evidence  for  the  importance  of  antibodies  in  protection 
against  infection  comes  from  studies  of  passive  transference  of  IgG  (Cohen  et  al., 
1961;  Sabchareon  et  al.,  1991).  In  addition,  in  vitro  studies  have  shown  that 
antibodies  are  involved  in  the  inhibition  of  red  cell  invasion  by  merozoites  of  P. 
knowlesi  (Miller  et  al.,  1975a)  or  P.  falciparum  (Phillips  et  al.,  1972;  Mitchell  et  al., 
1976).  Purified  IgG  anti-P.  falciparum  antibodies  promote  in  vitro  phagocytosis  of 
merozoites  and  schizont-infected  erythrocytes  by  monocytes  (Bouharoun-Tayoun  et 
al.,  1990).  The  observation  that  some  individuals  with  high  levels  of  antimalarial 
antibodies  may  evidence  clinical  disease  can  be  explained  by  functional  differences 
existing  among  antibodies  of  the  same  antigenic  specificity  (Bouharoun-Tayoun  & 
Druilhe,  1992).  Opsonization  by  cytophilic  antibodies  may  be  inhibited  by  IgG2  and 
IgM,  which  in  addition  are  unable  to  arm  monocytes  (Ho  &  Sexton,  1995).  It  has 
been  observed  that  in  a  P.  falciparum  endemic  population,  IgG2  and  IgM  level  are 
increased  in  susceptible  groups,  while  IgGI  and  IgG3  increase  with  age  was 
correlated  with  clinical  immunity  (Bouharoun-Tayoun  &  Druilhe,  1992). 
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b).  Cellular  immunity 
Development  of  immunity  to  malaria  requires  an  intact  and  functioning  T  cell  system. 
This  has  been  demonstrated  in  thymectomised  hosts,  which  had  higher  and  more 
persistent  parasitaemias  when  compared  with  controls.  Experiments  of  this  type  have 
been  carried  out  in  P.  berghei  infected  rats  (Brown  et  al.,  1968);  in  P.  chabaudi 
infected  mice  (McDonald  &  Phillips,  1978)  and  P.  yoelii  infected  mice  (Jayawardena 
et  al.,  1977).  Furthermore,  B-cell-depleted  mice  are  able  to  control  infection  with  P. 
chabaudi  adami  (Grun  &  Weidanz,  1981)  or  P.  vinckei  (Kumar  et  al.,  1989) 
probably  through  T-cell  mediation.  In  P.  falciparum  infection,  both  humoral  and 
cellular  immune  responses  have  been  implicated  in  mediation  of  anti-parasite 
immunity  (reviewed  by  Ho  &  Sexton,  1995). 
(i).  T  cells  general  features 
The  majority  of  mature  T  cells  express  either  CD4  or  CD8  surface  glycoproteins.  The 
main,  but  not  exclusive,  role  of  CD8+  T  cells  is  antigen-specific  cytoxicity  (Bloom  et 
at,  1992;  Salgame  et  al.,  1991),  which  results  in  the  destruction  of  autologous 
infected  cells,  in  order  to  prevent  spread  of  pathogens.  CD4+  T  cells  are  involved  in  a 
variety  of  functions  but  their  major  role  is  the  regulation  of  the  immune  response 
necessary  for  both  the  induction  of  cellular  effector  mechanisms  and  for  production  of 
antibodies  to  foreign  antigens  (reviewed  by  Troye-Blomberg  et  al.,  1994). 
T  cells  recognise  antigens  via  their  T  cell  receptors  (TCR)  as  peptides  in  the  context 
of  major  histocompatibility  complex  (MHC)  molecules  of  either  class  I  or  class  II. 
MHC  class  I  molecules  present  mainly  endogenously  derived  antigenic  peptides  and 
are  required  for  the  TCR-mediated  response  of  CD8+  T  cells  (Townsend  &  Bodmer, 
1989).  On  the  other  hand,  exogenously  derived  peptides  are  presented  by  MHC  class 
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II  molecules  and  are  responsible  for  induction  of  CD4+  T  cells  (Rammensee  et  al., 
1993). 
The  TCR  on  the  majority  of  peripheral  T  cells  is  a  disulphide-linked  heterodimer  of 
polypeptides  designated  a  and  ß  chains.  A  smaller  subset  of  CD3+  cells  carries  an 
alternative  TCR  composed  of  y  and  S  chains  (Haas  et  al.,  1993).  y/8  TCR  repertoire 
appears  to  be  more  limited  than  that  of  the  a/ß  TCR  (Haas  et  al.,  1993).  The 
predominance  of  y/S  T  cells  in  epithelial  tissue  has  led  to  the  suggestion  that  these 
cells  may  preferentially  see  antigen  presented  by  non-conventional  antigen  presenting 
cells  (APC),  such  as  epithelial  cells  or  keratinocytes  (Band  et  al.,  1991).  The 
significance  of  y/S  T  cells  in  infection  is  under  investigation  but  accumulating 
evidence  suggests  that  they  play  a  role  in  the  defence  against  micro-organisms  (Band 
et  al.,  1991).  Human  and  murine  y/S  T  cells  showed  strong  proliferative  responses  to 
mycobacterial  extracts  in  the  presence  of  APC  (Haregewoin  et  al.,  1989;  Janis  et  al., 
1989).  Human  y/S  cells  also  showed  cytotoxicity  toward  lymphoma  cells  (Fisch  et  al., 
1990).  Activation  of  these  T  cells  results  in  proliferation,  cytokine  production  and 
induction  of  cytolytic  effector  functions  (Kabelitz,  1991) 
A  major  advance  in  the  understanding  of  immune  response  to  infection  was  the 
identification  in  mice  of  regulatory  CD4+  T  helper  (TH)  cell  termed  TH1  and  TH2 
based  on  their  production  of  either  IL-2  and  IFN  y  (TH1  cells);  or  IL-4,  IL-5,  IL-6, 
and  IL-10  (TH2  cells)  (Mosmann  et  al.,  1986;  Mosmann  &  Coffman,  1989; 
Mosmann  &  Moore,  1991).  CD4+  T  cells  that  are  capable  of  producing  several  or  all 
of  these  cytokines  have  been  designated  THO  cells  (Swain  et  al.,  1991;  Mosmann  et 
al.,  1991).  Furthermore,  although  cytokines  synergise  with  each  other  and  may 
duplicate  the  activities  of  others,  some  of  those  derived  from  TH1  and  TH2  cells  act 
antagonistically  (Mosmann  &  Moore,  1991;  Fernandez-Botran  et  al.,  1988;  Gajewski 
et  al.,  1989;  Fiorentino  et  al.,  1989).  Initially,  it  was  stated  that  the  distinction 
between  Till  and  TH2  cells  does  not  hold  up  in  humans.  These  two  functional 
populations  of  CD4+  T  cells  have  been  demonstrated  in  humans,  however,  in 
response  to  a  variety  of  antigens  (Maggi  et  al.,  1992;  Parronchi  et  al.,  1991;  Modlin 
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&  Nutman,  1993).  In  human  infectious  diseases,  the  TH1  pattern  of  cytokine 
production  has  been  associated  with  immunity  or  resistance  to  infection.  However  the 
critical  question  of  which  factors  regulate  the  TH1/TH2  balance  in  the  course  of  an 
immune  response  is  largely  unresolved.  One  early  host  factor  that  has  recently  been 
identified  to  be  responsible  for  development  of  adaptive  immunity,  involving  TH  cells, 
cytotoxic  T  cells,  and  B  cells,  is  the  cytokine  IL-12  (Trinchieri,  1993;  Chehimi  & 
Trinchieri,  1994).  IL-12  was  originally  identified  as  NK  cell  stimulatory  factor  and 
has  been  shown  to  have  pleiotropic  effects  on  both  NK  and  T  cells  (Kobayashi  et  al., 
1989).  This  cytokine  induces  production  of  IFN  y  as  well  as  TNFa  and  GM-CSF 
(Stevenson  et  al.,  1995).  Because  of  this  ability  to  induce  IFN  y  production,  IL-12 
promotes  the  differentiation  of  CD4+  T  cells  in  vitro  (Hsieh  et  al.,  1993;  Manetti  et 
al.,  1993;  Seder  et  al.,  1993) 
In  parasitic  infections,  TH-dependent  immuno-regulation  is  often  associated  with  a 
phenomenon  called  cross-regulation.  This  concept  is  based  on  a  mechanism  of  down- 
regulation  exerted  by  cytokines.  Thus,  IFN  y  inhibits  the  proliferation  of  TH2  cells 
and  Interleukin  (IL)-4  secretion,  while  IL-10  inhibits  both  the  production  and  the 
activity  of  IFN  y  (Taverne,  1993).  Cytokine  production  by  normal  T  cells,  especially 
from  non-immunised  mice,  showed  that  many  normal  T  cells,  when  first  stimulated, 
produce  large  amounts  of  IL-2  but  no  other  T-cell  cytokines  (Street  et  al.,  1990). 
Thus  the  resting  T  cells  that  have  not  recently  been  stimulated  may  produce  only  IL- 
2  on  that  first  contact  with  the  antigen,  and  T  cells  producing  multiple  cytokines  may 
present  later  and  in  more  differentiated  phenotypes. 
(ii).  Role  of  CD4  T  cells 
The  role  of  CD4+  T  cells  in  protection  against  blood  stage  P.  chabaudi  adami  malaria 
in  mice  has  been  established  by  using  antigen-specific  cell  lines  and  clones  (Brake  et 
al.,  1988),  and,  in  P.  chabaudi  chabaudi  infection,  by  in  vivo  T-cell  depletion 
(Langhorne  et  al.,  1990)  and  adoptive  transfer  of  T  cells  or  T-cell  clones  to 
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thymectomised  or  T-cell-deficient  mice  (McDonald  &  Phillips,  1978  &  1980;  Süss  et 
al.,  1988;  Cavacini  et  al,  1986;  Brake  et  al.,  1986;  Meding  &  Langhorne,  1991).  In 
P.  chabaudi  AS  murine  malaria  cells  of  TH1  type  were  activated  during  the  early 
acute  phase,  once  this  phase  was  under  control,  the  activated  CD4+  T  cells  were 
shown  to  be  mainly  of  the  TH2  type,  providing  antibody  help  (Langhorne  et  al., 
1989;  Langhorne  1989;  Langhorne  &  Simon  1989).  P.  chabaudi  AS-specific  CD4+  T 
cell  clones  derived  from  early  infection  were  mainly  TH1  type,  while  the  clones 
derived  from  reinfected  mice  were  TH2  type  (Taylor-Robinson  &  Phillips,  1992).  In 
addition,  adoptive  transfer  of  these  clones  into  naive  mice  resulted  in  resistance  to  P. 
chabaudi  AS  challenge  (Taylor-Robinson  &  Phillips,  1994a).  This  involvement  of 
TH1  and  TH2  T  cell  in  a  sequential  order  has  also  been  observed  by  Stevenson  & 
Tam  (1993).  They  have  found,  however,  that  induction  of  a  strong  TH2  response 
early  in  infection  may  result  in  a  severe  and  lethal  course  of  infection. 
The  generation  of  TH2  cells  late  during  the  primary  infection  appears  to  be  dependent 
on  the  presence  of  B  cells  (Meding  &  Langhorne,  1991;  von  der  Weid  &  Langhorne, 
1993b;  Taylor-Robinson  &  Phillips,  1996).  Most  likely,  these  B  cells  may  act  as  APC 
and  produce  cytokines  or  specific  costimulatory  signals  that  promote  TH2 
development  (Troye-Blomberg  et  al.,  1994).  Such  is  the  case  observed  in  other 
experimental  systems  in  which  different  types  of  APC  have  been  shown  to  activate 
CD4`  T  cells  in  a  selective  form  (reviewed  by  Troye-Blomberg  et  al.,  1994) 
Infection  of  mice  with  P.  berghei-  parasitised  erythrocytes  leads  to  activation  of  T 
cells,  thereby  enhancing  IFNy  production  (Grau  et  al.,  1989).  IFNy  exerts  a  priming 
effect  on  monocytes/macrophages  for  the  production  of  TNFa  as  was  demonstrated 
by  Gifford  et  al.,  (1987).  IFNy  primed  monocytes,  activated  by  plasmodia  antigens, 
readily  produce  increased  amounts  of  TNFa  (Bate  et  al.,  1988),  as  well  as  reactive 
oxygen  intermediates  (ROI)  (reviewed  by  Weidanzet  al.,  1990)  and  NO  (Kremsner  et 
al.,  1993).  This  process  almost  certainly  occurs  in  the  spleen,  where  parasites  are 
filtered  through  a  network  of  T  cells  as  well  as  monocyte-macrophages.  Thus,  both 
the  presence  of  a  spleen  and  an  intact  splenic  architecture  are  required  for  a 
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successful  achievement  of  antibody-independent  immunity  (Kumar  et  al.,  1989, 
Weiss,  1990). 
TNFa  is  an  important  cytokine  that,  along  with  ROI  and  NO,  generates  a  delayed- 
type  hypersensitivity  immune  response  modulating  macrophage  populations 
granulocytes  and  eosinophils.  Moreover,  it  contributes  to  the  activation  of  B  cells. 
Clark  et  al.  (1976)  suggested  that  blood  stage  parasites  were  killed  by  an  unknown 
mechanism  that  resulted  in  the  appearance  of  "crisis"  forms.  Subsequent  studies 
reported  that,  in  rodents,  recombinant  TNF  (Taverne  et  al.,  1981)  reduced 
parasitaemias  in  acute  malaria  infections.  Clark  et  al.,  (1987b)  noted  that  clinical 
findings  observed  in  malaria  infection  were  similar  to  side  effects  observed  in  cancer 
patients  under  treatment  with  TNFa  infusions.  The  amounts  of  circulating  TNF  in  P. 
falciparum  infections  can  be  correlated  with  many  of  the  complications  of  the  disease, 
including  death  from  cerebral  malaria,  perhaps  through  the  local  production  of 
noxious  amounts  of  NO.  These  findings  corroborate  the  view  that  cytokines  may 
mediate  the  clinical  symptoms  of  malaria  and  that  clinical  acquired  immunity  in  adults 
living  in  endemic  regions  might  be  achieved  by  controlling  the  production  of  high 
amounts  of  these  cytokines. 
Stevenson  et  al.  (1995),  have  observed  IL-  12-regulation  of  development  of  resistance 
to  P.  chabaudi  AS  via  a  TH1  response  that  involves  CD4+  T  cells  as  well  as 
cytokines,  IFN  y  and  TNF  a'  and  NO.  They  concluded  that  the  treatment  with 
recombinant  IL-12  in  the  appropriate  dose,  may  be  useful  in  the  induction  of 
protective  immunity  against  this  blood-stage  malaria. 
Langhorne  et  al.  (1990),  showed  that  there  were  increased  levels  of  IL-2  early  in 
murine  malaria.  IL-2  may  act,  initially,  in  the  activation  of  natural  killer  (NK)  cells  to 
induce  a  cytotoxic  immune  response  and  could  also  participate  in  the  activation  of 
macrophages  in  order  to  produce  a  delayed-type  hypersensitivity  immune  response. 
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(iii).  Role  of  CD8+  T  cells 
The  role  of  CD8+  T  lymphocytes  during  the  erythrocytic  stage  of  malaria  is  far  from 
clear.  They  may  contribute  to  the  control  of  the  parasite  in  early  stages  of  infection  as 
exacerbation  and  prolongation  of  P.  chabaudi  primary  parasitaemia  was  observed  in 
CD8+  T  cells  depleted  mice  (Süss  et  al.,  1988).  In  a  similar  model  of  blood-stage  P. 
chabaudi  AS,  protection  against  infection  was  related  to  presence  of  both  CD4+  and 
CD8+  cells  (Podoba  &  Stevenson,  1991).  Mogil  et  al.  (1987),  demonstrated  that 
adoptive  transfer  of  CD8+  T  cells  from  P.  yoelii-immune  animals  into  naive  mice 
accelerated  recovery.  However,  in  vivo  observations  confirmed  that  only  CD4+  T 
cells  are  crucial  for  protection  when  using  adoptive  transfer  of  immune  T-cell  subsets 
or  T-cell  depletion  of  mice  by  antibody  (Vinetz  et  al.,  1990).  CD8+  T  cells  themselves 
were  neither  protective  nor  did  they  enhance  immunity.  In  addition,  CD8+  cells  were 
suggested  to  be  involved  in  pathogenesis  in  P.  berghei  by  inducing  TNF  a  secretion 
from  macrophages  (Waki  et  al.,  1993) 
(iv).  Role  of  y/S  T  cells 
y/6  T  cells  may  contribute  to  parasite  killing  via  their  cytolytic  activity  (Langhorne  et 
at,  1995  ).  It  has  been  shown  that  human  y/S  T  cells  can  inhibit  the  growth  of  P. 
falciparum  in  vitro  and  that  their  activity  is  directed  primarily  against  the 
extracellular  merozoite  (Elloso  et  at,  1994).  However,  in  a  murine  P.  chabaudi 
infection,  y/8  T  cell  were  not  able  control  a  primary  erythrocytic  infection  in  absence 
of  aß  T  cells,  and  were  inefficient  as  helper  cells  for  B  cell  production  of  malaria- 
specific  IgG  antibodies  in  vivo  (Langhorne  et  at,  1995). 
Due  to  the  magnitude  of  the  proliferative  response  of  y/S  T  cells  in  malaria  infection 
and  the  predominance  of  inflammatory  cytokines  secreted  by  them,  it  has  been 
suggested  that  y/S  cells  may  have  a  role  in  the  pathology  associated  with  the  infection 
(Langhorne,  1996) 
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1.8.  Development  of  a  malaria  vaccine 
Antigens  for  vaccine  development  are  being  identified  from  sporozoites,  pre- 
erythrocytic  forms,  asexual  and  sexual  stages.  Attenuated  (Clyde  et  al.,  1973; 
Weinbaum  et  al.,  1976;  Rieckman  et  al.,  1979;  Waki  et  al.,  1986)  and  killed 
(Desowitz  &  Miller,  1980)  malaria  parasites  have  shown  to  be  efficacious  as  vaccines 
for  humans  and  animals.  Such  vaccine  preparations  are  not  currently  used  for  disease 
prevention  because  of  the  difficulties  of  large  scale  of  in  vitro  cultivation  of  plasmodia 
(Trager  &  Jenson,  1976)  and  the  associated  risks  of  preparing  pRBCs  from  cultures 
containing  human  serum,  which  is  an  essential  requirement  of  in  vitro  cultivation.  At 
present,  the  goal  is  to  stimulate  protective  immunity  to  the  whole  parasite  from  only 
one  or  few  parasite  proteins,  or  derived  peptides,  prepared  by  recombinant  or 
synthetic  peptide  technology,  i.  e.  a  subunit  vaccine.  It  is  necessary  that  these  vaccines 
contain  multiple  T  cell  epitopes,  to  overcome  genetic  restriction,  for  natural  boosting 
of  the  antibody  response.  Moreover,  these  vaccines  must  preferentially  induce 
immune  effector  mechanisms  rather  than  responses  with  no  protective  activity  or 
worse  still  causing  immunopathology.  Salmonella  mutants  have  been  successfully 
used  to  deliver  heterologous  antigens  to  the  immune  system  in  mice.  This  system  may 
also  be  taken  further  by  generating  constructs  that  contain  cytokines  alongside 
malarial  antigens.  Thus  it  would  be  possible  to  use  the  adjuvant  effect  of  a  specific 
cytokine  to  enhance  the  immunogenicity  of  a  particular  malarial  antigen.  A  brief 
review  of  the  malarial  antigens  which  may  be  important  to  consider  for  inclusion  in  a 
Salmonella  system  follows. 
1.8.1.  Sporozoite/pre-erythrocytic  stage  antigens 
A  fully  protective  effective  sporozoite  vaccine  is  expected  to  induce  immunity  which 
either  stops  invasion  of  liver  cells,  or  if  invasion  occurs  it  should  prevent  the  parasite 
of  completing  its  pre-erythrocytic  cycle. 
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The  major  sporozoite  protein  is  a  coat  protein  (circumsporozoite/CS  protein)  which 
has  the  same  general  makeup  in  human,  simian  and  murine  malarias.  The  central  third 
of  the  protein  consists  of  multiple  repeating  immunogenic  sequences  which  are  unique 
for  each  species.  In  P.  falciparum  the  major  central  region  of  the  protein  is  a 
repeating  sequence  (about  40  times)  of  asparagine-alanine-asparagine-proline 
(NANP).  This  region  is  an  immunodominant  B  cell  epitope  and  antibodies  to  the 
repetitive  region  block  sporozoites  in  culture  (Zavala  et  at,  1985).  It  is  also 
conserved  in  different  isolates  of  P.  falciparum  (Weber  &  Hockmeyer,  1985).  For 
these  reasons  the  repeat  region  was  an  attractive  vaccine  candidate  and  human  trials 
were  carried  out  (Ballouet  at,  1987,  Herrington  et  at,  1987).  However,  failure  of 
CSP  subunit  vaccines  to  protect  humans  fully  (Ballou  et  at,  1987;  Herrington  et  at, 
1987;  Fries  et  al.,  1992),  highlighted  the  important  role  of  T  cells  responses  in 
development  of  protective  immunity  (Krzych  et  at,  1995).  Protective  cell-mediated 
immunity  to  sporozoites  by  immunisation  with  attenuated  S.  typhimurium 
transformed  with  the  P.  berghei  CS  gene  has  been  observed  in  mice  in  the  absence  of 
antisporozoite  antibodies  (Sadoffet  al.,  1988). 
Several  non-CSP  sporozoite  surface  molecules  have  been  identified  (Galey  et  at, 
1990).  These  include  among  other:  sporozoite  threonine-  and  asparagine-rich  protein 
(STARP),  thrombospondin-related  anonymous  protein  (TRAP)  (Robson  et  at,  1988) 
and  sporozoite-  and  liver-  stage  antigen  (SALSA)  (Bottius  et  at,  1996).  However, 
their  precise  contribution  on  acquisition  of  immunity  against  sporozoite  challenge  is 
subject  of  intense  research. 
1.8.2.  Asexual  blood  stage  antigens 
A  large  number  of  antigens  derived  from  asexual  blood-stages  of  malaria  parasites 
have  now  been  described  and  conserved  and/or  antigenically  conserved  portions  of 
many  of  the  target  antigens  for  vaccine  development  have  now  been  identified. 
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Antigens  currently  considered  for  inclusion  in  an  anti-P.  falciparum  asexual  blood 
stage  vaccine  are  briefly  described  below. 
An  antigen  which  has  been  examined  in  great  detail  as  a  potential  malaria  vaccine 
component  is  the  major  merozoite  surface  protein  (MSP-1  or  MSA).  P.  falciparum 
MSP-1  is  on  the  surface  of  the  merozoite  as  a  complex  of  polypeptides  after  the 
proteolytic  cleavage  of  a  precursor.  The  protein  is  held  on  the  membrane  surface  by  a 
42kDa  fragment  that  has  a  GPI  anchor.  At  the  moment  of  red  cell  invasion  (or 
immediately  before),  the  complex  is  released  from  the  surface  by  protease  cleavage 
within  the  42kDa  fragment.  A  19  kDa  anchored  domain,  which  consists  of  two 
epidermal  growth  factor-like  motifs,  is  produced  after  this  cleavage  and  is  retained 
on  the  intracellular  parasite  (reviewed  by  Egan  et  at,  1996).  Antibodies  raised  against 
the  MSP-1  protein  have  shown  to  block  merozoite  invasion  in  vitro  (Howard  et  al., 
1993),  possibly  by  inhibiting  the  protease  cleavage  (Blackman  et  at,  1994).  Similarly, 
in  vivo  immunisation  of  monkeys  with  the  native  protein  resulted  in  protection 
against  P.  falciparum  challenge  (Etlinger  et  at,  1991).  The  successful  expression  of 
a  C-terminal  fragment  ofMSP-1  in  yeast  of  a  baculovirus  recombinant  system  elicited 
antibodies  that  blocked  the  in  vitro  growth  of  the  parasite  (Chang  et  at,  1992).  A 
synthetic  peptide,  SPf66,  which  contains  a  sequence  of  MSP-1  protein,  has  partially 
protected  humans  and  monkeys  (Patarroyo  et  al.,  1987,  Patarroyo  et  at,  1988) 
against  natural  and  experimental  challenges.  This  vaccine  is  now  undergoing  trial  in 
humans  and  initial  results  showed  protection  in  38.8%  of  subjects  resident  in  a 
endemic  region  of  Colombia  (Patarroyo  et  al.,  1987;  Patarroyo  et  at,  1988),  in 
66.8%  in  a  similar  population  in  Ecuador  (Sempertegui  et  at,  1994)  and  31%  in  an 
endemic  region  in  Tanzania  (Alonso  et  al.,  1994).  However,  conflicting  results  have 
been  obtained  in  different  populations.  Recent  trials  carried  out  in  The  Gambia  and 
Thailand  found  no  co-relation  between  protection  and  vaccination  in  children  under 
15  year  old  (Nosten  et  al.,  1996). 
MSP-2  is  another  P.  falciparum-merozoite  surface  protein,  contains  T-cell  epitopes, 
both  in  the  constant  and  variant  parts  of  the  antigen  (Rzepczyk  et  at,  1992). 
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Immunisation  with  this  P.  falciparum  protein  has  led  to  protection  of  mice  against  an 
otherwise  mortal  challenge  with  P.  chabaudi  (Saul  et  al.,  1992). 
The  antigen  P.  falciparum  (PO  155/RESA  was  first  detected  by  a  modified 
immunofluorescence  assay  on  erythrocytes  infected  with  ring  forms  of  P.  falciparum 
(Holder  et  al.,  1988;  Foley  et  al.,  1983).  Pf155/RESA  is  a  merozoite-derived 
polypeptide  deposited  in  the  erythrocyte  membrane  during  parasite  invasion. 
Antibodies  against  Pfl55/RESA  have  shown  to  inhibit  invasion  of  P.  falciparum 
merozoites  in  vitro  (Berzins  et  al.,  1985,  Ruangjiraporn  et  al.,  1988).  The  majority  of 
antibody  responses  against  this  protein  are  directed  to  conserved  repeat  regions  of  the 
molecule  (Hviid  et  al.,  1992).  A  specific  T  cell  response  has  been  described  against 
this  Pf155/RESA  antigen  in  malaria-exposed  donors.  The  strongest  and  most  frequent 
of  the  T  cell  responses  are  also  directed  towards  conserved  repeat  regions  of  the 
molecule  (Troye-Blomberg  et  al.,  1988). 
PfEMP-1  (Leech  et  al.,  1984,  Van  Schravendijk  et  al.,  1991),  is  a  protein  which 
mediates  cytoadherence  of  P.  falciparum  parasitised  red  blood  cells  to  the  vascular 
endothelium  and  is  an  attractive  vaccine  candidate  since  induction  of  immunity 
against  this  molecule  could  result  in  a  prevention  of  cerebral  malaria.  Antibodies  to 
PfEMPI  prevented  cytoadherence  and  therefore  sequestration.  Previously,  David  et 
al.  (1983)  and  more  recently,  Goldring  et  al.,  (1992),  have  demonstrated  reversal  of 
sequestration  after  inoculation  of  polyspecific  IgG 
. 
In  addition,  antibodies  that 
prevent  rosetting  (Carlson  et  al.,  1990)  have  been  associated  with  the  absence  of 
cerebral  malaria.  The  importance  of  these  findings  relates  not  only  to  the  abolishment 
of  pathology  in  the  main  organs,  but  such  treatment  could  lead  to  an  increase  in 
parasite  circulation  which  enables  the  immune  system  to  make  better  contact  with  it. 
Two  P.  falciparum  histidine  rich  proteins  (PfHRP-1  and  PfHRP-2)  (Howard  et  al., 
1986;  Rock  et  al.  1987),  and  Ag332  (Mattei  &  Scherf,  1992;  Mattei  et  al.,  1992)  are 
other  membrane  surface  antigens  which  have  been  studied  as  potential  vaccines. 
The  rupture  of  parasitised  red  blood  cells  permits  the  release  of  large  amounts  of 
antigen  derived  both  from  the  parasite  and  the  parasitised  cell.  Immunisation  with 
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phosphatidyl-inositol  and  phosphatidylserine  has  resulted  in  production  of  high  and 
prolonged  IgG  titres  against  toxic  malarial  antigens  (Bate  et  al.,  1993)  as  measured 
by  reduction  in  ability  of  peritoneal  macrophages  to  produce  TNFa  in  vitro.  The 
effect  of  these  antibodies  on  induction  of  TNFa  in  vivo  is  yet  to  be  studied  (reviewed 
by  Clark  &  Rockett,  1994).  In  1988  Riley  et  al.  evaluated  cellular  immune  responses 
in  Gambian  adults  finding  that  50%  of  immune  patients  produced  IFN  y  when  cells 
were  stimulated  with  soluble  antigens.  Later,  proliferative  immune  responses  have 
been  found  against  identified  soluble  antigens  such  as  Agl  which  was  associated  with 
trophozoites  and  schizonts  but  not  with  merozoites,  and  Ag7  was  found  associated 
with  schizont  only.  Both  antigens,  Agl  and  Ag7,  have  been  reported  as  inducers  of  T 
cell  responses  with  production  of  IFN  y  but  have  not  been  associated  with  humoral 
responses. 
1.8.3.  Sexual  stage  antigens 
Immunity  to  sexual  stages  of  the  parasite,  though  of  no  immediate  benefit  to  the  host,  can 
prevent  transmission  of  the  disease  by  blocking  the  parasite  life  cycle  within  the  mosquito. 
Such  immunity  is  known  as  transmission  blocking. 
A  humoral  response  against  sexual  form  of  rodent  malaria  parasites  has  been  described  by 
Harte  et  al.  (1985).  Antibodies  against  macro-  and  micro-gametocytes  may  disrupt  the 
transmission  cycle  of  the  disease  by  inhibiting  the  fertilisation  and  development  of  the 
zygote  (  reviewed  by  Kaslow,  1993).  Expression  of  recombinant  Pfs25,  a  protein  normally 
found  on  the  surface  of  P.  falciparum  gametocytes/gametes  and  ookinetes,  has  been  used 
successfully  to  induce  transmission  blocking  immunity  antibodies  (Kaslow  et  al.,  1991). 
The  vaccine  candidate  antigens  which  have  been  examined  in  some  detail  are  P.  falciparum 
230  and  P.  falciparum  48/45  (Howard  et  al.,  1993).  Riley  et  al.  (1990),  demonstrated  T- 
cell  responses  against  P.  falciparum  48/45  in  40%  of  immune  donors  and  association  with 
IFN  y  production  in  vitro. 
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A  large  product  of  P.  falciparum  coded  by  the  Pfl  1-1  gene,  has  been  recently  described  in 
the  cytoplasm  of  gametocytes  and  in  the  membrane  of  lysed  erythrocytes,  suggesting  a  role 
for  Pfl  1-1  in  erythrocyte  rupture  within  the  mosquito  gut  (Sherf  et  al.,  1993).  After 
studying  the  immune  response  against  this  protein  in  mouse  and  humans  exposed  to  malaria, 
it  was  concluded  that  the  Pfl  1-1  molecule  might  induce  an  unusually  heterogeneous  B  and 
T  cell  response  during  natural  infection  in  man. 
1.9.  Salmonella  vectors 
1.9.1.  Attenuated  Salmonella 
Current  developments  in  recombinant  DNA  technology  have  resulted  in  the 
production  of  highly  effective  live  attenuated  vaccines  (Hone  et  al.,  1994),  which 
offer  major  advantages  over  killed  preparations  since  induction  of  immunity  via  live 
systems  (e.  g.  Escherichia  coli,  S.  typhi  and  S.  typhimurium)  allows  the  generation  of 
stronger,  cellular  and  longer-lasting  immune  responses  (Chatfield  et  al.,  1995).  This 
probably  occurs  because  some  of  them  have  the  ability  to  replicate  within  the  host  in 
antigen  presenting  cells  (MacKaness,  1971).  Genetically  engineered  live  vaccines 
possess  stable  and  well  defined  non-reverting  mutations  of  genes  essential  for  survival 
in  the  host  and  therefore  they  establish  self-limiting  infections  that  mimic  early  stages 
of  the  natural  infection  (Chatfield  et  al.,  1995).  These  characteristics  make 
recombinant  live  vaccines  more  suitable  for  immunogenicity  studies  when  compared 
with  other  attenuated  vaccines  (i.  e.  irradiated  vaccines).  Agents  studied  as  live 
vaccine  vectors  include  vaccinia  virus,  avipoxviruses,  adenovirus,  polioviruses, 
herpesviruses,  E.  coli,  Salmonella  and  Mycobacterium  bovis  (BCG). 
Several  promising  Salmonella  vaccines  candidates  have  been  investigated  (Chatfield 
et  al.,  1992).  One  group  of  the  Salmonella  mutants  that  has  been  extensively  studied 
includes  those  strains  harbouring  defined  mutations  in  gene  encoding  enzymes  in  the 
pre-chorismate  biosynthetic  pathway  (aro  mutants)  (Chatfield  et  al.,  1995).  The 
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explanation  of  the  attenuation  of  aro  mutants  is  presumed  to  lie  in  their  in  vivo 
inability  to  scavenge  essential  aromatic  metabolites,  para-aminobenzoic  acid  among 
others  (Chatfield  et  al.,  1995).  Since  vertebrates  lack  the  pre-chorismate  pathway, 
sustained  bacterial  replication  is  impossible  (Chatfield  et  al.,  1995).  An  important 
advantage  of  these  mutants  is  that  their  reduced  virulence  results  from  starvation  of 
essential  nutrients  and  not  from  their  inability  to  resist  the  host's  immune  response 
(Chatfield  et  al.,  1995).  Hence,  they  are  safe  to  use  in  immunosuppressed 
populations. 
1.9.2.  Salmonella  life  cycle  and  pathogenesis 
Orally  administered  S.  typhimurium  penetrate  the  wall  of  the  small  intestine  through 
the  Peyer's  patches  (WHO,  1989),  where  antigen-sampling  cells  known  as  microfold 
or  M  cells  (Walker,  1994)  reside.  M  cells  transport  antigens  or  whole  micro- 
organisms  from  the  intestinal  lumen  to  the  follicle  underneath,  leave  the  Peyer's 
patches  via  the  efferent  lymphatics  and  enter  the  systemic  circulation  via  the  thoracic 
duct.  What  follows  involves  the  return  of  lymphocytes  to  the  effector  site  (i.  e.  the 
lamina  propria  of  the  gastrointestinal  tract)  and  the  production  of  secretory  IgA  in 
external  secretions  (Williamson  et  al.,  1995). 
In  mice,  S.  typhimurium  delivered  orally  can  also  reach  other  organs  such  as  liver  and 
spleen,  after  invading  the  lamina  propria  and  the  draining  mesenteric  lymph  nodes 
(O'Callaghan  et  al.,  1988),  and  hence  allowing  the  production  of  specific  systemic 
immune  responses  after  colonisation  of  macrophages  within  the  spleen  and  liver. 
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1.9.3.  Immunity  to  Salmonella  infection 
Mice  infected  with  S.  typhimurium  divide  into  susceptible  and  resistant  according  to 
the  presence  of  different  alleles  of  the  Lsh/ItyBcg  gene.  BALB/c  mice  cannot  control 
the  infection  with  virulent  salmonellae  and  succumb  to  fatal  infection.  However,  when 
they  are  immunised  with  live  attenuated  strains  of  S.  typhimurium,  protective 
immunity  to  further  virulent  challenge  can  be  induced  (Hosieth  &  Stocker,  1991).  A 
period  of  non-specific  immunity  has  been  observed  as  the  initial  replication  of  the 
attenuated  organisms  reaches  a  plateau,  during  which  resistance  to  infection  with 
Listeria  monocytogenes  as  well  as  virulent  Salmonella  has  been  reported  (Hormaeche 
et  al.,  1991).  NK  cells  and  macrophages  are  primary  mediators  of  this  non-specific 
protection  (Schafer  &  Eisenstein,  1992). 
Resistance  to  virulent  infection  after  the  initial  phase  is  antigen  specific  and 
requires  the  presence  of  T  cells  (Mastroeni  et  al.,  1992).  In  order  to  transfer  this 
immunity  to  naive  susceptible  animals,  T  cells  in  addition  to  serum  from  immune 
animals  are  required  (Mastroeni  et  al.,  1992).  Antibodies  are  though  to  contribute 
with  killing  of  extracellular  organisms  and  so  help  to  contain  infection.  Macrophage 
activation  and  increase  production  of  IFNy  and  TNFa  are  critical  in  the  killing  of 
intracellular  micro-organisms  (Mastroeni  et  al.,  1992)  and  can  cause  S.  typhimurium 
killing  if  administered  in  vivo  during  infection  (Nakanu  et  al.,  1990).  Since  infection 
with  salmonella  elicits  a  strong  CD8+  CTL  response  (Aggarwal  et  al.,  1990),  lysis  of 
infected  cells  by  cytotoxic  T  cells  is  also  suggested  to  contribute  to  bacteria  clearance 
(Conlan  &  Norh,  1992). 
1.9.4.  Attenuated  Salmonella  as  heterologous  carriers 
The  first  reports  of  the  use  of  a  live  vaccinia  virus  expressing  foreign  antigens  were 
made  in  1982  (Panicalli  &  Paoletti,  1982,  Mackett  et  al.,  1982).  Since  then  other 
vectors  have  been  shown  to  be  useful  for  the  transport  of  antigens.  Among  them  are 
E.  coli,  S.  typhimurium,  S.  typhi,  BCG,  poxvirus,  adenovirus,  herpesvirus  and 
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poliovirus.  Of  particular  interests  is  the  potential  of  attenuated  S.  typhimurium  and  S. 
typhi  strains  as  carriers  of  diverse  antigens  from  a  number  of  other  pathogens. 
Salmonella  mutants  can  induce  strong  humoral  and  cellular  immune  responses  and 
therefore  can  be  manipulated  to  induce  such  immune  responses  to  foreign  antigens. 
Antigens  of  bacterial,  viral  and  parasite  origin  have  been  expressed  in  S.  typhimurium 
as  prospective  vaccines  against  a  number  of  diseases. 
S.  typhimurium  have  been  engineered  to  express  Leishmania  antigens.  The  gene 
encoding  L.  major  gp63  was  expressed  in  a  aroA  mutant  of  S.  typhimurium  and  mice 
were  immunised  with  this  construct.  Susceptible  BALB/c  mice  had  reduced  lesion 
development  after  oral  immunisation  with  the  vaccine  probably  through  acquisition 
of  a  protective  TH1-  like  response  to  L.  major  (McSorley,  1995). 
This  technology  has  been  applied  to  research  in  malaria  achieving  the  expression  of 
malarial  antigens  such  as  P.  falciparum  serine-rich  protein  (SERP)  and  P.  falciparum 
histidine  rich  protein-2  (PfHRP-2)  by  S.  typhimurium  (Schorr  et  al.,  1991).  More 
significantly,  recombinant  Salmonella  expressing  the  circumsporozoite  protein  (CSP) 
has  shown  to  protect  mice  against  sporozoite  challenge  (Sadoff  et  al.,  1988,  Flynn  et 
al.,  1990).  A  CSP  expressing  Salmonella  vaccine  was  used  in  humans  which  later 
developed  significant  humoral  responses  against  the  protein  (Gonzalez  et  al.,  1994). 
In  mice,  S.  typhimurium  mutants  have  also  been  engineered  to  deliver  biologically 
active  cytokines.  S.  typhimurium  expressing  murine  IL-10  confer  protection  against 
lethal  gamma  irradiation  due  to  functional  IL-10  activity  (Carrier  et  al.,  1992). 
Murine  IL-4  has  also  been  expressed  in  S.  typhimurium  and  shown  to  have  activity  in 
vivo  (McSorley,  1995).  Similarly,  administration  of  a  S.  typhimurium  mutant 
expressing  murine  TGFß  had  a  significant  effect  in  reducing  induced  oedema  (lanaro 
et  al.,  1995). 
Attenuated  S.  typhimurium  can  be  used  as  carriers  of  heterologous  antigens  to  the 
immune  system  in  animal  models  and  future  progression  from  a  single  attenuated 
typhoid  fever  vaccine  to  a  multivalent  vaccine  against  diverse  pathogens  may  be 
possible. 
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1.10.  Immune  evasion  by  malaria  parasites 
1.10.1.  Sequestration 
In  order  to  kill  malaria  parasites,  the  host  immune  system  must  have  access  to  the 
parasite  and  an  opportunity  to  interact  with  other  cells  of  the  system  (reviewed  by 
Allred,  1995).  Because  asexual  forms  of  malaria  parasites  are  intracellular,  they  are 
not  accessible  to  immune  system  during  most  of  their  reproductive  cycle.  Alterations 
in  the  red  cell  membrane  may  result  in  changes  in  cytoadhesion  when  infected  with 
some  Plasmodium  species  (i.  e.  P.  falciparum).  Cytoadherence  of  infected  RBCs  to 
post-capillary  venous  endothelium  results  in  withdrawal  from  the  peripheral 
circulation  (sequestration)  of  the  trophozoite  and  schizont-stage  parasite. 
Regardless  of  the  host's  immune  state,  only  very  immature  sexual  forms  or  mature 
gametocytes  are  usually  found  circulating  in  the  blood  of  humans  infected  with  P. 
falciparum.  The  more  mature  stages  localise  to  the  post-capillary  venular 
endothelium  of  the  brain,  placenta  or  gut.  Host  factors  seem  to  influence 
sequestration.  In  humans,  P.  falciparum  schizont  sequestration  is  almost  complete.  In 
other  non-human  primates  this  phenomena  does  not  occur  to  the  same  extent  and  the 
main  sites  are  different  (Miller,  1969;  David  et  al.,  1983).  P.  vivax  undergoes 
sequestration  to  some  degree  (Garnham,  1966). 
In  other  primate  and  rodent  malarias,  some  degree  of  sequestration  has  been 
demonstrated.  These  include  P.  coatneyi,  P.  fragile  (Desowitz  et  al.,  1969;  Fremount 
&  Miller,  1975),  P.  knowlesi  (Miller  et  al.,  1971)  and  P.  berghei  (Alger,  1963;  Weiss, 
1983;  Mackey  et  al.,  1980;  Rest,  1982;  Warrell,  1987).  Similarly,  markedly 
sequestration  of  pRBC  occurs  in  the  liver  during  P.  chabaudi  infection. 
Cytoadherence  of  infected  red  cells  to  endothelial  cells  represents  the  acquisition  of 
specific  properties  on  the  membrane  of  the  infected  cell.  These  binding  properties  of 
P.  falciparum  are  directed  towards  individual  ligands.  However,  they  are  not  constant 
37 INTRODUCTION 
and  vary  with  the  isolate  and  previous  cytoadherence  history  (Marsh  et  al.,  1988; 
Magowan  et  al.,  1988;  Biggs  et  al.,  1991  &1992;  Roberts  et  al.,  1992;  Ockenhouse 
et  al.,  1992).  Parasitised  RBC  can  adhere  to  five  different  endothelial  cell  surface 
molecules:  thrombospodin  (Roberts  et  al.,  1985),  CD36  (Ockenhouse  et  al.,  1988  & 
1991;  Oquendo  et  al.,  1989;  Barnwell  et  al.,  1989),  intercellular  adhesion  molecule  1 
(ICAM-1)  (Berendt  et  al.,  1989),  vascular  cell  adhesion  molecule  1  (VCAM-1)  and 
E-selectin  (or  endothelial  cell  adhesion  molecule  1,  ELAM-1)  (Ockenhouse  et  al., 
1992).  Upregulation  of  ICAM-1  expression  can  mediated  by  cytokines  (Staunton  et 
al.,  1988).  IL-1,  IL-2,  IFNy  and  TNFa  can  all  induce  ICAM-1  expression  on  diverse 
cell  types  (Dustin  et  al.,  1986;  Rothlein  et  al.,  1988;  Asarnow  et  al.,  1989).  TNFa 
dependent  upregulation  of  ICAM-1  is  of  particular  importance  since  elevated  TNFa 
expression  has  been  associated  with  cerebral  malaria  (Udomsangpetch  et  al.,  1989; 
Kwiatkowski  et  al.,  1990). 
The  identity  of  the  components  on  the  surface  of  the  P.  falciparum  infected  red  blood 
cell  mediating  cytoadherence,  is  under  debate.  For  some  authors  the  receptor 
involved  in  the  expression  of  the  cytoadherent  phenotype  is  PfEMPI,  which  is  a 
large,  parasite  derived  molecule  expressed  on  the  surface  of  the  infected  erythrocyte 
(Biggs  et  al.,  1992;  Leech  et  al.,  1984).  Others  have  demonstrated  that  sequestrin,  a 
large  molecule  which  is  also  expressed  on  the  pRBC  (Ockenhouse  et  al.,  1991)  and  a 
modified  erythrocyte  endogenous  component  derived  from  band  3  (Winograd  & 
Sherman,  1989;  Crandall  &  Sherman,  1994),  selectively  bind  CD36  (Ockenhouse  et 
al.,  1991;  Crandall  et  al.,  1994). 
Cytoadherence  of  pRBC  to  the  endothelium  may  prevent  their  opsonisation  and 
phagocytosis  both  by  physically  blocking  circulating  phagocytic  cells  engulfing 
infected  cells  and  by  preventing  passage  through  the  spleen.  However,  the  pRBC  still 
be  accessible  to  action  of  monocytes,  neutrophils,  NK  cells  or  other  effector  cells 
(reviewed  by  Allred,  1995). 
1.10.2.  Antigenic  variation 
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Cox  (1962)  was  the  first  to  suggest  that  malaria  parasites  undergo  antigenic  variation, 
when  he  studied  mice  infected  with  blood  forms  of  P.  berghei.  Later,  conclusive 
studies  were  made  by  Brown  &  Brown  (1965)  when  working  with  P.  knowlesi.  They 
studied  rhesus  monkeys  infected  with  the  parasite  and  treated  with  antimalarials  at 
subcurative  doses  which  develop  recrudescent  parasitaemias.  This  allowed  them  to 
demonstrate  that  each  recrudescence  was  characterised  by  a  specific  antigen  which 
elicited  a  specific  antibody  response.  Parasites  collected  from  later  relapse 
populations  in  the  same  host  did  not  react  significantly  with  earlier  sera.  These 
findings  have  also  been  confirmed  by  other  authors  using  clone  parasite  lines  of  P. 
knowlesi  (Howard  et  al.,  1983). 
Antigenic  variation  in  P.  falciparum  has  been  observed  in  vivo,  when  using  a  cloned 
line  to  infect  Saimiri  monkeys  (Hommel  et  al.,  1983)  and  in  vitro  (Biggs  et  al.,  1991; 
Roberts  et  al.,  1992).  Antigenic  variation  of  P.  falciparum  can  occur  very  rapidly  in 
vitro,  2%  per  generation,  when  no  immune  pressure  is  being  exerted  (Roberts  et  al., 
1992),  indicating  that  could  be  a  non-induced  event  (reviewed  by  Allred,  1995). 
During  the  period  of  a  single  infection,  asexual  parasites  repeatedly  change  antigens 
presented  to  the  host.  The  new  antigenic  variants  are  little  affected  by  immunity  to 
previous  variants,  and  by  the  time  the  response  to  the  new  antigens  reaches  effective 
levels,  a  newer  variant  is  being  produced.  Such  mechanism  allows  parasite's  survival 
regardless  of  the  effect  of  the  specific  acquired  immunity. 
The  first  evidence  that  P.  chabaudi  undergoes  antigenic  variation  was  observed  in 
experiments  using  NIH  mice.  Immune  sera  proved  to  be  significantly  less  protective 
against  recrudescent  parasites  than  against  their  parent  parasite  (Brannan  et  al., 
1993).  Infection  with  recrudescent  clones  of  P.  chabaudi  has  resulted  in  important 
differences  in  the  course  of  parasitaemia,  with  some  clones  producing  higher  peak 
infections  than  other  (Phillips  et  al.,  1997,  in  press).  It  has  been  suggested  that  this  in 
vivo  difference  may  reflect  alterations  in  immunogenicity  and  functional 
characteristics  associated  with  expression  of  antigenically  variant  antigens  on  the 
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surface  of  the  infected  red  blood  cell  (Phillips  et  al.,  1997,  in  press).  In  P.  falciparum, 
the  PfEMP1  antigen  is  involved  in  antigenic  variation  (Biggs  et  al.,  1991),  and 
undergoes  changes  in  vitro  in  both  apparent  size  and  immunoreactivity  (Magowan  et 
al.,  1988;  Biggs  et  al.,  1992;  Roberts  et  al.,  1992).  The  significance  of  these  changes 
is  not  clear,  but  altered  sequestration  of  these  antigenically  variant  parasites  may 
result  in  increased  pathological  sequelae  and  could  explain  some  of  the  binding 
diversity  observed  in  field  isolates  (Goldring  et  al.,  1992),  and  why  some  young 
children  develop  cerebral  malaria  in  the  absence  of  other  significant  clinical  signs. 
(reviewed  by  Allred,  1995). 
1.10.3.  Antigenic  diversity 
Antigenic  diversity  is  the  expression  of  antigenically  different  forms  of  an  antigen  by 
different  malaria  parasites.  Differences  in  geographical  location,  individuals  within  the 
same  location,  or  bouts  of  malaria  within  the  one  individual;  may  result  in  antigenic 
diversity  of  the  parasite.  Furthermore,  diversity  may  also  be  recognisable  in  pRBCs 
taken  at  various  times  from  a  non-cloned  parasite  isolated  cultivated  in  vitro. 
Antigenic  diversity  has  been  suggested  to  confer,  in  some  occasions,  selective 
advantage  to  the  parasite  by  mechanisms  that  may  be  antibody-independent. 
Significant  antigenic  diversity  in  P.  falciparum  in  humans,  has  been  observed  when 
volunteers  infected  with  the  parasite  showed  more  resistance  when  they  were 
subsequently  challenged  with  a  homologous  strain  than  with  a  heterologous  one  (e.  g. 
Jeffrey,  1966). 
For  many  years,  geographical  variation  in  drug  resistance  and  transmissibility  through 
mosquitoes  has  been  demonstrated  (Shute  et  al.,  1976.  McGregor  et  al.,  (1963)  have 
shown  that  immune  serum  from  West  African  patients  was  less  effective  that  East 
African  serum  on  disease  in  East  Africa. 
Numerous  malarial  antigens  exhibit  antigenic  diversity  in  different  P.  falciparum 
isolates,  e.  g.  the  major  glycoprotein  on  the  surface  of  the  asexual  stage  pRBC 
40 INTRODUCTION 
(reviewed  by  McBride  et  al.,  1982)  and  a  soluble  antigen  released  into  the  plasma 
during  rupture  of  schizont-infected  RBCs  (Wilson,  1980). 
Antigenic  diversity  is  thought  to  be  the  result  of  the  expression  of  different  allelic 
forms  of  a  single  gene.  The  diverse  forms  are  generated  either  by  genetic  re- 
arrangements  during  meiosis  or  by  accumulation  of  mutations.  Heterogeneity  is 
maintained  by  genetic  recombination  in  addition  to  the  mutation,  as  has  been  shown 
in  P.  chabaudi  chabaudi  (Walliker  et  al.,  1975)  and  in  human  malaria  (Walliker  et  al., 
1987). 
1.11.  Immunopathology 
1.11.1.  Non-specific  cell  activation 
Polyclonal  B  lymphocyte  activation  occurred  during  malaria  infection  leads  to  IgG 
hyperproduction  (McGregor  et  at,  1956,  Cohen  &  Butcher,  1969).  In  P.  falciparum 
infection  IgG  produced  is  non-specific  and  has  been  demonstrated  against  a  wide 
range  of  self-antigens,  auto-antibodies  recognising  heart,  thyroid  and  gastric  parietal 
cells  (Shaper  et  at,  1968),  lymphocytes  (Wells  et  at,  1980),  and  erythrocytes 
(Rosenberg  et  al.,  1973;  Ronai  et  at,  1981;  Zoulai  et  at,  1982;  Wahlgren  et  al., 
1983).  High  titres  of  antibodies  to  nuclear  components  (Greenwood  et  al.,  1970;  Adu 
et  al.,  1982),  single  strand  DNA  (Ribeiro  et  al.,  1984),  mitochondria  (Boonpucknavig 
&  Ekapanyakul,  1984),  and  smooth  muscle  (Phanuphak  et  al.,  1983)  have  also  been 
found  in  association  with  malaria  infections. 
Hypergammaglobulinaemia  have  shown  to  be  aT  cell-mediated  event  (Weidanz, 
1982),  probably  due  to  production  of  B  cell-activating  cytokines  (Ballet  et  at,  1987, 
Kabilan  et  al.,  1987). 
1.11.2.  Immunosuppression 
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Antigen-specific  unresponsiveness  is  often  observed  in  association  with  clinical 
disease  among  residents  of  P.  falciparum  endemic  areas  (Ho  et  al.,  1986,  Riley  et  al., 
1988b).  Children  affected  with  malaria  have  been  shown  to  be  deficient  in  their  ability 
to  mount  primary  immune  responses  against  tetanus  toxoid  (McGregor  &  Barr, 
1962),  The  0  Ag  of  S.  typhi  (Greenwood  et  al.,  1972;  Greenwood,  1984)  and  Group 
C  meningococcal  vaccine  (Williamson  &  Greenwood,  1978). 
Immunosuppression  during  malaria  infection  can  be  demonstrated  in  vitro  as  a 
lowered  lymphocyte  response  to  mitogenic  or  antigenic  stimuli.  It  has  been  suggested 
that  NO  may  be  responsible  for  this  malaria-induced  immunosuppression  (reviewed 
by  Mendis  &  Carter,  1995).  Spleen  cells  of  P.  vinckei-infected  mice,  which  showed 
lowered  responsiveness  to  mitogen  stimulation  in  vitro,  restored  to  normal  levels  of 
responsiveness  when  cultured  in  presence  of  NOL-monomethyl  arginine  acetate 
(LNMMA)  (reviewed  by  Mendis  &  Carter,  1995).  During  P.  chabaudi  infection,  the 
immunosuppressed  state  was  reversed  when  LNMMA  was  introduced  into  their 
drinking  water  before  and  during  infection  (Rockett  et  al.,  1994) 
1.11.3.  Cerebral  Malaria 
Cerebral  malaria  (CM)  is  a  serious  complication  of  P.  falciparum  infection  and 
constitutes  the  most  common  cause  of  death  due  to  malaria.  Pathological  changes 
during  CM  include:  vascular  congestion  and  plugging  of  blood  vessels  with  heavily 
parasitised  RBCs  (Polder  et  at,  1983),  brain  oedema  (Oo  et  at,  1987),  and  damage 
of  endothelial  cells  with  altered  capillary  permeability  (Areekul  et  at,  1984; 
Depierreux  et  al.,  1987). 
Two  types  of  phenomenon  have  been  studied  in  attempts  to  understand  the 
underlying  pathogenic  mechanisms  of  CM.  The  first  involves  the  adherence  of  pRBCs 
to  host  cells  in  the  post-capillary  venules  of  the  brain.  The  second,  relates  induction  of 
host  cytokines  with  effects  on  brain  tissues  through  production  of  secondary 
mediators,  such  as  NO  and  free  oxygen  radicals. 
42 INTRODUCTION 
The  most  obvious  cell  to  cell  attachment  involved  in  human  CM  is  that  of  pRBC  with 
the  endothelial  cell  lining  of  blood  vessels  (Trager  et  al.,  1966;  Luse  &  Miller,  1971; 
MacPherson  et  al.,  1985).  Cellular  adhesion  between  pRBCs  and  other  host  cells  , 
including  nRBC  (Handunnetti  et  al.,  1987;  1989)  may  also  be  important  in 
sequestration  and  pathology  of  acute  P.  falciparum  malaria. 
The  molecules  involved  in  the  adhesion  of  pRBC  to  the  endothelial  cell  surface  are: 
vascular  cell  adhesion  molecule  1  (VCAM-1),  intercellular  adhesion  molecule  1 
(ICAM-1)  (Berendt  et  al.,  1989),  endothelial  adhesion  molecule  1  (ELAM-1)  or  E- 
selectin,  CD36  (Oquendo  et  al.,  1989),  and  thrombospondin  (Robert  et  al.,  1985) 
(reviewed  by  Mendis  &  Carter,  1995).  Induction  of  ICAM-1  expression  is  regulated 
by  cytokines  (Staunton  et  al.,  1988),  indeed,  TNFa,  IL-1,  IL-2  and  IFNy  can  all 
upregulate  ICAM-1  levels  on  diverse  cell  types  (Dustin  et  al.,  1986;  Rothlein  et  al., 
1988;  Asarnow  et  al.,  1989).  Berendt  et  al.  (1992)  have  suggested  that  severe 
malaria  may  occur  when  those  individuals  expressing  high  levels  of  ICAM-1  are  also 
infected  with  a  strain  of  malaria  parasite  that  has  a  high  affinity  for  the  molecule.  To 
support  this  theory  they  performed  in  vitro  studies  of  cytoadherence  of  P. 
falciparum  pRBCs  comparing  isolates  form  patients  with  uncomplicated  malaria, 
severe  malaria  or  cerebral  forms  of  the  disease.  They  showed  that  high  binding  of  the 
pRBCs  to  ICAM-1  was  correlated  with  cerebral  involvement  in  the  patients  from 
whom  the  parasites  derived  (Berendt  et  al.,  1992). 
In  the  P.  berghei/CBA/Ca  mouse  model,  it  has  been  demonstrated  that  excessive 
release  of  TNF  plays  a  critical  role  in  the  pathogenesis  of  experimental  CM  (Grau  et 
al.,  1987).  Elevated  serum  TNF  levels  were  seen  only  at  the  time  of  neurological 
syndrome;  in  vivo  depletion  of  CD4+  T  cells,  which  blocks  neurological 
complications,  prevented  the  dramatic  rise  in  serum  titres  of  TNF  (Grau  et  al.,  1986). 
Moreover,  treatment  with  a  single  injection  of  anti-TNF  antibody  exerted  a  protective 
effect  on  the  P.  berghei-induced  neurological  syndrome  (Grau  et  al.,  1987)  and 
prevented  all  forms  of  lesions.  Administration  of  recombinant  murine  TNF  to  a  strain 
of  mouse  resistant  to  CM  induced  a  lethal  neurological  complication  with  all  the 
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clinical  and  histopathological  features  of  CM  (Grau  et  at,  1989b).  These  observations 
show  that  TNF  has  both  beneficial  and  deleterious  effects  depending  on  the  degree  of 
activation,  timing  and  location,  and  thus  may  confer  protective  immunity,  or, 
alternatively  cause  immunopathology  during  malaria  infection. 
In  man,  altered  levels  of  TNF  have  been  reported  in  the  serum  of  malaria  patients 
(Scoured  et  at,  1986;  Van  der  Meid  et  at,  1988;  Grau  et  at,  1989c)  and  the  levels 
have  shown  to  correlate  with  disease  severity.  Indicating  that  TNF  may  also  be  of 
pathogenic  significance  in  human  CM. 
TNF  induces  activation  of  an  inducible  NO  synthase  (iNOS)  to  produce  NO  using 
arginine  as  initial  substrate.  iNOS  activation  due  to  cytokines  results  in  a  rise  of  up  to 
1000-fold  of  NO  concentrations  (reviewed  by  Mendis  &  Carter,  1995)  which  can 
shut  down  important  aspects  of  synaptic  transmission  (Schuma  &  Madison,  1994). 
However,  the  importance  of  this  NO-theory  as  a  basis  of  pathology  in  malaria  remains 
controversial  (reviewed  by  Mendis  &  Carter,  1995). 
1.12.  Inducible  nitric  oxide  synthase  defective  mice 
Mice  lacking  iNOS  were  first  described  by  Wei  et  al.,  (1995).  Wild-type  MF1  mice 
were  manipulated  and  the  NOS  gene  disrupted  in  their  embryonic  stem  cells.  Mice 
heterozygous  for  the  mutation  were  bred  to  obtain  homozygous  which  were  viable 
and  fertile,  with  no  evidence  of  histopathology  within  major  organs.  Peritoneal 
macrophages  from  wild-type  or  heterozygous  mice  produced  substantial  amounts  of 
NO  and  expressed  iNOS'  mRNA  and  iNOS  protein  when  stimulated  with  IFNy  and 
LPS  in  vitro.  On  the  other  hand,  homozygous  mice  produced  an  altered  iNOS 
mRNA,  had  no  detectable  levels  of  iNOS  protein,  and  produced  background  levels  of 
nitrite  (Wei  et  al.,  1995). 
When  challenged  with  L.  major,  wild-type  and  heterozygous  mice  showed  high 
resistance  to  infection.  In  contrast,  NOS  defective  mice  were  highly  susceptible  to 
infection.  Spleen  cells  of  these  mice  had  increased  T-cell  proliferative  responses  when 
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cultured  with  leishmanial  antigens  or  ConA  in  vitro.  Upon  stimulation  with 
leishmanial  antigens,  IFNy  production  was  higher  and  IL-4  lower  by  cells  from 
homozygous  mice  in  comparison  with  wild-type  and  heterozygous  mice  (Wei  et  al., 
1995). 
The  ability  of  these  mice  to  develop  local  inflammation  in  response  to  carrageenin 
injection  has  also  been  studied.  Homozygous  mutant  mice  developed  significantly  less 
footpad  swelling  than  wild-type  mice.  As  when  infected  with  L.  major,  spleen  cells 
from  carrageenin-treated  mice  produced  more  IFNy  than  wild  type  mice.  Mutant  mice 
were  also  more  resistant  to  LPS-induced  death  (Wei  et  al.,  1995). 
1.13.  History  of  Plasmodium  chabaudi  chabaudi 
The  parasite  used  in  this  study,  Plasmodium  chabaudi  chabaudi  AS,  was  isolated 
from  the  blood  of  thicket  rats  (Thamnomys  rutilans)  in  the  Central  African  Republic 
by  Landau  (1965).  The  parasite  infects  mainly  mature  erythrocytes  (Landau,  1965) 
although  it  can  also  invade  reticulocytes  under  conditions  of  anaemia  (Carter  & 
Walliker,  1975;  Jana  &  Brown,  1989).  The  parasite  can  produce  multiple  infection  of 
red  cells  (Carter  &  Walliker,  1975) 
Asexual  stages  of  the  parasite  have  a  synchronous  cycle  of  24  hrs  and,  under  normal 
light  conditions,  rings  and  trophozoites  are  observed  in  peripheral  blood  during  the 
day,  while  schizonts  appear  around  midnight.  Peripheral  withdrawal  of  schizonts  to 
deep  tissue  capillaries  occur  in  this  species  as  schizont  maturation  takes  place 
(Shungu  &  Arnold,  1972;  McDonald,  1977;  McDonald  &  Phillips,  1978;  Gilks  et  al., 
1990). 
Blood  induced  infection  with  P.  chabaudi  AS  strain  in  inbred  NIH  mice  usually  last 
around  60  days.  A  primary  patent  parasitaemia  is  observed  which  is  followed  by  one 
or  two  patent  recrudescences  (Figure  2).  In  its  natural  host,  P.  chabaudi  follows  a 
less  acute  course  of  infection  during  its  early  stages,  persisting,  afterwards,  as  a 
chronic  infection.  In  contrast,  Injection  of  106  pRBC  of  P.  chabaudi  chabaudi  AS 
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result  in  a  fulminant  parasitaemia  in  A/J  mice,  100%  of  animals  died  with  a  mean 
survival  time  of  10  days  (Stevenson  et  al.,  1990a). 
46 Days  after  malaria  infection 
Figure  2.  The  course  of  P.  chabaudi  chabaudi  AS  infection  usually 
observed  in  naive  NIH. INTRODUCTION 
1.14.  Aim  of  the  Project 
The  nature  of  the  protective  immune  response  against  malaria  is  not  completely 
understood.  Murine  models  of  malaria  infection  have  been  widely  used  to  study  some 
of  the  factors  responsible  for  acquisition  to  immunity  against  the  infection.  Indeed  a 
great  part  of  the  knowledge  of  the  biology,  immunology  and  biochemistry  of  the 
malaria  parasites  comes  from  studies  using  rodent  malarias. 
The  murine  parasite  P.  chabaudi  AS  is  widely  recognised  as  a  model  of  the  human  P. 
falciparum  (Mons  &  Sinden,  1990).  Asexual  stages  of  these  parasites  possess  a 
synchronised  asexual  cycle  in  the  circulation  and  their  late  asexual  stages  undergo 
sequestration  in  deep  tissues  (MacDonald  &  Phillips,  1978;  Gilks  et  al.,  1990). 
P.  chabaudi  infection  in  the  thicket  rat,  the  natural  host,  is  essentially  lifelong. 
Immunocompetent  NIH  mice  have  a  genetically  controlled  resistance  to  P.  chabaudi 
infection.  After  blood  infection  with  the  parasite,  they  exhibit  a  high  primary 
parasitaemia  which  is  followed  by  one  or  two  recrudescenses  and  after  8-10  weeks, 
the  infection  is  controlled.  On  the  other  hand,  A/J  mice  infected  with  blood  forms  of 
P.  chabaudi,  normally  have  a  fulminant  parasitaemia  which  results  in  100%  mortality 
within  2  weeks  of  infection  (Stevenson  &  Ghadirian,  1989). 
It  is  now  generally  agreed  that  acquisition  of  immunity  to  P.  chabaudi  by  'resistant' 
strains  (such  as  NIH)  of  mice,  is  dependent  on  CD4+  T  cells,  with  both  TH1  and  TH2 
playing  a  crucial  role.  TH1  cells  seem  to  be  dominant  in  the  control  of  the  primary 
parasitaemia,  while  TH2  are  predominant  in  the  control  of  recrudescenses  (reviewed 
by  Phillips  et  al.,  1997,  in  press).  However,  unravelling  the  interactions  of  CD4+  T 
cells,  cytokines  and  effector  mechanisms  against  P.  chabaudi,  has  proved  complex. 
Phillips  et  al.  (1997,  in  press)  have  suggested  that  the  initial  control  of  the  rising 
parasitaemia  is  mediated  through  non-specific  effector  mechanisms,  which  are  largely 
driven  by  TH1  cells.  Others  have  shown  that  treatment  of  mice  with  IFN  y  has  a 
protective  affect  against  blood  stage  P.  chabaudi  infection  in  'susceptible'  mice 
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(Stevenson  et  al.,  1990),  while  injection  of  TNFa  into  susceptible  mice  resulted  in 
protection  against  infection  (Stevenson  &  Ghadirian,  1989). 
The  experiments  described  in  this  thesis  aimed  to  assess  further  the  role  of  T  cells 
during  the  acquisition  of  immunity  against  P.  chabaudi  AS  strain.  Initial  experiments 
were  designed  to  define  the  feasibility  of  utilising  a  S.  typhimurium  mutant  as  a 
delivery  vehicle  for  cytokines  by  studying  the  effects  of  their  inoculation  on  the 
course  of  P.  chabaudi  infection.  This  was  followed  by  studies  on  the  role  of  the 
different  TH1  and  TH2  cytokines,  such  as  IFNy,  TNFa,  TGFß  or  IL-4,  in  host 
defence  against  the  infection  in  'resistant'  NIH  and  'susceptible'  A/J  mice.  The 
cytokines  were  delivered  in  vivo  using  the  S.  typhimurium  recombinant  system 
described  by  Carrier  et  al.  (1992).  The  confirmation  that  a  S.  typhimurium  mutant  can 
be  used  in  malaria  infection  to  deliver  murine  cytokines  in  vivo  would  also  be  an 
important  contribution  in  the  study  of  a  malaria  vaccine.  The  long  term  intention  of 
this  work  is  to  achieve  coexpression  of  malarial  antigens  and  cytokine  genes  by  S. 
typhimurium  and  to  obtain  a  synergistic  action  for  acquisition  of  malaria  immunity. 
Another  approach  might  be  the  vaccination  against  malaria  of  individuals  inoculated 
with  S.  typhimurium  expressing  cytokines,  in  this  case  the  cytokine(s)  would  enhance 
the  immune  response  against  the  malarial  antigens. 
Previously,  others  have  demonstrated  that,  in  NIH  mice,  NO  plays  a  significant  role  in 
host  control  of  the  primary  patent  parasitaemia  but  has  no  effect  on  the  control  of 
recrudescences  (reviewed  by  Taylor-Robinson,  1996).  Recently  available  inducible- 
NO-synthase(iNOS)-deficient  mice  might  constitute  a  valuable  model  in 
understanding  the  in  vivo  role  of  NO  in  the  control  of  a  murine  infection  with  P. 
chabaudi.  To  investigate  this,  the  course  of  a  blood  infection  in  these  mice  was 
followed  and  changes  in  humoral  and  cellular  responses  were  evaluated. 
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2.1.  Mice 
Three  different  strains  of  mice  were  used:  inbred  NIH  and  A/J,  and  outbred  inducible 
nitric  oxide  synthase  (iNOS)  knockout  mice. 
Female  NIH  and  A/J  mice  were  purchased  from  Harlan  Olac  (Bicester,  UK)  and  kept 
in  the  Wellcome  Laboratories  for  Experimental  Parasitology  (WLEP)  animal  house 
breeding  facility  or  in  the  Joint  Animal  Facility  at  Glasgow  University.  Rooms  were 
maintained  at  22  C±2C  and  50-60%  relative  humidity  with  12  hours  artificial 
light  from  0800  to  2000  or  0700  to  1900  hr.  Mice  were  fed  pelleted  CRM  breeder 
diet  (Labsure  Ltd).  Both  water  and  food  were  administered  on  an  ad  libitum  basis. 
All  mice  were  used  for  experimental  purposes  when  they  were  6-12  weeks  old  and 
weighed  approximately  25  g. 
iNOS  depleted  mice  were  provided  by  the  Department  of  Immunology  of  the 
University  of  Glasgow.  These  mice  originated  from  the  strain  MF1  but  due  to  a 
mutation  in  the  iNOS  gene  they  have  a  deficient  production  of  the  enzyme  and 
therefore  of  the  inducible  form  of  NO  (Wei  et  al.,  1995).  Mice  that  are  heterozygous 
for  the  mutation  produce  the  enzyme  normally  and  were  used  as  controls. 
2.2.  Parasites 
The  AS  strain  of  Plasmodium  chabaudi  chabaudi  was  originally  isolated  from  adult 
thicket  rats  (Thamnomys  rutilans)  caught  at  La  Maboke,  Central  African  Republic,  in 
March  1969  by  Professor  David  Walliker  (University  of  Edinburgh).  The  strain  was 
established  in  laboratory  mice  and  then  cloned  by  limiting  dilution  (Walliker  et  al., 
1971).  The  parasites  were  supplied  to  the  Department  of  Zoology,  University  of 
Glasgow,  by  Professor  Walliker  in  1973.  Since  then,  the  parent  AS  clone  has  been 
maintained  by  cryopreservation  and  subpassage  through  mice  (see  below)  (Figure  3). 
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Figure  3.  History  of  Plasmodium  chabaudi  chabaudi  AS  strain. MATERIALS  &  METHODS 
2.3.  Maintenance  of  parasites 
Suspensions  of  pRBCs  taken  at  a  specific  time  from  a  known  source  were  designated 
stabilates  as  proposed  by  Lumsen  &  Hardy  (1965).  For  long  term  preservation 
stabilates  of  P.  chabaudi  AS  strain  are  kept  in  liquid  N2  (-196_C).  When  required  for 
experimental  use,  infected  blood  was  recovered  from  liquid  N2  and  defrosted  by 
immersion  of  the  vial  in  a  37_C  waterbath  (Gallencamp),  then  diluted  in  an  equal 
amount  of  a  solution  of  sorbitol  (17.5%  sorbitol  in  PBS  pH  7.2)  added  slowly 
dropwise  with  frequent  mixing.  This  was  immediately  followed  by  i.  p.  injection  into 
one  or  two  recipient  naive  mice. 
Parasites  were  maintained  by  blood  passage  in  mice  every  2-4  days.  The  mice  were 
sacrificed  in  a  CO2  chamber  and  infected  blood  was  obtained  by  cardiac  puncture.  For 
this  blood  was  collected  into  a  syringe  containing  0.1  ml  sodium  heparin  (10  IU/ml) 
in  PBS  (pH  7.2)  as  an  anticoagulant.  The  infected  blood  was  sub-inoculated  i.  v.  into 
recipient  mice.  The  infected  blood  was  subinoculated  into  naive  recipient  mice  either 
by  i.  v.  or  i.  p.  injection.  Experimental  mice  were  infected  with  blood  one  passage  from 
stabilate. 
2.4.  Cryopreservation  of  blood 
Blood  with  a  parasitaemia  of  5-10%  containing  ring  stage  parasites,  was  collected  by 
cardiac  puncture  as  described  above  and  diluted  1:  1  with  a  solution  of  sorbitol- 
glycerol  (see  2.3),  added  slowly  with  frequent  mixing  (Gray  &  Phillips,  1981).  200  µl 
aliquots  were  dispensed  into  1.2  ml  cryopreservation  vials;  a  code  was  assigned  to 
each  of  them.  These  were  immediately  snap  frozen  by  immersing  in  liquid  N2  and 
stored. 
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2.5.  Challenge  infections 
Infected  blood  for  challenge  was  obtained  by  cardiac  puncture  immediately  after  the 
mice  were  sacrificed  in  a  CO2  chamber.  Giemsa's  stained  thin  blood  smears  were 
used  to  evaluate  the  donor's  parasitaemia  and  the  blood  was  diluted  to  the  required 
concentration  of  pRBCs/ml  in  RPMI  1640  medium  (Moore  et  al.,  1967) 
Before  infection,  the  mice  were  placed  in  a  warm  box  at  32_C  for  10  min  in  order  to 
allow  vasodilatation  and  200  µl  (1  x  105  or  1x  106  pRBC)  of  the  suspension  of 
pRBCs  were  administered  via  one  of  the  lateral  tail  veins.  For  this  purpose  a1  ml 
syringe  fitted  with  a  26G  needle  was  used. 
2.6.  Determination  of  parasitaemias 
Parasitaemias  were  determined  by  daily  examination  of  Giemsa's  stained  thin  blood 
smears  made  from  peripheral  blood.  Samples  were  taken  between  0900-10:  30  hr 
every  day  by  piercing  the  tip  of  the  tail  with  a  lancet.  A  new  lancet  was  used  for  each 
group  of  mice  and  within  the  group  this  was  routinely  dipped  in  alcohol  in  order  to 
minimise  the  possibility  of  transfer  of  infected  erythrocytes  between  animals.  A  drop 
of  blood  was  placed  onto  washed  glass  microscope  slides,  smeared  and  air  dried  at 
room  temperature  (RT).  Smears  were  fixed  in  100%  methanol  and  incubated  for  20 
min  in  a  solution  1:  10  of  Giemsa  stain  in  Giemsa's  phosphate  buffer  (pH  7.2).  They 
were  then  rinsed  in  tap  water,  air  dried  and  examined  under  the  microscope  at  x1000. 
Parasitaemias  were  obtained  by  calculating  the  proportion  of  parasitised  red  blood 
cells  (pRBC)  from  a  total  number  of  red  blood  cells  (RBC).  For  this,  at  least  20 
fields  containing  between  200  and  300  erythrocytes  were  examined.  Infection  was 
considered  sub-patent  when  no  parasites  were  observed  in  50  fields.  Smears  were 
normally  taken  from  day  3  to  60  post-infection. 
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2.7.  Presentation  of  parasitaemic  data 
The  geometric  mean  of  the  parasitaemia  (mean  Log10  of  the  number  of  pRBC  in  105 
RBC)  of  a  group  of  mice  was  plotted  against  time  (expressed  in  days)  and  the 
resultant  graph  expressed  the  course  of  infection.  Vertical  bars  showing  S.  D.  are 
included  when  differences  in  the  courses  of  parasitaemia  among  different 
experimental  groups  are  not  self-evident.  ' 
From  the  data  collected  and  their  graphical  presentation,  five  main  criteria  were  used 
to  evaluate  the  effects  of  protective  immune  responses  on  challenge  parasitaemias. 
These  were  (i)  the  time  taken  for  mice  to  show  a  2%  parasitaemia  (the  pre-2%  latent 
period)  (Warhurst,  1966); 
_(ii)  the  day  and  level  of  the  peak  parasitaemia;  (iii)  any 
"I 
extension  of  the  time  taken  for  the  primary  parasitaemia  to  be  resolved  relative  to 
controls  (assessed  by  recording  the  total  time  for  the  parasitaemia  to  rise  from  the  2% 
level  to  peak  and  then  to  fall  to  subpatency)  (a  modification  of  the  data  evaluation  of 
Jarra-,  et  al.,  1986));  (iv)  any  extension  of  the  pre-recrudescent  subpatent  period 
relative  to  controls;  (v)  survival  to  infection  in  the  case  of  'susceptible'  mice. 
In  all  experiments,  the  minimum  number  of  mice  in  each  experimental  group  was  5. 
For  such  a  group  size,  the  reproducibility  of  individual  parasitaemia  determinations, 
which  includes  the  variable  of  smear  preparation  as  well  as  the  parasite  counting,  is 
close  to  predicted  theoretical  minimal  level  calculated  using  the  binomial  distribution 
(Gilks,  1988).  Groups  of  at  least  5  mice  were  used  so  that  the  random  scatter  of 
parasitaemias  would  be  expressed  to  cancel  each  other  out.  Thus,  parasitaemia  curves 
are  relatively  smooth.  Despite  these  precautions,  some  variability  was  encountered  in 
the  counts,  especially  after  crisis  and  resolution  of  the  primary  parasitaemia.  The  data 
were  transformed  using  Microsoft  excel  version  6.0  on  a  Viglen  Genie  Professional 
45x25  PC  and  Cricket  graph  III  1.5  on  an  Apple  Macintosh  Performa  630 
microcomputer.  Nonparametric  statistical  analysis  was  performed  on  parasitaemia 
data  using  the  Microsoft  excel  program  on  a  PC. 
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2.8.  Haematology 
2.8.1.  Haematocrit 
Heparinised  capillaries  were  used  to  collect  blood  from  the  tip  of  the  tail  as  described 
above.  Samples  were  centrifuged  for  5  min  at  12,000  g  in  a  micro-haematocrit 
centrifuge  (Hawksley)  and  the  proportion  of  the  column  of  packed  red  blood  cells 
(haematocrit)  was  determined  using  a  haematocrit  reader  (Hawksley). 
2.8.2.  Reticulocytes 
Peripheral  blood  obtained  from  the  tail  was  used  to  determine  the  proportion  of 
immature  red  blood  cells  or  reticulocytaemia.  For  this  purpose  a  drop  of  blood  was 
smeared  onto  1%  brillial  cresyl  blue  pre-treated  glass  slides.  They  were  incubated  for 
30  minutes  in  a  humidified  chamber  at  RT  and,  after  drying,  stained  with  Giemsa's 
stain  as  for  determination  of  parasitaemia.  Remnant  nuclear  material  present  in 
immature  erythrocytes  is  observed  as  dark  blue  spots  distributed  within  the  cell.  The 
proportion  of  reticulocytes  and  mature  red  blood  cells  was  determined  by  observation 
under  x1000  and  presented  as  a  percentage. 
2.9.  Collection  of  serum 
Large  volumes  of  sera  were  collected  after  exsanguination  by  cardiac  puncture 
immediately  after  sacrificing  the  mice.  Blood  was  allowed  to  clot  and  this  was 
loosened  from  the  edges  of  the  container  and  left  to  contract  for  1  hour  at  37 
_C 
(or 
overnight  at  RT).  The  overlying  serum  was  collected  by  pipetting  and  contaminating 
RBC  were  removed  by  centrifugation  (300  g  for  5  min).  The  cleared  serum  was  then 
aliquoted  and  stored  frozen  at  -20  C  until  required. 
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For  collection  of  smaller  volumes  of  serum,  mice  were  warmed  in  a  warm  box  at 
32_C  for  10  min  and  up  to  100  µl  of  blood  were  withdrawn  from  the  tail.  The  blood 
was  processed  as  for  larger  volumes. 
For  the  collection  of  immune  serum  from  infected  mice  to  study  the  levels  of  specific 
anti-malarial  antibodies  or  levels  of  nitric  oxide  (as  nitrate)  during  the  course  of 
infection,  serum  was  collected  from  individual  mice  in  different  experimental  groups 
at  2-3  days  intervals  from  days  0  to  60  post-infection.  Within  each  group,  every 
mouse  was  bled  on  an  equal  number  of  occasions  to  ensure  that  anaemia  did  not 
result  from  repeated  bleeding  of  an  individual  mouse. 
2.10.  Determination  of  anti-malarial  antibody  titres 
The  slide  IFAT  procedure  of  Van  Meirvenne  et  al.  (1975)  modified  by  McLean  et  al. 
(1982)  was  used  to  establish  total  anti-parasite  antibody  present  in  serum  of  infected 
mice.  The  technique  is  based  on  the  indirect  fluorescent  antibody  method  for  malaria 
parasites  as  described  by  Voller  (1964)  and  O'Neill  &  Johnson  (1970). 
2.11.  Preparation  of  malarial  antigen  slides 
Trophozoite/schizont  stage  parasites  were  collected  from  infected  mice  and  used  as 
the  source  of  antigen.  Donor  mice  with  a  rising  parasitaemia  of  5-15%  were  bled  into 
0.1  ml of  heparin  up  to  a  final  concentration  of  10  IU.  /ml.  pRBCs  were  washed  three 
times  in  20  ml  PBS  (pH  7.2)  by  centrifugation  (250  g  for  5  min)  and  resuspended. 
The  final  pellet  of  cells  was  resuspended  to  at  about  a  half  of  the  original  blood 
volume  and  used  to  make  thin  blood  smears  covering  the  microscope  slide.  The 
slides  were  dehydrated  overnight  in  a  desiccator,  wrapped  in  tissue  in  batches  of  five, 
packed  with  silica  gel  and  stored  at  -20  _C 
until  required  (Manawadu  &  Voller, 
1978). 
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2.11.1.  Assay 
To  avoid  condensation,  slides  stored  at  -20  _C 
were  brought  up  to  RT  in  a  desiccator 
for  1-2  hours  before  use.  They  were  then  fixed  in  absolute  acetone  (Rhone-Poulenc 
Ltd.  )  for  5  min  and  air  dried.  Reaction  zones  were  marked  on  the  antigen  slides  using 
an  H  series  tex  pen  (Deacon  Laboratories).  The  slides  were  washed  into  successive 
coplin  jars  of  PBS,  drained  and  rehydrated  in  a  third  jar  of  PBS  (pH  7.2)  for  15  min. 
From  this  point  slides  were  never  allowed  to  dry  as  this  would  impair  fluorescence. 
The  area  around  each  reaction  zone  was  dried  and  20  µl  of  a  serial  1:  2  dilution  of 
test  and  control  sera  were  applied  to  reaction  zones.  Each  slide  had  PBS  (to  act  as  a 
control  for  non-specific  fluorescence),  a  negative  serum  and  a  hyperimmune  serum 
as  controls.  The  slides  were  incubated  for  15  min  at  RT  in  a  humidified  chamber,  then 
washed  and  rehydrated  as  above.  They  were  recovered  from  PBS  and  the  edges 
dried.  Then,  each  slide  was  applied  with  1  ml  of  FITC-conjugated  sheep  anti-mouse 
IgG  (Scottish  Antibody  Production  Unit  (SAPU))  diluted  1:  200  in  PBS  containing 
Evans  Blue  (1:  10,000  w/v)  (Merck)  and  incubated  for  15  min.  The  Evans  Blue  acts 
as  counterstain  (EI  Nahel  &  Bray,  1963).  Finally,  the  slides  were  washed  to  remove 
excess  conjugate  and  rehydrated  in  fresh  PBS  before  mounting  under  a  long  coverslip 
with  a  1:  1  solution  of  non-fluorescent  PBS-glycerol  (Merck). 
2.11.2.  Examination  of  slides 
A  Leitz  Ortholux  microscope  was  used  to  observe  fluorescence.  The  microscope  was 
linked  to  an  Epson  PX4  computer  through  a  Leitz  MPV  Compact  2  microscope 
photometer.  The  overhead  u.  v.  source  used  was  a  Wotan  HBO-50  mercury  lamp  with 
2x  kP490  exciting  filters  and  a  TK  510  dichronic  beam-splitting  mirror  and  a  k515 
suppression  filter. 
The  slides  were  examined  at  x  500  using  a  water  immersion  objective.  The  titre 
(endpoint)  of  the  serum  was  donsidered  to  be  the  last  dilution  of  serum  at  which 
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specific  fluorescence  was  observed.  The  control  zones  of  hyper-immune  and  normal 
serum,  as  well  as  that  of  PBS  only,  were  examined  for  comparison. 
2.12.  Determination  of  nitric  oxide  levels 
Nitrate  serum  levels  were  determined  as  a  measure  of  nitric  oxide  (NO)  production, 
nitrogen  oxidation  of  L-arginine  results  in  the  release  of  the  highly  reactive 
intermediate  NO,  which  has  a  half-life  of  milliseconds  before  being  further  oxidisation 
to  nitrite  (NO2)  and  nitrate  (NO3-).  Both  NO2-  and  NO3-  are  more  stable  forms  and 
can  be  detected  in  serum  as  a  result  of  NO  production  (reviewed  by  Green  et  al., 
1990).  Nitrate  serum  levels  were  determined  using  the  conversion  test  described  by 
Moncada  et  al.  (1991).  The  degree  of  conversion  was  assessed  by  the  Greiss  reaction 
(Migliorini  et  al.,  1991)  or  by  chemiluminescence  (Palmer  et  al.,  1987;  Dowes  et  al., 
1976).  This  was  set  up  in  96  well  v-bottomed  microtitre  plates  (Sterilin).  Standards 
of  both  NO2  and  NO3-  were  prepared  in  the  range  of  0-300  p.  M  by  diluting  a  10-2 
mM  stock  solution  of  NaNO2  and  NaNO3  respectively  in  distilled  water.  30  µ1  of  the 
standards  and  the  samples  were  plated  out  in  duplicate  and  then  30  p.  1  of  conversion 
buffer  (Appendix)  containing  the  enzyme  nitrate  reductase  and  the  cofactors  NADPH 
and  FAD  added.  The  plate  was  incubated  at  37 
_C 
for  two  hours,  after  which  time 
they  assayed  for  NO2-  or  frozen  at  -20  _C 
for  later  evaluation. 
The  Greiss  reaction  for  nitrite  analysis  was  carried  out  in  96-well  flat  bottomed  plates. 
50µl  of  samples  and  standards  were  plated  in  duplicate  and  50µl  of  the  Greiss  reagent 
(Appendix)  added  to  each  well.  After  10  minutes  of  incubation  at  room  temperature, 
the  plate  was  read  in  an  ELISA  reader  (Titertek  Multiskan  MCC/340)  at  540  nm. 
Nitrite  levels  were  read  from  the  standard  curve. 
In  some  cases,  a  chemiluminescence  method  was  used  for  the  determination  of  NO2. 
Briefly,  20µ1  of  sample  were  injected,  using  a  Hamilton  syringe,  into  a  reaction  vessel 
containing  75  ml  1%  sodium  iodide  in  glacial  acetic  acid  under  reflux.  NO  was 
removed  from  the  refluxing  mixture  under  reduced  pressure  in  a  stream  of  N2,  mixed 
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with  ozone  and  the  chemiluminiscent  product  measured  with  a  photomultiplier 
(Model  2107  Chemiluminescent  Nitric  Oxide  analyser,  Dasibi  Environmental 
Corporation),  and  quantified  by  reference  to  1  min  infusions  of  authentic  NO  into  the 
reflux  vessel.  Nitrite  levels  were  read  from  the  standard  curve. 
2.13.  Preparation  of  spleen  cell  suspensions 
Suspensions  of  spleen  cells  suitable  for  in  vitro  proliferation  were  prepared  as 
follows.  Mice  were  sacrificed  and  the  spleens  dissected  out  aseptically.  Each  spleen 
was  placed  in  a  9cm  Petri  disc  (Sterilin)  containing  incomplete  RPMI  1640  medium. 
The  spleens  were  cut  into  pieces  and  dissociated  by  pushing  through  a  sterile  stainless 
steel  sieve  (mesh  size  0.025  mm2)  using  the  inside  of  a  plunger  of  a  syringe,  and 
collected  into  the  medium.  The  cells  were  disaggregated  by  aspiration  through  a 
Pasteur  pipette,  and  the  supernatant  collected  after  tissue  debris  and  clumps  of  cells 
were  sedimented.  The  spleen  cells  were  washed  twice  by  centrifugation  at  250g  for  5 
min,  and  the  medium  was  changed after  each  wash.  The  final  pellet  was  resuspended 
in  1  ml  of  10%  FCS  RPMI  1640  medium. 
Contaminating  erythrocytes  were  removed  by  lysis.  For  this  1  ml  of  spleen  cell 
suspension  was  incubated  with  9  ml  0.83%  Tris-ammonium  chloride  (pH  7.4) 
(Appendix)  for  5  min  at  RT  (Boyle,  1968).  The  suspension  was  washed  twice  with 
10%  FCS  RPMI  1640  medium  at  250  g  for  5  min.  The  pellet  was  resuspended  in  1  ml 
of  10%  FCS  RPMI  1640  medium  and  appropriate  dilutions  were  made  to  determine 
cell  viability  (see  below). 
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2.14.  Determination  of  cell  viability 
The  viability  of  spleen  cell  preparations  was  measured  by  the  trypan  blue  dye 
exclusion  test  (Naysmith  &  James,  1968;  recommended  by  Jerne  et  al.,  1974).  A 
dilution  1:  10  or  1:  100  of  spleen  cells  in  PBS  (pH  7.2)  was  prepared  and  a  further  1:  1 
dilution  was  made  with  a  solution  of  0.2%  w/v  trypan  blue  (Gurr,  BDH  Ltd.  )  in  PBS 
(pH  7.2).  The  suspension  was  mixed  thoroughly  and  incubated  at  RT  for  2-3  min 
before  being  examined  by  phase  contrast  under  immersion  oil  (x1000)  on  a  light 
microscope.  Dead  cells  were  unable  to  exclude  the  vital  dye  and  stained  blue, 
whereas  viable  cells  remained  clear.  At  least  100  cells  were  observed  and  the 
proportion  of  live  to  dead  cells  was  expressed  as  a  percentage  viability,  and 
adjustments  to  total  cell  numbers  made  accordingly. 
2.15.  Proliferative  assays 
Spleen  cell  suspensions  were  prepared  as  described  above.  The  cells  were  adjusted  to 
a  final  concentration  of  1x106/ml  in  10%  FCS  RPMI  1640  medium.  Aliquots  of  200 
µl  in  triplicate  were  incubated  in  96  well  flat-bottomed  microtitre  plates  (Nunc)  with 
a  crude  P.  chabaudi  antigen  (200  µg/ml),  a  normal  RBC  antigen  (200  µg/ml),  ConA 
(5  gg/ml)  or  RPMI  1640  medium.  In  some  cases,  a  fresh  infected  red  blood  cell 
antigen  was  used  at  a  final  concentration  of  2x  106/ml  (see  2.18),  and  the  control 
cultures  were  incubated  with  a  non-infected  RBC  fresh  antigen  or  RPMI  1640 
medium.  Cells  were  incubated  at  37 
_C 
in  humidified  5%  CO2  atmosphere  for  72 
hours.  At  the  end  of  which  each  well  was  pulsed  with  1p  Ci  (37kBq)  of  [3H-methyl] 
thymidine  (Amersham  International)  diluted  in  10µl  of  10%  FCS  RPMI  1640 
medium.  After  a  further  18  hours  incubation,  the  wells  were  harvested  with  a  semi- 
automatic  cell  harvester  (Titertek,  Flow)  onto  glass  fibre  filter  paper  (FG/A, 
Whatman),  washed  twice  with  distilled  water  and  air  dried.  Each  filter  disc  was 
transferred  to  plastic  beta  vials  (LKB)  and  2  ml  non-aqueous  scintillation  fluid 
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(Optiscint  'safe',  LKB)  added  using  an  automated  dispenser  (Jencons  (Scientific) 
Ltd.  ).  All  the  insert  tubes  were  lidded,  labelled  and  placed  inside  outer  plastic 
scintillation  vials  ready  for  counting.  The  beta  activity  present  in  each  sample  was 
detected  during  1  min  using  a  scintillation  counter  (LKB  Wallac  1219  Rackbeta)  and 
quantified  on  a  programmed  computer  (Viglen  Genie  Professional  45x25). 
For  individual  wells,  total  counts  per  minute  were  measured,  from  which  the 
arithmetic  mean  for  triplicate  wells  could  be  calculated.  Cells  were  considered  to 
have  given  a  positive  proliferative  response  if  their  counts  were  32S.  D.  than  the 
values  of  the  appropriates  negative  controls. 
2.16.  Preparation  of  parasitised  and  normal  red  blood  cells  lysates 
For  use  in  stimulation  of  spleen  cells,  soluble  crude  P.  chabaudi  chabaudi  AS  strain 
antigens  were  prepared  from  whole  blood  cells  enriched  for  mature 
trophozoite/schizont-infected  RBCs.  Since  sequestration  of  mature  forms  occurs  in 
vivo,  a  modification  of  the  method  described  by  McDonald  &  Sherman  (1980)  was 
used  obtain  a  mature  forms  of  the  parasite  in  vitro  . 
Mice  to  be  used  as  the  source  of  antigen  were  kept  under  reversed  light  (12  hr  light 
between  19:  00-07:  00  hr)  conditions  for  a  minimum  of  10  days  before  infection, 
therefore  schizogony  which  under  normal  light  condition  would  occur  at  around 
01:  00  hr,  occurred  between  1100-1300  hr  (Jarra  &  Brown,  1985). 
When  mice  reached  peak  parasitaemia  (around  40%)  they  were  sacrificed  and  bled  by 
cardiac  puncture  into  an  heparinised  syringe  (0.1  ml  of  10  IU.  /ml  PBS).  RBCs 
containing  mainly  late  ring  stages  were  washed  twice  in  5%  FCS  RPMI  1640 
medium  at  200  g  for  5  min.  The  pellet  of  RBC  was  resuspended  to  a  10% 
haematocrit  in  the  same  medium  and  incubated  using  the  candle  jar  method  (Trager 
&  Jensen,  1976).  For  this  1.5  ml  of  the  RBCs  suspension  were  dispensed  in  35  mm 
Petri  dishes  (Cel-Cult,  Sterilin),  then  placed  together  with  a  candle  in  a  humidified 
glass  dessicator.  The  candle  lit  and  the  lid  put  on  with  the  stopcock  open.  When  the 
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candle  flame  started  to  extinguished,  the  stopcock  was  closed.  This  provided  a  gas 
phase  of  approximately  3%  CO2  and  15-17%  02.  The  candle  jar  was  placed  in  a 
37_C  incubator  until  the  parasites  had  reached  the  schizont  stage;  this  was  monitored 
every  30  min  by  examination  of  Giemsa's  stained  thin  blood  smears. 
After  harvesting,  the  cells  were  washed  in  5%  FCS  RPMI  1640  medium  at  200  g  for 
5  min  and  resuspended  to  their  original  volume  in  sterile  PBS.  The  blood  solution 
was  filtered  through  sterile  Whatman  CF11  powdered  cellulose  paper  columns  to 
remove  leukocytes  (Beutler  et  al.,  1976)  and  the  filtrate  subsequently  washed  in  5% 
FCS  RPMI  1640  medium  at  200  g  for  5  min.  The  pellet  containing  the  malaria 
parasites  was  restored  to  its  original  volume  in  PBS  (pH  7.2)  and  then  freeze-thawed 
five  times.  Each  cycle  of  freeze-thawing  entailed  snap  freezing  the  preparation  by 
plunging  into  liquid  N2,  then  immediately  defrosting  the  suspension  in  a  37  C 
waterbath  (Gallencamp).  The  disrupted  pRBC  suspension  was  centrifuged  at  1500  g 
for  10  min  and  the  supernatant  fluid  collected.  This  was  termed  the  pRBC  lysate 
antigen  and  was  stored  in  20  µl  aliquots  at  -20  _C 
until  required. 
Non-infected  blood  was  used  for  the  preparation  of  a  RBC  antigen.  For  this  the  same 
procedure  was  followed  as  for  the  preparation  of  the  pRBC  lysate  antigen  excluding 
the  steps  of  culturing  the  pRBC.  The  antigen  obtained  from  non-  infected  RBC  was 
called  nRBC  lysate  antigen.  This  antigen  was  used  as  a  control  for  testing  antigen 
specificity  (Dodge  et  al.,  1963). 
2.17.  Determination  of  total  protein  concentration 
A  quantitative  estimation  of  total  protein  present  in  the  RBC  lysate  antigens  was 
determined  using  the  method  described  by  Smith  et  al.  (1985).  The  assay  can  be  used 
to  measure  protein  concentration  in  the  range  150-1500  µg/ml,  where  the  colour 
response  is  relative  linear,  allowing  quick,  accurate  determinations.  For  this  known 
protein  concentrations  ranging  between  150-1500  p.  g/ml  were  prepared  by  diluting  2 
mg/ml  stock  bovine  serum  albumin  (BSA)  standard  (Pierce  Chemical  Co.  )  in 
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deionised  water.  5  ml  protein  assay  reagent  was  added  to  100  µl  of  each  of  the 
diluted  standards  or unknown  protein  samples  in  16  x  100  mm  clear,  clean  test  tubes. 
The  samples  were  mixed  well  and  the  absorbance  at  595  nm  was  read  versus 
deionised  water  using  a  spectophotometer  (Pye  Unicam  PU  8600).  The  net 
absorbance  of  each  standard  or  unknown  protein  sample  was  obtained  by  substracting 
the  absorbance  of  deionised  water  from  each  sample.  A  standard  curve  was 
constructed  from  which  the  protein  concentration  for  each  unknown  sample  was 
determined. 
2.18.  Preparation  of  a  fresh  antigen  of  P.  chabaudi 
A  fresh  antigen  of  P.  chabaudi  was  used  in  some  of  the  lymphoproliferative  assays. 
This  was  prepared  from  infected  blood  of  one  mouse  which  was  obtained  into 
heparinised  PBS  (10  IU/ml)  by  cardiac  puncture.  Parasitaemia  was  determined  (see 
2.6)  and  the  blood  was  washed  twice  in  RPMI  1640  medium.  Then,  the  pRBCs  were 
resuspended  in  medium  to  obtain  a  concentration  of  2x  106  or  2x  105  pRBCs/ml  (for 
a  final  concentration  in  the  well  of  106  or  105  pRBCs/ml).  A  control  antigen  was 
prepared  following  identical  procedure  using  blood  of  a  naive  mice.  The 
concentration  of  RBCs  of  the  control  antigen  was  defined  by  the  total  number  of  cell 
at  which  the  pRBC  antigen  was  prepared  (pRBC  plus  non-infected  RBC). 
2.19.  Salmonella  typhimurium  mutants 
The  S.  typhimurium  BRD509  mutant  is  an  aroA-,  aroD-  strain  derived  from  S. 
typhimurium  SL1344  (Strugnell  et  al.,  1992).  The  plasmids  NB/IFNy,  NB/TNFcc, 
NB/TGFP  or  NB/IL-4  were  transformed  into  the  mutant  at  the  Department  of 
Immunology  of  the  University  of  Glasgow  using  previous  published  procedures 
(Carrier  et  al.,  1992).  A  S.  typhimurium  mutant  not  carrying  cytokines  genes,  was 
used  as  a  bacteria  control. 
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2.20.  Bacteria  culture 
Bacteria  were  received  and  routinely  cultured  in  Millers-modified  Luria  Broth  (L- 
broth)  (Gibco  BRL,  Life  Technologies)  consisting  of  1%  SELECT  Peptone  140, 
0.5%  Yeast  Extract  and  1%  sodium  chloride.  A  Millers-modified  Luria  agar  (L-agar) 
(Gibco  BRL,  Life  Technologies)  containing  1%  SELECT  Peptone  140,0.5%  Yeast 
Extract,  1%  sodium  chloride  and  1.2%  Agar  was  also  used  routinely  to  replicate  the 
bacteria.  Both  media  were  sterilised  before  use.  Bacterial  strains  containing  plasmids 
were  cultured  in  the  presence  of  ampicillin  (100  mg/ml)(Sigma)  to  select  for 
transformed  bacteria.  The  mutant  used  as  control  was  cultured  without  adding 
ampicillin.  A  single  colony  of  S.  typhimurium  from  an  L-agar  plate  was  grown  in  11 
of  L-broth  overnight  at  37 
_C 
without  shaking.  The  optical  density  of  the  suspension 
was  measured  at  600  nm  using  a  spectophotometer  (Pye  Unicam  PU  8600)  and  the 
bacteria  centrifuged  at  600g  for  20  min  at  4_C  in  a  Mistral  3000i  (Fisons)  centrifuge. 
The  pellet  was  resuspended  in  sterile  PBS  (pH  7.2)  to  obtain  a  bacterial  concentration 
of  approximately  1x  1010/ml.  The  volume,  in  ml,  of  PBS  in  which  the  pellet  should 
be  resuspended  was  equivalent  to  five  times  the  optical  density  reading.  The  number 
of  bacteria  in  the  suspension  was  checked  by  culturing  dilutions  of  the  suspension  on 
L-agar  Plates. 
Mice  received  tube  0.2  ml  of  the  bacteria  suspension  by  gavage  . 
Immediately  prior  to 
the  Salmonella  inoculation  the  mice  were  given  0.1  ml  5%  sodium  bicarbonate  orally 
in  order  to  neutralise  the  gastric  pH. 
2.21  Bacterial  growth  and  plasmid  stability  in  vivo 
Two  of  the  mutants  were  tested  for  their  growth  and  stability  in  vivo.  Groups  of  18 
mice  each  were  set  up,  each  group  received  orally  S.  ryphimurium  BRD509/NB/IFNy 
or  S.  typhimurium  BRD509/NB/TNFa.  Mice  were  inoculated  as  described  above. 
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Colonisation  of  the  bacteria  in  NIH  mice  was  monitored  by  performing  viable  bacteria 
counts  from  homogenates  of  spleen,  liver  and  mesenteric  lymph  nodes  as  previously 
described  (O'Callaghan  et  al  1988).  Three  mice  were  sacrificed  each  time  point,  at  3 
days  and  1,2,3,4  and  5  weeks  after  inoculation.  Spleen,  livers  and  mesenteric  lymph 
nodes  were  obtained  under  sterile  conditions,  placed  in  10  ml  of  sterile  PBS  (pH  7.2) 
and  homogenised  by  passing  through  a  sterile  stainless  steel  sieve  (mesh  size  0.025 
mm2)  using  the  inside  of  a  plunger  of  a  syringe  to  push  the  cells  through.  Ten  fold 
dilutions  of  the  homogenate  of  each  individual  organ  were  plated  in  a  volume  of  100 
µl  onto  L-agar  plates  both  with  and  without  100  µ1/m1  ampicillin.  Samples  were 
incubated  overnight  at  37_C.  The  number  of  colonies  which  grew  in  the  absence  of 
ampicillin  was  used  to  calculate  Salmonella  colonisation  of  organs  and  the  number 
growing  with  ampicillin  was  used  to  calculate  plasmid  stability. 
2.22  IFN-gamma  ELISA 
To  quantify  IFNy  in  spleen  cell  supernatants  a  capture  ELISA  was  performed.  Spleen 
cells  were  processed  and  suspensions  prepared  as  described  above  (see  2.16). 
Aliquots  of  1  ml  in  duplicate  were  plated  in  24  well  flat-bottomed  tissue  culture  plates 
(Nunc)  with  a  crude  P.  chabaudi  antigen  (200  µg/ml),  a  normal  RBC  antigen  (200 
µg/ml),  and  ConA  (5  µg/ml).  Control  cultures  were  unstimulated.  Cells  were 
incubated  at  37 
_C 
in  humidified  5%  CO2  and  24,48  or  72  hours  later  supernatants 
were  collected  and  stored  at  -70  _C 
until  they  were  assayed  for  IFNy  production. 
Flat-bottomed  96-well  plates  (Immulon  IV)  were  coated  with  50  tl  per  well  of  a  0.5 
µg/ml  dilution  of  the  purified  rat  anti-mouse  IFNy  (Pharmingen)  capture  antibody  in 
PBS 
. 
Plates  were  incubated  at  4 
_C 
overnight.  The  wells  were  blocked  with  150  µl 
of  10%  FCS  in  PBS  and  incubated  for  45  min  at  37 
_C. 
The  plates  were  then  washed 
three  times  with  PBS/0.05%  Polyoxyethylenesorbitan  monolaurate  (Tween  20) 
(Sigma)  for  three  minutes  each  time.  The  IFNy  recombinant  standards  were  prepared 
in  10%  FCS  RPMI  and  the  samples  to  be  assayed  were  defrosted  at  37 
_C. 
50  tl  of 
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standards  and  samples  were  plated  in  each  well  and  incubated  at  RT  for  2  hr.  The 
plates  were  washed  as  above  and  50  µl  of  rat  anti-mouse  IFNy  biotinylated  antibody 
(Pharmingen)  in  1%  BSA/PBS-Tween  20  added  and  incubated  for  1  hour  at  room 
temperature.  After  a  washing  step,  75  µl  of  streptavidin  peroxidase  in  1%  BSA/PBS- 
Tween  20  was  added  to  each  well  and  incubated  for  1  hour  at  room  temperature.  The 
plates  were  washed  and  100  µl  of  substrate  (TUB  peroxidase)was  added  per  well. 
Plates  were  read  after  15  minutes  in  an  ELISA  reader  (Titertek  Multiskan  MCC/340) 
at  a  wavelength  of  630  nm.  Units  of  IFNy  were  calculated  from  the  standard  curve 
constructed  from  the  recombinant  cytokine  standard. 
2.23.  Reverse  transcription-  Polymerase  chain  reaction  (RT-PCR) 
2.23.1.  RNA  extraction 
A  semiquantitative  RT-PCR  technique  (Osborne,  personal  communication)  was  used 
to  measure  production  of  IFNy  mRNA  in  livers  and  spleens  of  NIH  mice  inoculated 
with  S.  typhimurium/IFNy  8  days  before  P.  chabaudi  infection.  Control  groups  were 
included. 
Organs  were  extracted  aseptically  and  kept  at  -70°  C.  Livers  from  uninfected  mice 
were  used  fresh  as  controls. 
Samples  were  defrosted  when  required  and  total  RNA  was  isolated  using  GIBCO 
TRIzolTm  reagent.  Presence  of  RNA  was  confirmed  by  running  of  the  samples  on  a 
MOPS  gel.  For  this  a  50ml  mini-gel  was  prepared  (see  appendix),  and  1-5µl  RNA 
sample  were  added  to  14l  500ng/ml  EtBr,  1µl  dye  and  5µl  formamide.  The  solution 
was  incubated  at  65°  C  for  10  min,  loaded  and  run  in  a  MOPS  buffer  in  fumehood. 
Quality  of  RNA  was  checked  by  U.  V. 
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2.23.2.  DNAase  Treatment 
RNA  samples  were  DNAase  treated  using  a  GIBCO  DNAase  I  Amplification  GradeTM 
kit.  Samples  of  1  gg  of  RNA,  1  gl  DNAase  buffer  and  1  µl  DNAase  enzymes  were 
mixed  and  incubated  at  room  temperature  for  15  min.  Then  1  pl  20mM  EDTA  and  6 
µl  DEPC  treated  water  were  added  and  the  solution  was  incubated  at  65  C  for  min. 
2.23.3.  Reverse  Transcription 
Reverse  transcription  was  carried  out  by  adding  2-5  gg  of  RNA  (DNAase-treated)  to 
2  µl  random  hexamers  and  0.5  µl  RNAsin  (Promega).  This  solution  was  incubated  at 
65°C  for  10  min,  pulsed  and  left  in  ice  for  5  min.  Then  4  µl  of  RT  Buffer  (Promega), 
2  µl  10mM  dNTPs  (Perkin  Elmer)  and  1  µl  RT  enzyme  (Promega)  were  added  and 
the  resultant  solution  was  incubated  at  37°C  for  60  min. 
2.23.4.  Polymerase  Chain  Reaction  (PCR) 
For  PCR,  an  Amplitaq  DNA  polymerase  kit  (Perkin  Elmer)  was  used.  50  µl  reaction 
mixture  were  prepared  by  mixing  4  µl  DNA,  5  µl  lOx  Buffer,  37.5  µl  sterile  ddH2O,  1 
gl  dNTPs  (10  mM),  1  µl  (20  uM)  of  each  primer  and  0.5  µl  amplitaq  enzyme.  The 
solution  was  incubated  at  94°C  for  45  sec,  60°C  for  45  seconds,  72°C  for  2  min,  for 
30  cycles.  Finally,  they  were  incubated  at  72°C  for  7  min.  Quality  of  the  product  was 
checked  on  a  1.2%  agarose  gel. 
2.23.5.  Primers 
Primers  of  IFNy  and  ß-actin  (control)  were  obtained  from  CRUACHEM  and  were 
prepared  as  follows  (Roberts,  personal  communication): 
"  3'ß-actin 
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CTC  TTT  gAT  gTC  ACG  CAC  gAT 
"  5'ß-actin 
gTg  ggC  CgC  TCT  Agg  CAC  CAA 
"  3'IFNy 
CgA  CTC  CTT  TTC  CgC  TTC  CTg  Ag 
"  5'IFNy 
TgA  Acg  CTA  CAC  ACT  gCA  TCT  Tgg 
2.24.  Cytochemical  identification  of  macrophages 
An  assay  for  the  detection  in  situ  of  macrophages  in  liver  and  spleen  samples  was 
standardised  based  on  a  technique  previously  described  by  Dockrell  et  al.  (1978). 
Macrophages  posses  a  high  non-specific  esterase  activity.  Using  a-naphthyl  acetate  as 
substrate,  macrophages  show  strong  cytoplasmic  staining.  In  addition  tests  for  acid 
phosphatase,  an  important  marker  of  lysosomes,  give  strong  positive  reactions  with 
macrophages. 
Livers  and  spleens  obtained  at  different  time-points  from  mice  inoculated  with  S. 
typhimurium/IFNy  and  from  controls,  were  analysed  for  the  presence  of  non-specific 
esterase  and  acid  phosphatase.  They  were  fixed  in  formol  sucrose  at  4°C  for  24  hr 
and  rinsed  for  further  24  hr  using  cacodylate-sucrose.  They  were  frozen  at  -20°C  and 
kept  until  required  for  cryostat  sectioning. 
Before  placing  the  sections,  the  slides  were  immersed  in  a  solution  of  gelatine  (5  gm) 
and  chromium  potassium  sulphate  (0.5  gm)  (SIGMA)  in  1  It  dH2O.  Slides  were 
dipped  at  room  temperature,  drained  and  allowed  to  dry.  Cryostat  sections  of  the 
tissues  were  cut  at  a  thickness  of  10  p.  m  and  mounted  on  glass  slides  before  staining 
for  non-specific  sterase  or  acid  phosphatase. 
69 MATERIALS  &  METHODS 
2.24.1.  Demonstration  of  non-specific  sterase 
A  stock  solution  containing  a-naphthyl  acetate  1  gm,  acetone  50  ml  and  dH2O  50  ml 
was  prepared  and  named  solution  A.  A  phosphate  buffer  0.1  M  pH  7.3  was  prepared 
by  mixing  23  ml  sodium  dihydrogen  orthophosphate  anhydrous  0.2  M,  77  ml 
disodium  hydrogen  orthophophate  anhydrous  (0.2M),  and  100m1  dH2O.  This  buffer 
was  named  solution  B. 
A  fresh  working  substrate  was  prepared  with  2  ml  solution  A,  15  ml  solution  B,  15  ml 
dH2O  and  20  gm  Fast  Red  TR  salt  (Sigma).  This  substrate  was  filtered  before  use. 
Mounted  samples  were  incubated  in  the  substrate  for  30-40  min  at  room  temperature. 
Then,  they  were  rinse  in  tap  water  and  counterstain  with  1%  methyl  green  (Sigma) 
for  1  min.  Finally  they  were  rinse  in  tap  water  and  mounted  in  glycerine  gelatine 
(Sigma)  before  observation.  Enzymatic  activity  was  seen  as  reddish  granules. 
2.24.2.  Standard  coupling  Azo-dye  technique  for  demonstration  of  acid 
phosphatase 
A  mixture  of  10  mg  sodium-naphthyl  phosphate  in  20  ml  veronal  acetate  buffer  0.1  M 
was  prepared.  To  this,  1.5  gm  polyvinyl  pirrolidine  (Sigma)  were  added  and  allowed 
to  dissolve  at  37°C,  then  20  mg  fast  Red  Garnet  GBC  salt  (Sigma)  were  added.  The 
solution  was  shaked  and  filtered. 
Dry  sections  were  incubated  in  the  stain  at  room  temperature  for  30  min,  wash  in  tap 
water  and  counterstain  with  1%  methyl  green  for  1  min.  Samples  were  washed  in  tap 
water  and  mounted  in  glycerin-gelatine  (SIGMA).  Sites  of  acid  phosphatase  activity 
are  seen  as  reddish  brown  areas. 
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EFFECT  OF  INTERFERON-GAMMA  ON  THE  COURSE  OF  Plasmodium 
chabaudi  INFECTION EFFECT  OF  IFNy 
3.1.  Introduction 
IFNy  is  a  potent  inducter  of  maturation  of  mononuclear  phagocytes  into 
macrophages,  and  increases  the  synthesis  of  the  enzymes  that  mediate  the  respiratory 
burst  (reviewed  by  Stevens,  1995).  Other  effects  of  IFNy  include  enhancement  of 
cellular  and  humoral  immune  responses  through  increased  expression  of  MHC  I  and 
II;  increased  T-  and  B-cell  differentiation;  neutrophil  and  natural  killer  cells  activation 
and  enhancement  of  TNFa  transcription  and  synthesis  (reviewed  by  Stevens,  1995). 
Evidence  from  several  experimental  murine  models  leads  to  the  conclusion  that  IFNy 
is  important  in  the  acquisition  of  immunity  against  malaria.  The  cytokine  has  been 
demonstrated  to  have  an  important  activity  both  in  vivo  and  in  vitro  against  pre- 
erythrocytic  stages  of  Plasmodium  (Ferreira,  1986;  Mellouk  et  al.,  1991; 
Maheshwari  et  al.,  1990). 
The  use  of  neutralising  anti-IFNy  antibodies  enabled  identification  of  IFNy  as 
responsible  for  killing  blood  forms  of  P.  yoelii  through  activation  of  macrophages 
(Ockenhouse  &  Shear,  1984).  In  P.  chabaudi  infection,  both  plasma  levels  and 
production  of  IFNy  in  vitro  by  spleen  cells,  increases  and  peaks  two  to  three  days 
before  the  peak  of  parasitaemia  (Slade  &  Langhorne,  1989;  Stevenson  et  al.,  1990c), 
indicating  a  role  for  IFNy  in  the  control  of  the  primary  parasitaemia.  Recent  findings 
confirmed  that  IFNy,  in  combination  with  TNFa,  is  responsible  for  the  induction  of 
one  or  more  factors,  other  than  NO,  which  are  involved  in  parasite  killing  (Jacobs  et 
al.,  1996a). 
Protective  mechanisms  associated  with  IFNy  during  primary  parasitaemia  are  not 
completely  antibody-independent.  Treatment  with  anti-IFNy  antibodies  resulted  in 
suppression  of  production  of  protective  antiplasmodial  IgG2a  immunoglobulin 
isotype  in  mice  infected  with  P.  berghei  (Waki  et  al.,  1995). 
Research  on  the  effects  of  IFNy  injection  on  the  course  of  a  malaria  infection  and  its 
role  in  protection  against  the  disease  has  been  limited.  Exogenous  IFNy  does  not 
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consistently  provide  complete  protection,  which  could  be  partially  explained  by  the 
fact  that  IFNy  is  a  short  lived  cytokine  (Sedegah  et  al.,  1994). 
The  phenomenon  of  sequestration  observed  in  P.  chabaudi  might  allow  close  contact 
of  the  parasite  with  effector  cells  and  their  products  in  organs  such  as  liver  and 
spleen.  Recently,  Faure  et  al.  (1995)  have  concluded  that  schizonts  are  responsible 
for  a  significant  homing  or  multiplication  of  lymphomyeloid  cells  in  the  extravascular 
compartment  of  the  liver.  This  may  imply  accumulation  of  effector  molecules  locally 
in  the  liver  which  come  in  close  contact  with  mature  forms  of  the  parasite  while 
sequestration  occurs.  S.  typhimurium  invades  deep  organs  and  multiplies  within 
them,  and  therefore  IFNy  delivered  by  a  mutant  is  expected  to  accumulate  in  organs 
such  as  the  liver,  and  contribute  to  better  control  of  a  malaria  infection.  This 
constitutes  an  important  advantage  over  experiments  where  the  cytokine  is 
administered  by  injection  as  inoculation  into  the  bloodstream  does  not  guarantee  its 
location  in  those  areas  where  sequestration  occurs. 
The  experiments  presented  in  this  chapter  investigated  the  effect  of  the  oral 
inoculation  of  a  S.  typhimurium  mutant,  carrying  the  murine  IFNy  gene,  on  the  course 
of  a  P.  chabaudi  infection  in  'resistant'  NIH  mice.  The  bacteria  were  given  at 
different  times  before  malaria  infection  to  achieve  IFNy  production  at  different  stages 
of  primary  parasitaemia.  Other  immune  parameters  such  as  NO,  and  antibody 
production,  and  in  vitro  proliferative  responses  and  cytokines  production,  were  also 
studied  in  the  mice.  Additionally,  the  course  of  P.  chabaudi  infection  was  followed  in 
susceptible'  A/J  mice  which  were  inoculated  with  the  S.  typhimurium  mutant  before 
the  malaria  infection. 
3.2.  Results 
3.2.1.  Colonisation  and  stability  of  the  S.  typhimurium  mutant  in  organs  of  NIII 
mice 
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Eighteen  age-matched  female  NIH  naive  mice  were  used  in  this  experiment.  A  stock 
of  the  S.  typhimurium  BRD509/NB/IFNy  (S.  typhimurium/IFNy)  mutant  was 
replicated  in  L-broth  with  Ampicillin  (100.  tg/ml)  and  cultured  overnight.  The 
concentration  of  the  bacteria  was  adjusted  with  PBS  (pH  7.2)  to  approximately  1x 
1010/ml.  Mice  were  administered  0.1  ml  5%  sodium  bicarbonate  by  gavage  tube 
followed  by  2x  109  bacteria  in  0.2  ml of  PBS. 
The  ability  of  the  bacteria  to  invade  organs  of  NIH  mice  and  the  in  vivo  stability  of 
the  plasmid  were  evaluated  by  culturing  homogenates  of  liver,  spleen  and  mesenteric 
lymph  nodes  in  L-agar.  The  plasmid  was  selected  by  adding  ampicillin  to  the  medium 
as  the  IFNy  gene  was  always  expressed  with  an  ampicillin  resistance  gene  . 
Thus,  lack 
of  expression  of  the  cytokine  due  to  reversion  of  the  mutation  was  associated  with 
susceptibility  to  the  antibiotic. 
Samples  from  three  mice  were  obtained  each  time  at  different  time  points  after 
inoculation.  S.  typhimurium/IFNy  grew  well  in  vivo.  Viable  organisms  were  first 
isolated  from  mesenteric  lymph  nodes  at  day  3  p.  i..  The  bacteria  persisted  until  day  28 
p.  i.  (Figure  4.  a.  ).  Liver  homogenates  were  positive  for  the  bacteria  expressing  the 
construct  at  days  7  and  14  p.  i.  (Figure  4.  b.  ).  Isolation  of  S.  typhimurium/IFNy  from 
spleen  was  made  at  day  14  p.  i  (Figure  4.  c.  ). 
The  IFNy  gene  was  shown  to  be  stable  in  vivo  as  is  evident  from  the  high  number  of 
bacteria  growing  in  medium  with  Ampicillin  (Figure  4.  a.,  b.  &  c.  ). 
3.2.2.  Effect  of  S.  typhimurium  delivered  IFNy  on  the  course  of  a  malaria 
infection  in  NIH  mice. 
In  order  to  study  the  in  vivo  effect  of  IFNy  on  P.  chabaudi,  a  series  of  experiments 
were  carried  out  in  which  NIH  mice  inoculated  with  S.  typhimurium/IFNy,  were 
infected  with  the  parasite  at  different  times  after  administration  of  the  bacteria 
In  a  first  experiment,  12  mice  were  administered  orally  the  IFNy  mutant  7  days  before 
infection  with  105  pRBCs  with  P.  chabaudi.  Two  control  groups  were  set  up  each 
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consisting  of  six  mice,  the  mice  of  one  group  were  given  the  S.  typhimurium  control 
and  7  days  were  later  infected  with  P.  chabaudi  at  the  same  time  as  the  experimental 
group  and  the  second  control  group  was  also  infected  with  the  parasite. 
Mice  in  the  experimental  group  had  a  primary  patent  parasitaemia  from  day  3  p.  i.  to 
16  p.  i..  A  peak  of  parasitaemia  was  observed  in  the  experimental  group  at  day  8  p.  i. 
(mean  43.45%  +/-  7.81)  which  was  not  different  from  controls.  Similarly,  no 
differences  were  observed  in  the  resolution  of  this  primary  parasitaemia  with  all 
groups  reaching  subpatency  at  day  17  p.  i.  A  recrudescent  parasitaemia  was  observed 
in  the  experimental  mice  from  day  29  p.  i.  to  44  p.  i.,  while  in  the  control  groups  this 
occurred  earlier  (from  day  23  p.  i.  to  36  p.  i.  ).  The  mean  peak,  at  day  35  p.  i.,  of  this 
recrudescent  parasitaemia  was  0.013%  ±  0.019,  which  was  lower  and  delayed  when 
compared  with  the  recrudescent  peak  parasitaemia  of  both  control  groups,  occurring 
at  day  31  p.  i..  No  differences  were  observed  in  the  course  of  the  parasitaemia 
between  the  two  control  groups  (Figure  5). 
In  P.  chabaudi  infection,  a  role  for  IFNy,  has  been  suggested  in  the  control  of  the 
primary  parasitaemia  as  levels  of  the  cytokine  increase  to  reach  a  peak  two  to  three 
days  before  the  peak  of  parasitaemia  (see  above)  (Slade  &  Langhorne,  1989; 
reviewed  by  Stevenson  et  al.,  1990b).  This  finding  suggests  that  the  time  of  IFNy 
production  during  the  malaria  infection  might  be  crucial  in  mediation  of  a  protective 
effect.  To  assess  this,  three  groups  of  six  mice  each  were  given  the  S. 
typhimurium/IFNy  10  or  3  days  before  or  on  the  same  day  as  the  malaria  infection. 
Three  groups  of  six  mice  each  were  given  the  S.  typhimurium  control  construct  at  the 
same  time  points  as  the  experimental  groups.  Finally  a  control  group  for  the  malaria 
infection  alone  was  included  in  the  experiment.  All  mice  were  infected  i.  v.  with  1x 
106  pRBC. 
Mice  inoculated  with  the  S.  typhimurium/  IFNy  10  days  before  the  malaria  infection 
had  a  primary  patent  parasitaemia  from  day  3  p.  i.  to  14  p.  i.  with  a  peak  (mean  43.33 
%  17.67)  at  day  6  p.  i..  This  course  of  infection  was  not  different  from  that  observed 
in  the  two  control  groups  (Figure  6.  a.,  Table  1).  However  two  of  the  mice  (20%)  of 
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the  malaria  control  group  died  at  day  8  p.  i.  due  to  intense  parasitaemia.  A 
recrudescent  parasitaemia  was  observed  in  half  of  the  mice  from  the  experimental 
group  between  day  32  p.  i.  and  50  p.  i.  no  recrudescences  were  observed  in  the 
remaining  mice  of  this  group  during  the  period  of  study  (60  days).  The  mice  given  the 
S.  typhimurium  control  bacteria  had  no  recrudescences,  while  in  the  P.  chabaudi 
control  group  a  recrudescent  parasitaemia  was  observed  between  days  35  p.  i  and  45 
p.  i.  The  group  of  mice  inoculated  with  the  S.  typhimurium/IFNy  construct  3  days 
before  the  malaria  infection  had  a  primary  parasitaemia  which  reached  a  peak  (mean 
50.5%  ±  10.14)  at  day  6  p.  i.  and  resolved  at  day  14  p.  i.  (Figure  6.  b.,  Table  1).  This 
primary  parasitaemia  resolved  earlier  in  the  experimental  group  than  in  the  two 
control  groups,  at  day  12  p.  i.  an  apparent  was  observed  between  the  parasitaemias.  A 
recrudescent  parasitaemia  was  observed  in  half  of  the  mice  of  the  experimental  group 
between  days  31  p.  i.  and  51  p.  i..  In  the  S.  typhimurium  group  no  recrudescences  were 
observed.  In  the  malaria  control  group,  however,  a  recrudescence  was  present  in  all 
surviving  mice  from  day  35  p.  i.  to  45  p.  i..  When  the  S.  typhimurium/IFNy  construct 
was  administered  on  the  same  day  of  the  P.  chabaudi  infection,  a  primary  patent 
parasitaemia  was  observed  from  day  3  p.  i.  to  12  p.  i.  with  a  peak  parasitaemia 
(42.65%  ±  7.76)  at  day  6  p.  i.  (Figure  6.  c.,  Table  1).  Although,  no  differences  were 
observed  in  the  peak  parasitaemia  between  the  groups,  in  the  S.  typhimurium  control 
group  one  mouse  died  at  day  6  p.  i.  due  to  severe  parasitaemia.  Moreover,  resolution 
of  this  primary  parasitaemia  occurred  2  days  earlier  in  the  S.  typhimurium/  IFNy 
group  compared  with  the  two  control  groups,  differences  between  them  in  the 
parasitaemia  were  observed  at  day  12  p.  i..  One  mouse  in  the  experimental  group  had 
a  recrudescent  parasitaemia  from  day  32  p.  i.  to  37  p.  i.  In  the  S.  typhimurium  control 
group  a  recrudescent  parasitaemia  was  observed  in  2  (of  5)  mice  between  days  33  p.  i. 
and  38  p.  i..  In  the  malaria  control  group  this  was  observed  in  all  mice  between  days 
35  p.  i.  and  45  p.  i.  No  differences  were  seen  in  the  course  of  the  recrudescent 
parasitaemia,  when  present,  between  the  groups. 
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In  all  the  following  experiments  the  S.  typhimurium  constructs  were  inoculated  8 
days  before  the  infection  with  1x  105  pRBC  since  in  a  first  experiment  an  obvious 
difference  in  the  course  of  infection  was  seen  in  mice  from  the  experimental  group. 
These  had  a  delay  in  the  onset  of  the  primary  parasitaemia  which  was  evident  as  a  one 
day  delay  to  reach  a  2%  parasitaemia  when  compared  with  control  mice.  In  addition, 
the  peak  parasitaemia  at  day  8  p.  i.  in  the  IFNy  recipient  mice  was  lower  (mean 
13.44%  ±  5.86,  n=8)  than  control  mice  (28.59%  ±  6.83,  n=10)  which  occurred  at  day 
7  p.  i. 
In  a  different  experiment,  three  groups  of  at  least  13  mice  each  were  studied  as 
follows:  (i)  inoculated  with  S.  typhimurium/IFNy  and  infected  8  days  later  with  1x 
105  pRBC,  (ii)  inoculated  with  S.  typhimurium  control  and  infected  8  days  later  with 
1x  105  pRBC,  and  (iii)  infected  with  1x  105  pRBC  only.  In  the  mice  inoculated  with 
the  cytokine  construct  a  primary  parasitaemia  was  observed  from  day  3  p.  i.  to  day  12 
p.  i.,  while  in  the  two  control  groups  this  patent  parasitaemia  persisted  for  2  more 
days  (Figure  7,  Table  2).  Moreover,  the  peak  of  this  parasitaemia  was  higher  in  the 
two  control  groups,  mean  19.2%  (±  7.99,  n=14)  for  the  S.  typhimurium  and  mean 
17.60%  (±  9.73,  n=14)  for  the  P.  chabaudi,  than  in  the  experimental  group  (mean 
9.68%  ±  5.01,  n=13).  The  mice  in  this  experiment  were  followed  for  16  days  and 
therefore  differences  in  the  recrudescent  parasitaemia  could  not  be  studied.  However 
in  two  additional  experiments  which  were  followed  for  60  days  (see  3.2.2),  no 
differences  in  the  course  of  the  recrudescent  parasitaemia  were  detected. 
Finally,  an  experiment  where  the  S.  typhimurium/IFNy  and  TNFoc  (see  Chapter  4) 
constructs  were  tested  concurrently  was  performed.  In  this,  4  groups  of  six  mice  each 
were  infected  with  1x  105  pRBC  8  days  after  they  were  given  the  constructs  as 
follows:  (i)  S.  typhimurium/IFNy,  (ii)  S.  typhimurium/TNFa  (results  are  presented  in 
chapter  4),  (iii)  S.  typhimurium/TNFct  and  IFNy,  and  (iv)  S.  typhimurium  control.  A 
fifth  group  was  only  infected  with  P.  chabaudi  and  was  the  malaria  control  group.  In 
the  S.  typhimuriumi  IFNy  a  primary  parasitaemia  was  observed  from  day  3  p.  i.  to  11 
p.  i.,  with  a  mean  peak  parasitaemia,  on  day  8  p.  i.,  of  26.59%  (±  9.75)  (Figure  8.  a., 
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Table  3).  The  mice  which  were  recipients  of  the  IFNy  and  TNFa  constructs  had  a 
primary  parasitaemia  which  also  resolved  at  day  11  p.  i.  and  with  a  mean  peak  at  day  8 
pi  of  27.53%  (±  12.92)  (Figure  8.  b.,  Table  3).  No  differences  were  observed  during 
the  peak  primary  parasitaemia  among  these  two  groups  and  the  control  mice.  Mice 
given  the  S.  typhimurium  control  bacteria,  had  a  mean  peak  of  infection  on  day  9  p.  i. 
of  31.33%  (±  7.28)  (Table  3),  while  control  mice  infected  with  P.  chabaudi  only,  had 
a  peak  parasitaemia  at  day  8  p.  i.  (mean  25.18%  ±  7.76).  All  mice  given  the  IFNy  or 
IFNy-TNFa  constructs  resolved  this  primary  parasitaemia  one  day  earlier  than  the 
control  groups.  One  recrudescence  was  observed  in  all  groups  between  days  23  p.  i. 
and  32  p.  i..  No  differences  were  observed  in  the  course  of  this  recrudescent 
parasitaemia  between  the  experimental  and  the  control  groups.  (Values  of  peak 
parasitaemias  of  the  experiments  performed  in  NIH  mice  are  presented  in  Table4) 
3.2.3.  Effect  of  S.  typhimurium  delivered  IFNy  on  the  course  of  a  malaria 
infection  in  A/J  mice. 
While  studying  the  effect  of  S.  typhimurium/TNFa  on  the  course  of  a  malaria 
infection  in  'susceptible'  A/J  in  comparison  with  that  in  'resistant'  NIH  mice,  it  was 
noted  that  there  were  differences  in  the  A/J  mice  after  administration  of  the  construct 
compared  with  control  mice,  while  the  course  of  infection  remained  unmodified  in  the 
NIH  mice,  confirming  previous  observations  which  suggest  that  the  role  of  this 
cytokine  in  the  control  of  malaria  was  dependent  on  the  genetic  background  of  the 
mice  (Stevenson  &  Ghadirian,  1989).  It  was  then  decided  to  carry  out  two 
experiments  studying  the  effect  of  S.  typhimurium/IFNy  on  the  course  of  P.  chabaudi 
infection  in  A/J. 
In  the  first  of  these  experiments,  a  group  of  six  mice  were  administered  the  S. 
typhimurium/IFNy  construct  three  days  before  infection  with  1x  105  pRBC.  The 
mice  had  a  primary  patent  parasitaemia  from  day  3  p.  i.,  with  a  peak  at  day  7  (mean 
37.04%  ±10.29)  and  which  became  subpatent  at  day  22  p.  i..  They  survived  the 
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infection  and  no  recrudescences  were  observed  over  a  period  of  60  days  after 
infection.  No  differences  were  observed  in  the  course  of  parasitaemia  of  the 
experimental  group  when  compared  with  controls,  in  which  the  mean  peak 
parasitaemia  was  30.17%  (±4.9)  in  the  S.  typhimurium  control  group,  and  45.16% 
(±7.31)  in  the  malaria  control  group.  All  mice  from  control  groups  became  subpatent 
at  day  16  p.  i.  and  survived  the  infection  without  recrudescences  in  the  parasitaemia 
(Figure  9,  Table  5). 
A  second  experiment  evaluating  the  effect  of  administration  of  the  IFNy  construct  8 
days  before  the  malaria  infection  with  105  pRBC,  resulted  in  similar  finding  as  the 
previous  experiments.  The  course  of  a  malaria  infection  was  studied  in  3  groups  of  six 
A/J  mice:  one  experimental  group  was  given  S.  typhimurium/TFNy,  a  control  group 
received  the  S.  typhimurium/control  bacteria,  and  a  second  control  group  was  only 
infected  with  P.  chabaudi.  The  experimental  mice  showed  a  patent  parasitaemia  from 
day  3  p.  i.  to  day  18  p.  i.  with  a  mean  peak  of  infection  at  day  8  p.  i.  of  34.65%  (±5.87). 
Mice  inoculated  with  the  control  mutant  had  a  patent  parasitaemia  with  a  mean  of 
28.4%  (±8.43)  at  peak  (day  8  p.  i.  ),  while  in  the  malaria  control  group  this  was 
35.22%  (±7.12)  at  day  8  p.  i..  Parasitaemia  became  subpatent  at  day  19  p.  i.  in  both 
control  groups.  No  differences  were  observed  in  the  course  of  parasitaemia  between 
the  experimental  mice  and  the  control  groups. 
3.2.3.  Immune  responses  in  S.  typhimurium  recipient  NIH  mice 
3.2.3.1.  Nitric  oxide  production 
Serum  samples  collected  during  three  different  experiments  were  assayed  for  NO 
production.  For  this,  mice  were  inoculated  with  S.  typhimurium/1FNy  and  8  days  later 
were  given  105  pRBC.  At  least  three  samples  from  different  mice  in  experimental  and 
control  groups  were  obtained  daily  during  the  primary  patent  parasitaemias.  NO 
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levels  before  the  malaria  infection  and  after  the  inoculation  of  the  S.  typhimurium 
mutants  were  measured  in  one  experiment. 
In  the  experimental  group  the  serum  samples  no  rise  of  serum  NO  was  detected 
during  the  primary  parasitaemia  (Figure.  10.  a.  ).  However,  control  groups  infected 
with  S.  typhimurium  control  and  P.  chabaudi,  or  P.  chabaudi  only,  showed  a  sharp 
rise  of  NO  levels  around  peak  parasitaemia  (Figure.  10.  b.  &  c.  ).  Neither  the  S. 
typhimurium/IFNy  nor  the  S.  typhimurium  control  bacteria  were  able  to  induce 
production  of  NO  to  detectable  levels  in  serum  before  the  malaria  infection. 
3.2.3.2.  Proliferative  responses 
NIH  mice  were  inoculated  with  S.  typhimurium/IFNy  and  8  days  later  were  given  105 
pRBC.  Four  groups  of  mice  were  set  up  (i)  S.  typhimurium/IFNy-P.  chabaudi;  (ii)  S. 
typhimurium/control-P.  chabaudi;  (iii)  P.  chabaudi  (control),  and  (iv)  Naive  mice. 
Spleens  of  two  mice  from  each  group  were  collected  as  described  in  Chapter  2.  Cells 
were  cultured  with  antigen  of  fresh  P.  chabaudi  pRBCs  (at  concentrations  of  105/ml 
and  106/ml),  fresh  RBC  (see  2.18),  RPMI  medium  (negative  control),  or  ConA. 
Cultures  were  performed  from  2  days  before  P.  chabaudi  infection  (6  after  S. 
typhimurium  inoculum)  to  day  10  after  the  malaria  infection.  Cells  were  cultured  for 
72h  and  pulsed  for  the  last  18h  with  [3H-methyl]  thymidine  (see  2.15). 
High  incorporation  of  the  isotope  was  observed  in  all  groups  when  cultured  in  the 
presence  of  ConA  but  not  when  a  P.  chabaudi  antigen  was  added.  In  assays 
I 
performed  before  day  8  p.  i.,  both  control  groups  had  a  significantly  higher 
proliferative  response  when  stimulated  with  Con  A  than  the  experimental  group 
(Figure  11).  All  groups  exhibited  increased  proliferative  responses  in  response  to 
ConA  at  day  6  p.  i..  This  was  followed  by  a  significant  suppression  at  around  peak 
parasitaemia  (Figure  11). 
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3.2.3.3.  IFNy  production 
Samples  from  liver  and  spleen  were  obtained  to  study  differences  in  IFNy  mRNA 
production  between  mice  inoculated  with  S.  typhimurium/IFNy  and  controls.  Organs 
from  mice  given  the  mutants  (S.  typhimurium/IFNy  and  S.  typhimurium  control)  and 
infected  8  days  later  with  P.  chabaudi,  and  from  mice  infected  only  with  malaria, 
were  aseptically  obtained  and  kept  frozen  at  -70  C  for  six  months. 
RT-PCR  was  performed  as  described  in  2.23.  Fresh  tissue  samples  were  included  as 
controls. 
RT-PCR  was  always  successful  when  fresh  samples  were  used.  However  RNA  was 
no  detectable  in  any  of  the  frozen  samples  from  experimental  mice.  It  was  concluded 
that  samples  should  be  kept  at  -196_  C  for  optimal  preservation  of  mRNA. 
3.2.3.4.  Macrophage  migration 
To  study  changes  in  the  pattern  of  macrophage  migration  between  mice  inoculated 
with  S.  typhimuriumfWNy  and  controls,  liver  and  spleen  samples  were  processed  and 
staining  for  non-specific  esterase  and  acid  phosphatase  was  carried  out  (see  2.24). 
Organs  from  mice  administered  the  mutants  (S.  typhimurium/IFNy  and  S. 
typhimurium  control)  and  infected  8  days  later  with  P.  chabaudi,  and  from  mice 
infected  only  with  malaria,  were  aseptically  obtained  fixed  and  kept  frozen  at  -20  C 
for  one  year. 
Staining  for  acid  phosphatase  and  non-specific  esterase  were  successfully 
standardised  in  fresh  spleen  samples  from  malaria  infected  and  non  infected  mice. 
However,  the  techniques  failed  when  applied  to  liver  samples.  One  run  made  using 
frozen  tissues  showed  that  structures  were  not  well  preserved  due  to  dehydration 
occurred  during  the  time  they  were  kept  frozen.  Therefore,  it  was  concluded  that  in 
order  to  obtain  optimal  results,  fresh  samples  of  spleen  are  best.  The  problems 
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encountered  with  standardisation  of  the  technique  using  liver  samples  remain  to  be 
addressed. 
82 Loglo  Colony  forming  units  per  Organ 
ITl 
ý 
n  ý+ 
cýD  O 
y'O 
.. 
C 
W 
"o. 
..  " 
n 
ý 
10 
ýD 
ý 
ýB 
II 
ýº  B  yNo 
cr  cý  D 
CO 
(D 
r! 
dq 
cD  " 
0 
º+ý  c 
(D 
... ýD 
... 
..  i 
M 
B 
... 
0a 
do  ac 
ý. 
ý. 
ýw 
Sý 
a 3ý 
ý  5. 4,5 
3,5  -ý 
3. 
10  15  20  25  30  35 
Days  after  malaria  infection 
40  45 
S.  typhimurium/  IFNr 
S.  typhimurium  control 
P.  chabaudicontrol 
50  55 
Figure  5.  Course  of  P.  chabaudi  infection  in  NIH  mice  inoculated 
with  S.  typhimurium/IFNy  7  days  before  malaria  infection. EFFE('T  (JF/FNy 
1FVy  mutallt 
lUllil\\'ý 
aG 
'outrol  nttttattt 
1(Illavs 
n-6 
IFFy  nuttant 
-311ayý 
a=6 
('ontrvl  nudant 
;  11A\1 
n-6 
IF\y  mutant 
()Ililp, 
n-6 
('untrol  wutalt 
Illla\!  I 
n-5 
I'l  rllehaudr 
1'Inltr111 
n4 
Day  p,  i, 
1%1 
mean  parasitacmia  (S.  D.  ) 
3  I 
, 
62  (0,28)  3,28  (0,68)  3,58  (1,02)  4.43  (I  ,  05  )  1,62  (1,29)  3,08  (1,02)  6,29  1,01 
4  6,1  (1,07)  16,59  (3,17)  15,24  (3,04)  16,36  (2,95)  6,1  (1,07)  12,  O2  (3,7)  27,10  0.73 
5  18,83  (2,41)  36,89  (6,41)  42,07  (7,25)  51,4  (9,94)  18,83  (  3,23  )  22.8  (4,21)  61.51  (  103  ) 
6  43,33  (7,67)  54,57  (8,87)  50,5  (10,14)  65,31  (10,9)  42,65  (7,76)  41.87  (6,96)  77,6  (  12,32) 
7  36,98  (9,51)  50,93  (6,92)  42,26  (8,86)  46,45  (9,98)  36,98  (8,05)  30,83  (5,67)  39,72  (5.78) 
8  6,87  (1,39)  19,4  (5,27)  16,36  (5,37)  16,03  (4,59)  6,87  (2,35)  7,94  (4,18)  12,24  (327) 
9  2,71  (0,84)  4,35  (1,73)  6,19  (2,75)  8,43  (4.9)  2,71  (0,74)  0,86  (0,75)  4,2  (2.03) 
10  2,09  (0,91)  1,49  (0,93)  2,8  (0,31)  2,87  (0,51  )  2,09  (0,93)  3,38  (1,62)  2,89  ((1,81 
I1  0,30  (0,06)  0,67  (0,06)  0,47  (0,5)  1,48  (0,16)  0,3  ((),  43)  0,14  (0,16)  1.64  I(I 
12  0,05  ((1,02)  0,08  (0,9)  0,01  (0,02)  O,  67((),  72)  0  0.01  (U02)  089W  s1., 
13  0,01  (0,01)  0,005  (0,05)  0,001  (0,01)  0,14  (0,15)  11  0  023  0n  ￿, 
14  0,001  (0,01)  0  0  0,004  (0,07)  0  0  (1,11(181U  f11 
15  0  0  0  0  1)  I)  (111(13  (u  uI 
16  0  0  0  I)  Il  1) 
Table  1.  Mean  value  (%)  and  standard  error  of  parasitaemias  in  NIII  mice  inoculated 
orally  S'.  iy/)hinnUrhUm/IFNy  10  days  before  (IFNy  mutant,  -10  days),  3  days 
before  (IFNy  mutant,  -3  days),  or  on  the  same  day  (IFNy  mutant,  0  days)  of 
malaria  infection.  Groups  inoculated  with  S.  !  t/Vjmjiu"iiiin/control  (control 
mutant)  and  P.  chahaudi  only  (P.  chuhaiidi  control)  are  also  presented 
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IFNy  mutant 
n-13 
Control  mutant 
n=14 
P.  chcihuucli  control 
n=14 
Day  post- 
infection 
'%  mean  parasitaemia  (S.  D.  ) 
3  0,004  (0,08)  0,005  (0,1)  0,006  (0,1  3) 
4  0,06  (0,10)  0,09  (0,13)  0,21  (0,79) 
5  0,79  (0,09)  1,36  (2,45)  1,37  (1,05) 
6  2,54  (4,56)  5,04  (3,97)  5,02  (2,34) 
7  5,74  (5,43)  12,56  (2,65)  12,76  (2,09) 
8  9,68  (5,01)  19,2  (7,99)  17,6  (9,731) 
9  2,02  (4,32)  4,65  (3,3  1)  5,21  (2,41) 
10  0,12  (1,2)  0,29  (1,09)  0,349  (0,95) 
11  0,005  (0,02)  0,03  (0,89)  0,07  (0,12) 
12  0,004  (0,01)  0,02  (0,95)  0,03  (0,51) 
13  0  0,02  (0,08)  0,008  (0,064) 
14  0  0,09  (0,23)  0,003  (0,032) 
15  0  0  u 
Table  2.  Mean  value  (%)and  standard  error  of  parasitaernias  in  NIII  mice  inoculated 
orally  with  S.  ryphimmrimn/IFNy  (IFNy  mutant)  8  days  before  malaria  infection 
Parasitaemia  of  mice  inoculated  with  S.  typhimuririm/control  (control  mutant) 
and  P.  chahaucli  only  (P.  chuhaudi  control)  are  also  presented. 
87 ,0 0 
pUq 
Days  after  infection 
Figure  7.  Course  of  P.  chabaudi  infection  in  NIH  mice  inoculated 
with  S.  typhimurium/IFN7  8  days  before  malaria  infection. EFFECT  OF  /FN), 
IFNy  mutant 
nWG 
IFNy/TNFot 
mutants 
n=6 
Control  mutant 
n=6 
P.  chuhcuuc/i 
control 
n=6 
Day 
p.  i. 
'%,  mean  parasitaemia  (S.  D.  ) 
3  0,007  (0,014)  0,01  (0,03)  0,01  (0,07)  0,007  (u,  ()8) 
4  0,12  (0,25)  0,01  (0,08)  0,098  (0,12)  0,02  (0,94) 
5  0,77  (1,09)  0,4  (0,47)  0,52  (0,94)  0,63  (1,05) 
6  3,45  (3,6)  1,15  (2,79)  1,84  (2,95)  2,85  (3,8  1) 
7  12,35  (6,57)  6,49  (3,87)  7,01  (3,59)  8,41  (4,19) 
8  26,59  (9,75)  27,53  (12,92)  21,67  (9,3  1)  25,19  (7,76) 
9  12,73  (4,73)  15,77  (7,67)  31,33  (7,28)  20,94  (1  1,71) 
10  4,72  (6,98)  9,24  (4,9)  3,63  (3,04)  15,95  (6, 
-')) 
11  0,09  (0,78)  0,19  (0,88)  0,44  (0,69)  0,42  (0,82) 
12  0  0  0,005  (0,09)  0,14  (0,52) 
13  0  0  0  0 
Table  3.  Mean  value  (%)and  standard  error  of  parasitaemias  in  NIII  mice  inoculated 
orally  with  S.  iyphimmrium/l  FNy  (IFNy  mutant)  or  S.  hp/himnivrun/II  N;  and 
S.  iyphinnn"ium/TNFa  (1FNy/TNF(t  mutants)  8  days  before  malaria  infection 
Parasitaemia  of  mice  inoculated  with  S.  Itphimm  inm/control  (control  mutant  ) 
and  P.  chahaudi  only  (P.  chahaudi  control)  are  also  presented. 
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Figure  8.  Course  of  P.  chabaudi  infection  in  NIH  mice  inoculated  with 
S.  typhimurium  mutants  8  days  before  malaria  infection.  Two 
groups  were  inoculated  with  S.  typhimurium/IFNy  (a)  or 
S.  typhimurium/IFNy  and  S.  typhimurium/TNFa  (b).  Two  control 
groups  were  included,  one  received  S  typhimurium  control  and  the 
other  P.  chabaudi  only.  Each  point  represents  the  average 
parasitaemia  of  six  mice. EFFECT  OF  IFN1 
Day 
of  inoculation' 
IFNy  mutant  Control  mutant  I?  chabaudi 
control 
°/,  mean  parasitaemia  (S.  D.  ) 
-10'  43,33  (7.67)  54.57  (8,87)  77.6  (12.32) 
-8  9,68  (5,01)  19.2  (7,99)  17,6  (9,73) 
-8  26.59  (9,75)  31.33  (7,28)  25.18  (7,76) 
-7  43,45  (7,81)  36,67  (12,42)  25,23  (1  1,32) 
-3'  50.5  (10,14)  65.31  (10,09)  77,6  (12.32) 
0*  42,65  (7,76)  41.87  (6,96)  77,6  (12.32) 
of  the  bacteria  mutant.  ±  were  administered  Iu"  pRI3C.  were  administered  10  )RF3(' 
Table  4.  Mean  value  (%)  and  standard  error  of  parasitaernia  at  peak  of 
infection  in  NIH  mice  inoculated  orally  with  S. 
i  'phinnu"imn/IFNy  (IFNy  mutant)  in  different  experiments. 
Parasitaemia  of  nice  inoculated  with  S.  !  qViinnu"ium/control 
(control  mutant)  and  P.  chahatu/i  only  (11.  c/hahauc/i  control) 
are  also  presented. 
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IFNy  mutant 
n=G 
Control  mutant 
n=G 
P.  cltabaiuli 
control 
n=6 
Day  post- 
infection 
%  mean  parasitaemia  (S.  D.  ) 
3  0,02  (0,01)  0,02  (0,02)  0,14  (0,04) 
4  0,91  (0,56)  0,42  (0,082)  0,99  (0,43) 
5  5,04  (1,69)  2,88  (1,16)  3,68  (3,1  1) 
6  16,59  (5,47)  9,2  (1,6)  23,4  (5,46) 
7  37,04  (10,29)  30,08  (4,28)  45,16  (7,3  1) 
8  37,02  (7,99)  30,17  (4,9)  42,88  (I  1,03) 
9  18,27  (7,02)  28,54  (10,77)  22,1  1  (9,17) 
10  3,74  (2,35)  10,74  (7,56)  2,36  (I,  3  3) 
11  0,41  (0,24)  1,17(0,47)  0,25  (0,15) 
12  0,21  (0,16)  0,21  (0,11)  0,14  (0,06) 
13  0,22  (0,09)  0,06  (0,06)  0,11  (0,05) 
14  0,16  (0,15)  0,04  (0,03)  0,28  (0,23) 
15  0,14  (0,09)  0,13  (0,14)  0,15  (0,15) 
16  0,12  (0,09)  0,03  (0,03) 
_0, 
')  (0,3  I) 
17  0,05  (0,06)  0  0 
18  0  0  0 
Table  5.  Mean  value  (%)  and  standard  error  of  parasitaemias  in  A/.  I  mice  inoculated 
orally  with  S.  iyphimtn"ium/IFNy  (IFNy  mutant)  3  days  before  malaria 
infection.  Parasitaemia  of  mice  inoculated  with  S.  '.  rhhimiuuiim,  /control  (control 
mutant)  and  P.  chuhatidi  only  (1'.  chuhcnnli  control)  are  also  presented 
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Figure  9.  Course  of  P.  chabaudi  infection  in  A/J  mice  inoculated 
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3.3.  Discussion 
Auxotrophic  Salmonella  mutants  have  been  modified  to  express  cytokines  genes 
which,  when  used  in  vivo,  proved  to  be  biologically  active.  Inoculation  into  mice  of  a 
IL-10  carrying  S.  typhimurium  mutant  has  resulted  in  protection  against  lethal  7- 
irradiation  (Carrier  et  al.,  1992).  Similarly  administration  in  mice  of  a  S.  typhimurium 
mutant  expressing  the  TGFI  significantly  inhibited  carrageenin  induced  local 
inflammation  (Ianaro  et  al.,  1995).  The  strain  BRD509  of  S.  typhimurium  has  been 
previously  used  as  a  delivery  vehicle  for  heterologous  antigens  in  BALB/c  mice  (Xu 
et  al.,  1995).  The  work  presented  in  this  Chapter  describes  the  successful 
establishment  of  the  transformed  S.  typhimurium  BRD509/IFNy  in  NIH  mice. 
S.  typhimurium  delivered  IFNy  had  a  significant  effect  on  the  course  of  a  P.  chabaudi 
infection  in  NIH  mice.  This  was  most  evident  as  a  reduction  in  the  parasitaemia  at 
peak  of  infection.  Evidence  accumulated  from  other  in  vivo  studies  has  suggested  a 
role  for  IFNy  in  acquired  immunity  to  asexual  erythrocytic  stages  of  P.  chabaudi 
(Stevenson  et  al.,  1990a,  Clark  et  al.,  1987b).  Although  IFNy  appears  to  be 
important  for  the  control  of  parasite  multiplication  in  the  early  stages  of  infection 
(Stevenson  et  al.,  1990a),  it  has  been  suggested  that  later  on  during  the  primary 
parasitaemia,  the  control  of  P.  chabaudi  infection  occurs  by  an  IFNy-independent 
mechanism  (reviewed  by  Stevenson  et  al.,  1990b).  However  in  A/J  mice,  treatment 
with  S.  typhimurium/IFNy  during  the  early  stages  of  infection  did  not  affect  the 
course  of  parasitaemia.  This  could  be  due  to  genetic  differences  among  'resistant'  NIH 
and  'susceptible'  A/J  mice  which  make  the  first  better  responders  to  IFNy  treatment. 
However,  adaptation  of  the  strain  of  P.  chabaudi  to  A/J  mice  might  also  account  for 
these  results,  since  this  strain  has  been  routinely  passaged  into  NIH  mice  before 
infection  of  A/J  mice  and  hence,  A/J  mice  failed  to  show  the  same  susceptibility  to 
infection  reported  by  others  (Stevenson  et  al,  1990b). 
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Administration  of  S.  typhimurium/IFNy  to  NIH  mice  8  and  3  days  before,  or 
simultaneously  with  malaria  infection  resulted  in  a  better  control  of  the  malaria 
infection  during  the  primary  parasitaemia  when  compared  with  controls.  A  more 
consistent  result  was  obtained  when  the  mutant  bacteria  were  administered  8  days 
before  infection  with  1x105  pRBC.  Characteristically,  peak  parasitaemia  was  lower 
and  primary  patent  parasitaemia  resolved  earlier  than  in  controls.  Mice  inoculated 
with  S.  typhimuriumINNy  10  days  before  P.  chabaudi  infection  exhibited  a  similar 
pattern  of  infection  as  controls.  Taken  together  these  results  suggest  that  the  interval 
between  the  S.  typhimurium/IFNy  administration  and  the  malaria  infection,  is 
important  and  the  maximum  antimalarial  activity  of  delivered  IFNy  is  seen  when  there 
are  high  levels  of  expression  of  the  cytokine  in  early  stages  of  infection. 
The  effect  of  IFNy  on  reducing  parasite  multiplication  in  NIH  mice  might  explain  the 
results  obtained  in  a  single  experiment  when  mice  were  inoculated  with  the  construct 
7  days  before  malaria  infection.  No  difference  in  the  course  of  primary  patent 
parasitaemia  was  observed  between  the  groups,  but  a  significantly  reduced  and 
delayed  recrudescent  parasitaemia  was  observed  in  the  experimental  group  when 
compared  with  controls.  Since  this  result  was  recorded  on  a  single  occasion  only,  it 
can  be  speculated  that  it  is  a  consequence  of  a  more  effective  parasite  killing  during 
the  subpatent  stages  between  primary  and  recrudescent  parasitaemias. 
High  IFNy  levels  might  result  in  increased  NO  production  from  macrophages.  A  role 
for  NO  against  blood-stage  P.  chabaudi  AS  infection  in  NIH  mice  has  been 
suggested  by  other  workers  (Taylor-Robinson  et  al.,  1993).  In  order  to  assess  the 
role  for  NO  in  the  enhanced  control  of  parasitaemia  in  S.  typhimurium/IFNy  recipient 
NIH  mice,  serum  samples  from  around  peak  parasitaemia  were  assayed  for  in  vivo 
NO  production.  A  sharp  rise  of  NO  levels  was  observed  in  control  groups  at  peak 
parasitaemia.  However,  NO  levels  in  the  S.  typhimurium/IFNy  recipient  mice 
remained  at  baseline  levels  along  the  course  of  primary  parasitaemia.  Taylor- 
Robinson  et  al.,  (1996)  have  observed  persistence  of  background  levels  of  NO 
production  in  mice  reinfected  with  P.  chabaudi,  in  which  increased  NO  levels  can  be 
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detected  only  at  peak  parasitaemia  during  a  first  infection,  subsequent  challenge  was 
not  associated  with  increased  levels  of  the  molecule  unless  the  mice  were  re-infected 
with  a  large  parasite  dose  several  months  after  clearance.  This  might  indicate  the 
presence  of  a  prolonged  refractory  period  for  NO  production  after  the  initial  burst  of 
NO  during  the  first  malaria  infection.  NO  production  in  S.  typhimurium  recipient  mice 
was  studied  before  P.  chabaudi  infection,  and  such  a  refractory  period  of  NO 
production  in  these  mice  could  not  be  confirmed.  These  results  suggest  that,  in  the 
NIH  model,  NO  is  not  exclusively  responsible  for  the  control  of  blood  forms  of  P. 
chabaudi  during  primary  parasitaemia.  A  plausible  explanation  for  the  persistence  of 
background  levels  in  the  S.  typhimurium/IFNy  treated  mice,  is  that  the  low  antigenic 
load  is  not  enough  stimulus  to  trigger  NO  production  to  detectable  levels. 
Furthermore,  IFNy  might  be  responsible  for  mediation  of  other  immune  mechanisms 
that  have  been  shown  to  be  effective  in  the  control  of  malaria  parasites  including 
production  of  reactive  oxygen  intermediates  (Shear  et  al.,  1989;  reviewed  by 
Weidanz  et  al.,  1990)  and  TNFa  (Bate  et  al.,  1988)  from  activated  macrophages. 
IFNy  is  the  major  macrophage  activating  factor  and  therefore  is  the  primary  cytokine 
responsible  for  inducing  non-specific  cell-mediated  mechanisms  of  host  defence 
(reviewed  by  Farrar  &  Schreiber,  1993).  In  addition,  IFNy  enhances  the  ability  of  the 
macrophage  to  participate  in  other  immune  effector  functions. 
The  ability  of  monocytes/macrophages  to  participate  in  antibody  dependent  cellular 
cytotoxicity  (ADCC)  reactions  is  enhanced  through  increased  expression  of  high 
affinity  Fc,  receptors  particularly  FcyRI  (Erbe  et  al.,  1990).  However,  Bouharoun- 
Tayoun  et  al.  (1995)  suggested  that  increase  by  IFNy  of  ADCC  intensity  was  not 
related  to  induction  of  FcyRI,  but  rather  was  the  result  of  IFNy-dependent  increased 
ability  of  monocytes  to  release  TNFa,  which  is  triggered  by  FcyRII  cross-linking 
(Munoz-Fernandez  et  al.,  1992;  Polat  et  al.,  1993).  Evidence  for  the  role  of  specific 
ADCC  activity  in  vivo  during  malaria  parasitaemia,  is  conflicting,  with  some  authors 
reporting  non-specificity  in  murine  models  of  P.  berghei  (Coleman  et  al.,  1975)  P. 
chabaudi  (McDonald  &  Phillips,  1978),  and  in  P.  falciparum  in  humans  (Brown  & 
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Smalley,  1980).  However,  enhancement  of  cytotoxicity  against  these  parasites  has 
been  observed  in  vitro  in  the  presence  of  immune  serum  (reviewed  by  Phillips,  1994). 
IFNy  has  been  shown  to  enhance  the  biosynthesis  of  a  variety  of  complement  proteins 
(such  as  C2,  C4,  and  Factor  B)  by  macrophages  and  fibroblasts  (Strunk  et  at,  1994) 
and  regulates  the  expression  of  complement  receptors  on  the  mononuclear  phagocyte 
plasma  membrane  thereby  promoting  humoral  immunity  through  enhancement  of 
complement  activity  (reviewed  by  Farrar  &  Schreiber,  1993).  There  is  conflicting 
evidence  about  the  importance  of  complement  in  immunity  to  erythrocytic  stages  of 
Plasmodium.  Reduction  of  serum  complement  levels  has  been  observed  in  acute 
infections,  and  in  vitro  studies  with  P.  berghei  have  demonstrated  a  reduction  of 
phagocytosis  by  rat  macrophages  in  the  absence  of  complement  (reviewed  by  Phillips, 
1994).  On  the  other  hand,  in  vitro  immune  phagocytosis  of  P.  falciparum  pRBC  by 
human  monocytes  and  neutrophils,  and  inhibition  of  multiplication  of  P.  knowlesi  by 
immune  serum  was  independent  of  complement  (reviewed  by  Phillips,  1994).  Further 
work  on  the  role  of  IFNy  delivered  by  a  S.  typhimurium  mutant  should  include  the 
study  of  effector  mechanisms  responsible  for  the  better  control  of  P.  chabaudi 
infection  in  NIH  mice.  This  work  should  include:  (i)  expression  of  iNOS  in  organs 
such  as  a  liver  and  spleen  of  infected  mice  (this  is  a  better  indicator  of  increase  of  NO 
production  than  serum  NO  determination),  (ii)  proliferative  responses  of  spleen  cells 
against  malaria  antigen,  (iii)  in  vitro  cytokine  production  by  spleen  cells  stimulated 
with  malarial  antigen,  and  (iv)  evaluation,  using  histochemistry,  of  macrophage  and 
neutrophil  activation  in  situ 
In  conclusion,  the  results  presented  in  this  chapter  confirm  that  a  S.  typhimuriun: 
mutant  can  be  successfully  used  as  a  delivery  vehicle  for  IFNy  in  order  to  study  its 
role  in  acquisition  of  immunity  against  P.  chabaudi  malaria  and  confirm  the  important 
role  of  IFNy  in  the  control  of  the  parasite  during  early  stages  of  the  infection  in  NIH 
mice. 
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EFFECT  OF  TUMOUR  NECROSIS  FACTOR-ALPHA  ON  THE  COURSE 
OF  Plasmodium  chabaudi  INFECTION EFFECT  OF  TNFa 
4.1.  Introduction 
In  vivo  and  in  vitro  evidence  suggest  that,  along  with  IFNy,  tumour  necrosis  factor 
(TNF)  contributes  in  an  important  way  to  immunity  to  blood-stage  P.  falciparum 
infection  in  humans  (Peyron  et  al.,  1990;  Ockenhouse  et  al.,  1984;  Kumaratilake  et 
al.,  1991).  Macrophages  produce  TNFa  in  response  to  stimulation  with 
lipopolysaccharide  as  well  to  a  variety  of  bacterial  toxins  (Hacket  &  Stevens,  1992; 
1993).  Lymphocytes  produce  a  structurally  and  functionally  similar  protein  known  as 
TNF(3  (Stevens,  1995). 
TNFa  production  can  originate  from  a  small  pool  of  intracellular  mRNA  that  is 
maintained  in  an  untranslated  state,  or  after  production  of  newly  transcribed  TNFa 
mRNA  (reviewed  by  Stevens,  1995).  Stimuli  (such  as  LPS)  trigger  an  acceleration  of 
gene  transcription  which  is  followed  by  rapid  translation  of  the  newly  synthesised 
mRNA  and  the  stored  mRNA.  IFNy  increases  TNFa  synthesis  at  the  translational 
level.  On  the  other  hand,  cytokines  such  as  IL-10,  IL-1  and  IL-6  act  as  potent 
inhibitors  of  TNFa  synthesis  by  mononuclear  cells,  probably  at  the  gene 
transcriptional  level  (Wang  et  al.,  1994). 
In  addition  to  its  cytoxicity  against  tumour  cells,  TNFa  has  been  shown  to  stimulate 
and  prime  neutrophils  to  increase  oxygen  radical  production  (Jupin  et  al.,  1989)  and 
to  promote  their  degranulation  (Ferrante  et  al.,  1993).  Furthermore,  TNFa  exerts  a 
wide  range  of  immunomodulatory  effects  on  lymphocytes,  macrophages,  endothelial 
cells  and  haematopoietic  progenitor  cells  (reviewed  by  Stevenson  &  Ghadirian, 
1989). 
TNFa  has  been  shown  to  have  be  important  in  defence  against  Entamoeba  histolytica 
(Denis  &  Chadee,  1989),  Candida  albicans  (Ferrante,  1989)  and  Staphylococcus 
aureus  (Ferrante  et  al.,  1993)  infections.  In  some  models  of  bacterial  infection  a  dual 
effect  of  TNFa  has  been  demonstrated.  For  example,  in  Listeria  infection  excessive 
production  of  TNFa  may  be  associated  with  dramatic  shock  and  organ  failure,  while 
inhibition  of  TNFa  has  been  associated  with  increased  quantities  of  the  bacteria  and 
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decreased  circulating  granulocytes  (Van  Furth  et  al.,  1994).  Paradoxical  findings  of 
the  role  of  TNFa  have  also  been  reported  in  Mycobacterium  tuberculosis  infection 
because,  although  there  is  much  evidence  for  a  protective  role,  there  is  also  evidence 
that  it  plays  a  part  in  the  tissue  damage  present  during  the  disease  (Rook  et  al.,  1990; 
Rook,  1988;  Hernandez-Pardo  &  Rook,  1994).  Similar  observations  have  been  made 
in  murine  infection  with  Toxoplasma  gondii  (reviewed  by  Beaman  et  al.,  1992)  and 
human  and  murine  malaria  infections.  In  P.  falciparum  infection,  the  data  collected  so 
far  suggest  that  very  high  levels  of  TNFa  are  associated  with  severe  disease  and  fatal 
outcome  while  a  moderate  increase  in  TNFa  production  appears  to  be  a  normal  and 
possibly  beneficial  host  response  during  the  infection  (reviewed  by  Clark  et  al.,  1992; 
reviewed  by  Urquhart,  1994).  In  a  experimental  model  of  cerebral  malaria,  mice 
infected  with  P.  berghei  showed  increased  levels  of  TNFa  coincident  with  the 
development  of  the  neurological  syndrome,  and  passive  immunisation  with  anti-TNFa 
antibody  protected  them  against  cerebral  malaria  and  death  (Grau  et  al.,  1987). 
Further  support  for  the  involvement  of  TNFa  in  cerebral  malaria  comes  from 
experiments  with  non-  infected  CBA/Ca  mice,  in  which  the  clogging  of  cerebral  blood 
vessel  with  monocytes  that  has  been  associated  with  cerebral  malaria  was  reproduced 
after  administration  of  high  doses  of  recombinant  TNFa  (Grau  et  al.,  1989b)  More 
recently,  it  has  become  apparent  that  it  is  not  the  systemic  level  of  the  cytokine  which 
is  important  in  cerebral  malaria,  but  rather  the  increased  local  concentrations  of 
TNFa  resultant  from  sequestered  monocytes  within  the  cerebral  blood  vessels 
(reviewed  by  Taylor-Robinson,  1995).  Clark  et  al.  (1992)  have  suggested  that  one 
way  the  rise  in  TNFa  levels  during  malaria  infection  could  alter  brain  function  is  to 
generate  NO.  It  is  hypothesised  that  TNFa  stimulates  endothelial  cells  to  release  NO 
which  diffuses  into  the  brain  and  disrupts  the  regulation  of  glutamate-induced  neural 
NO,  resulting  in  altered  neurotransmission  and  coma  (reviewed  by  Taylor-Robinson, 
1995).  However,  the  involvement  of  NO  in  the  actual  processes  causing 
neurovascular  damage  at  advanced  stages  of  the  disease  remain  controversial. 
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While  TNFa  is  an  important  mediator  of  the  pathophysiology  associated  with  malaria 
infection,  it  is  also  known  to  play  an  important  role  in  immunity  against  the  parasite. 
TNFa  and  lymphotoxin  have  been  shown  to  enhance  the  killing  of  intraerythrocytic 
forms  (Kumaratilake  et  al.,  1990  &  1991)  and  merozoites  (Kumaratilake  et  al.,  1992) 
of  P.  falciparum  by  human  neutrophils.  Further  support  for  the  role  of  TNFct  in  the 
development  of  acquired  immunity  against  malaria  comes  from  recent  studies  in  a 
murine  model  of  P.  chabaudi,  in  which  treatment  with  a  synthetic  TNFa  peptide  was 
effective  in  suppressing  parasitaemia  (Kumaratilake  et  al.,  1995).  Earlier,  Stevenson 
and  Ghadirian  (1989)  demonstrated  that  injection  of  recombinant  TNFa  (rTNF(x) 
into  P.  chabaudi  susceptible  A/J  mice,  resulted  in  a  significantly  increased  survival 
rate.  However,  treatment  of  C57BL/6  resistant  mice  with  similar  concentrations  of 
rTNFa,  had  no  effect  on  the  course  of  infection  (Stevenson  &  Ghadirian,  1989). 
They  concluded  that  TNFa  dependent  immune  mechanisms  that  result  in  better 
protection  in  A/J  mice,  might  be  under  genetic  regulation  (Stevenson  et  al.,  1990b). 
In  vivo  studies  on  the  immunoregulatory  properties  of  TNFa  have  been  limited  due  to 
its  toxicity  (reviewed  by  Balkwill,  1994;  Schiller  et  al.,  1992).  Administration  of  the 
cytokine  in  D-galactosamine-sensitised  mice  causes  marked  toxic  effects  and  death 
within  48  hours  when  given  at  0.25  mg/kg  body  weight  (Kumaratilake  et  al.,  1995). 
The  use  of  a  S.  typhimurium  to  deliver  TNFa  might  offer  the  advantage  of  low 
systemic  concentrations  (thus  less  TNFa  toxicity)  but  increased  production  in  organs 
invaded  by  the  bacteria.  As  P.  chabaudi  undergoes  sequestration,  high  concentration 
of  TNFa  in  tissues  as  liver  and  spleen  may  result  in  increased  effector  mechanisms 
against  the  sequestered  parasites  and  better  clearance  of  the  parasitaemia. 
The  experiments  described  in  this  chapter  were  designed  to  evalute  the  feasibility  of 
using  a  S.  typhimurium  mutant  for  the  delivery  of  murine  TNFa  in  vivo  and  to  study 
its  role  in  immunity  against  P.  chabaudi.  For  this,  two  strains  of  mice,  'resistant'  NIH 
and  'susceptible'  A/J,  were  inoculated  with  the  mutant  and  later  infected  with  1x105  P. 
chabaudi  pRBC.  Following  infection  with  P.  chabaudi  , 
A/J  mice  have  been 
reported  to  develop  a  fulminant  parasitaemia  which  results  in  100%  mortality  within  2 
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weeks  of  infection  (Stevenson  &  Ghadirian,  1989).  Resistant  NIH  mice  develop  a 
moderate  level  of  peak  parasitaemia  which  resolves  spontaneously  before  4  weeks 
and  it  is  followed  by  one  or  two  recrudescences  before  an  apparent  sterile  immunity 
develops. 
4.2.  Results 
4.2.1.  Colonisation  and  stability  of  the  S.  typhimurium  mutant  in  organs  of  NIH 
mice 
In  order  to  evaluate  the  in  vivo  penetration  and  stability  of  the  S.  typhimurium 
BRD509/NB/TNFa  (S,  typhimurium/TNFa)  mutant,  20  age-matched  female  NIH 
naive  mice  were  inoculated  with  the  bacteria.  For  this,  a  stock  of  the  mutant  was 
cultured  overnight  in  L-broth  with  ampicillin  (100gg/ml).  The  concentration  of  the 
bacteria  was  adjusted  with  PBS  to  approximately  1x  1010/ml.  Mice  were  given  0.1 
ml  5%  sodium  bicarbonate  by  gavage  tube  followed  by  0.2  ml  of  the  bacterial 
suspension.  Homogenates  of  liver,  spleen  and  mesenteric  lymph  nodes  were  obtained 
at  3,7,14,21,28  and  35  days  after  inoculation.  These  were  cultured  in  L-agar  and 
the  plasmid  was  selected  by  adding  ampicillin  (100gg/ml)  to  the  medium.  The 
difference  between  the  numbers  of  bacteria  susceptible  and  resistant  to  the  antibiotic 
reflected  the  proportion  of  reversion  of  the  TNFa  gene. 
Samples  from  three  mice  were  obtained  at  each  of  the  time  points  and  these  indicated 
that  the  S.  typhimurium/TNFa  mutant  grew  well  in  vivo,  as  evident  by  the  isolation 
of  viable  bacteria  from  day  3  p.  i.  from  mesenteric  lymph  nodes.  The  bacteria  persisted 
until  day  14  p.  i.  (Figure  12.  a.  ).  Isolation  of  the  bacteria  from  livers  and  spleens  was 
achieved  from  day  3  p.  i  until  day  28  p.  i.  (Figure  12.  b.  &  c.  ). 
The  TNFa  mutation  was  shown  to  be  conserved  throughout  the  period  of  infection  as 
isolates  resistant  to  ampicillin  were  obtained  at  7,14  and  21  days  post-inoculation  in 
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samples  from  liver  and  spleen.  Mesenteric  lymph  nodes  samples  showed  bacterial 
growth  at  7  and  14  days  post-inoculation. 
4.2.2.  Effect  of  S.  typhimurium  delivered  TNFa  on  the  course  of  malaria 
infection  in  NIH  mice 
In  the  first  experiment,  a  group  of  six  mice  was  inoculated  with  the  S. 
typhimurium/TNFa  construct  and  on  the  same  day  they  were  infected  with  1x  105 
pRBC.  After  three  days,  the  mice  developed  a  primary  parasitaemia  which  peaked  at 
day  7  p.  i.  (mean  45%,  ±  5.89)  and  resolved  after  day  14  p.  i..  The  onset  of  this 
parasitaemia  in  the  experimental  groups  was  no  different  from  that  in  the  controls,  all 
groups  reaching  a  mean  2%  parasitaemia  at  day  5  p.  i..  A  recrudescent  parasitaemia 
was  detected  after  day  33  p.  i.,  with  a  peak  at  day  37  p.  i.  and  which  became  subpatent 
at  day  40  p.  i..  No  differences  were  observed  in  either  primary  or  recrudescent 
parasitaemias  in  the  mice  receiving  the  S.  typhimurium/TNFa  construct  when 
compared  with  the  two  control  groups  (Figure  13). 
In  a  second  experiment  NIH  and  A/J  mice  were  inoculated  with  S. 
typhimurium/TNFa  and  5  days  later  were  infected  with  1x  105  pRBC.  NIH  mice 
inoculated  with  the  S.  typhimurium/TNFa  mutant  had  a  primary  parasitaemia  from 
day  3  p.  i.  to  15  p.  i.,  which  reached  a  mean  peak  of  33.62%  ±  7.83,  at  day  8  p.  i.  A 
recrudescent  parasitaemia  was  observed  after  day  25  p.  i.  which  peaked  at  day  28  p.  i. 
(mean  0.92%  ±  1.098)  and  became  subpatent  after  day  31  p.  i..  Both  control  groups 
exhibited  a  similar  course  of  infection  (Figure  14.  a.,  Table  6).  Results  obtained  with 
A/J  mice  are  presented  in  4.2.3.. 
A  third  experiment  was  carried  out  in  NIH  mice  by  inoculating  them  with  the  TNFa 
construct  followed  by  infection  with  1x  105  pRBC  3  days  later.  The  mice  develop  a 
primary  parasitaemia  from  day  3  p.  i.  which  peaked  (mean  26.58%  ±  9.29)  at  day  8 
p.  i.  and  became  subpatent  after  day  13  p.  i..  Neither  the  onset  nor  the  peak  of  this 
primary  parasitaemia  were  different  from  the  controls.  A  recrudescent  parasitaemia 
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was  observed  after  day  25  p.  i.  which  reached  its  peak  (mean  0.29%  ±  0.16)  at  day  28 
p.  i..  Control  groups  exhibited  a  similar  recrudescent  parasitaemia  as  the  experimental 
group.  Parasitaemia  in  all  groups  was  subpatent  from  day  31  p.  i.  to  60  p.  i.. 
4.2.2.2.  Course  of  infection  in  A/J  mice 
In  the  first  experiment  with  A/J  mice  a  group  of  six  was  inoculated  with  S. 
typhimurium/TNFa  and  3  days  later  the  mice  were  infected  i.  v.  with  1x  105  pRBC. 
Control  groups  were  inoculated  with  the  S.  typhimurium  control  three  days  before 
malaria  infection  and  a  control  group,  infected  only  with  P.  chabaudi,  was  included. 
The  mice  developed  a  patent  parasitaemia  from  day  4  p.  i.  which  peaked  at  day  8 
p.  i.  (mean  6.94%,  ±  7.06)  and  resolved  at  day  23  p.  i.  Mice  inoculated  with  the  S. 
typhimurium  control  had  a  similar  course  of  parasitaemia.  This  became  patent  from 
day  3  p.  i.  and  peaked  at  day  8  p.  i  (mean  17.25%,  ±  13.31)  and  resolved  at  day  22  p.  i.. 
Control  mice  which  were  not  administered  S.  typhimurium,  exhibited  a  primary 
parasitaemia  from  day  3  p.  i.,  had  a  peak  parasitaemia  at  day  8  p.  i.  (mean  28.3%, 
±12.7)  and  resolved  the  infection  after  day  24  p.  i..  No  recrudescences  were  observed 
in  any  of  the  groups  and  all  mice  survive  the  infection  (Figure  15,  Table  8). 
In  a  second  experiment  (performed  simultaneously  in  NIH  mice,  results  are  presented 
in  4.2.2.  ),  six  mice  were  inoculated  with  S.  typhimurium/TNFa  and  5  days  later  were 
infected  with  1x  105  pRBC.  The  mice  developed  a  primary  parasitaemia  from  day  3 
p.  i.  which  peaked  at  day  9  p.  i.  (mean  24.36%,  ±12.74)  and  resolved  after  day  24  p.  i. 
Control  mice  inoculated  with  the  S.  typhimurium  had  a  similar  course  of 
parasitaemia,  with  a  peak  at  days  9  p.  i  (mean  30.45%,  ±6.28)  and  resolved  after  day 
22  p.  i..  Control  mice  infected  only  with  P.  chabaudi  had  a  peak  parasitaemia  at  day  9 
p.  i.  (mean  37.51%,  ±11.43)  and  resolved  the  infection  after  day  22  p.  i..  No 
recrudescences  were  observed  in  any  of  the  groups  (Figure  14.  b.,  Table  7). 
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Figure  13.  Course  of  P.  chabaudi  infection  in  NIH  mice  inoculated 
with  S.  typhimurium/TNFa  5  days  before  malaria 
infection.  Each  line  represents  the  average  of  six  mice. EFFECT  OF  TNFa 
TN  Fa  mutant 
n=6 
Control  mutant 
n=G 
P  chubaudi 
control 
n=G 
Day  post- 
infection 
'%,  mean  parasitaemia  (S.  D.  ) 
3  0,02  (0,01)  0,12  (0,02)  0,02  (0,02) 
4  0,18  (0,69)  0,06  (0,04)  0,21  (0,07) 
5  0,99  (0,4)  0,32  (0,22)  1,75  (0,67) 
6  3,61  (1,05)  1,83  (1,53)  8,7  (2,46) 
7  17,55  (2,15)  6,94  (6,91)  28,35  (12,7) 
8  33,62  (7,83)  16,81  (10,01)  20,53  (4,0) 
9  3  1,25  (11,18)  20,5  (9,02)  46,0  (12,09) 
10  19,41  (9,09)  16,26  (8,76)  35,8  (7,03) 
11  1,08  (0,74)  5,12  (3,16)  14,58  (5,3  3) 
12  0,15  (0,12)  1,16  (0,94)  1,25  (1,19) 
13  0,004  (0,1)  0,07  (0,1  1)  0,008  ((),  ()1) 
14  0,008  (0,01)  0,01  (0,03)  0 
15  0  0  0 
Table  6.  Mean  value  (%)  and  standard  error  of  parasitaemias  in  NIII  mice 
inoculated  orally  with  S.  lyphirnurium/TNFa  (TNFa  mutant)  5  days 
before  malaria  infection.  Parasitaemia  of  mice  inoculated  with  S. 
lyphinwriun  /control  (control  mutant)  and  P.  chahwk/i  only  (1'. 
chahaudi  control)  are  also  presented. 
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TNFa.  mutant 
n=6 
Control  mutant 
n=6 
P.  chubaridi  control 
n=6 
Day  P.  I.  mcan  parasitacmia  (S.  D.  ) 
3  0,01  (0.02)  0  0.02  (0.01) 
4  0,08(o.  07)  0.05  (0.03)  0.55  (0.7.3) 
5  0.29  (0,21)  0.23  (0.06)  0.43  (0.1) 
6  2.29  (1,95)  1,28  (0,  -42)  2.54  (1.32) 
7  9.1  (9.51)  6,94  (2.83)  12.41  (5.72) 
8  24.25  (15,37)  18,  (14  (4.75)  29.16  (8,37) 
9  24,36  (12,74)  30,45  (6,28)  37.51  (  11.43) 
10  15.65  (3,31)  20.77  (11,26)  21,29  (7.31) 
11  6,77  (6.16)  3.16(l.  8)  2,98  (3.75) 
12  5,22  (6,72)  2,07  (1,5-1)  0.75  (0.86) 
13  1,  (1-4  (1,55)  0.18  (0,17)  11,112  (0.02) 
14  0.91  (1,07)  0.17  (0,18)  0,004  (0,01 
15  0,  -17  (0,73)  0,13  (0,  II)  0.04  (().  06) 
16  0.51  (0.73)  0,23  (0.21)  0.0-1  (0.05) 
17  0,72  (1.17)  0,27  ((),  22)  O.  I  (U.  U9) 
18  0,65  (1,17)  0,15  (0_12)  0,34  (0.27) 
19  0,74(l.  08)  0,  I0  ((1,07)  0.42  ((),  44) 
20  0,35  (0,58)  0,1  0  (11,1  1)  11.25  (0.58) 
21  0.13  (0,09)  11,02  (0,03)  (),  11  (11,119) 
22  0,03  (0,05)  (1,1)118  (0,02)  11,02  (0,115) 
23  0,112  (0,04)  0  O 
24  (1,  (1115  (0,01)  0  0 
25  0  0  0 
Table  7.  Mean  value  (%)  and  standard  error  of'  parasitaemias  in  A/.  l  mice 
inoculated  orally  S.  11phhn!  u"imn/'TNF(I  (TNF(.  mutant)  5  days 
before  malaria  infection.  Parasitaemia  of'  mice  inoculated  with  S. 
ivphinnirinrn/control  (control  mutant)  and  P.  chahanc%  only  (I'. 
chahandi  control)  are  also  presented. 
iio S.  typhimurium/TNFa 
S.  typhimurium  control 
P.  chabaudi  control 
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Figure  14.  Course  of  P.  chabaudi  infection  in  NIH  (a)  and  A/J  (b) 
mice  inoculated  with  S.  typhimurium/TNFa  5  days  before 
malaria  infection.  Each  point  represents  the  average  of  six 
mice. EFFECT  OF  TNFa 
TNH'a  mutant 
n=6 
Control  mutant 
n=6 
P  chUIhuridi 
control 
n=6 
Day  post- 
infection 
'%  mean  parasitaemia  (S.  D.  ) 
3  0  0,008  (0,02)  0,02  (0,05) 
4  0,09  (0,09)  0,12  (0,13)  0,14  (0,12  ) 
5  0,5  (0,4)  0,81  (0,59)  1,02  (0,65) 
6  1,3  (1,04)  3,03(2,16)  4,84  (2,2) 
7  5,5  (5,12)  1  1,74  (10,49)  17,05  (6,65) 
8  6,94  (7,06)  17,25  (13,3  1)  28,315  (12,7) 
9  4,25  (3,19)  8,45  (8,0)  21,27  (8,18) 
10  1,12  (1,19)  1,24  (2,48)  3,74  (2,71) 
11  0,13  (0,14)  0,17  (0,31)  0,99  (0,87) 
12  0,03  (0,6)  0,004  (0,01)  0,1  1  (0,18) 
13  0,12  (0,08)  0,008  (0,01)  0,004  (0,01) 
14  0  0,004  (0,008)  0,004  (0,008) 
15  0,008  (0,01)  0,008  (0,01)  0,004  (0,01) 
16  0,025  (0,04)  0 
17  0  0  O 
Table  8.  Mean  value  (%)  and  standard  error  of  parasitaemias  in  A/J  mice 
inoculated  orally  with  S.  hyphiannrium/TNFx  ('I'NFa  mutant)  ,  days 
before  malaria  infection.  Parasitaemia  of  mice  inoculated  with  S. 
iy/phimrrrium/control  (control  mutant)  and  P.  c"habautli  only  (11 
. 
chuhaudi  control)  are  also  presented. 
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Figure  15.  Course  of  P.  chabaudi  infection  in  A/J  mice  inoculated 
with  S.  typhimuriundTNFoc  3  days  before  malaria 
infection. EFFECT  OF  TNFa 
4.3.  Discussion 
This  chapter  describes  the  successful  establishment  of  a  S.  typhimurium  mutant 
carrying  the  murine  TNFa  gene  in  liver,  spleen  and  mesenteric  lymph  nodes  of  NIH. 
Oral  inoculation  of  these  mice  with  S.  typhimurium/TNFa  7  days  before  or 
simultaneously  with  P.  chabaudi  infection  had  no  appreciable  effect  on  the  course  of 
the  patent  parasitaemia  when  compared  with  controls.  Similarly,  NIH  mice  inoculated 
with  the  TNFa  carrying  bacteria,  5  days  before  the  malaria  infection,  exhibited  no 
differences  in  the  course  of  the  patent  infection  when  compared  with  controls  infected 
with  P.  chabaudi  only.  However  in  this  experiment,  control  mice  inoculated  with  S. 
typhimurium  mutant  not  carrying  the  mutant  had  a  primary  parasitaemia  which  was 
lower  at  peak  when  compared  with  the  other  two  groups.  This  may  be  a  consequence 
of  induction  of  a  non-specific  mechanism  by  the  bacteria  itself. 
In  an  earlier  study  (Stevenson  &  Ghadirian,  1989),  treatment  of  resistant  C57BL/6 
mice  with  human  recombinant  TNFa  has  been  reported  to  have  no  effect  on  the 
course  or  outcome  of  P.  chabaudi  AS  infection.  On  the  other  hand,  similar  treatment 
of  susceptible  A/J  mice  resulted  in  survival  from  a  P.  chabaudi  AS  infection  and  a 
significant  decrease  in  the  peak  parasitaemia  (Stevenson  &  Ghadirian,  1989) 
compared  with  controls.  Untreated  A/J  mice  developed  a  fulminant  parasitaemia  with 
100%  mortality  and  a  mean  survival  time  of  10  days.  However,  the  experiments 
reported  in  this  chapter  failed  to  confirm  the  very  marked  susceptibility  of  A/J  mice  to 
P.  chabaudi  AS  infection.  The  mice  survived  after  development  of  an  acute 
parasitaemia  which  was  controlled  before  30  days  p.  i..  It  can  be  speculated  that 
differences  in  diet,  population  of  A/J  mice  and/or  parasite  strain  and  its  adaptation  to 
the  inbred  strain  of  mice,  are  responsible  for  the  different  course  of  malaria  infection 
observed  in  A/J  mice  in  this  study.  Nevertheless,  an  important  difference  observed  in 
the  course  of  infection  between  the  A/J  and  NIH  mice  was  the  absence  of 
recrudescences  after  a  primary  patent  parasitaemia  was  resolved  in  A/J  mice  when 
compared  with  NIH.  NIH  mice  had  a  primary  peak  of  patent  parasitaemia.  In 
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addition,  the  course  of  the  parasitaemia  remain  unaltered  in  NIH  after  treatment  (at 
any  time  before  infection)  with  the  S.  typhimurium/TNFa  mutant,  while  A/J  mice 
inoculated  with  the  construct  5  or  3  days  before  malaria  infection  had  a  significantly 
lower  peak  parasitaemia  when  compared  with  controls,  supporting  a  previous 
suggestion  that  the  genetic  background  might  be  a  determinant  of  the  relative 
importance  of  TNFc  in  acquired  immunity  against  P.  chabaudi  infection  (Stevenson 
&  Ghadirian,  1989). 
Elimination  of  the  asexual  blood  stage  of  P.  chabaudi  by  resistant  C57BL/6  mice  has 
been  demonstrated  to  involve  the  sequential  activation  of  CD4  Till  cells  followed 
by  activation  of  CD4  TH2  cells.  In  contrast,  in  susceptible  A/J  mice,  induction  of  a 
strong  TH2  response  early  during  the  malaria  infection  has  been  suggested  to  lead  to 
the  severe  course  of  infection  and  lethal  outcome  (Stevenson  &  Tam,  1993).  It  has 
been  confirmed  that,  early  during  malaria  infection,  resistant  C57BL/6  mice  have 
higher  levels  of  TNFa  messenger  RNA  (mRNA)  in  spleen  and  liver  than  susceptible 
mice  (Jacobs  et  al.,  1996b).  Furthermore,  increased  levels  of  TNFct  in  serum  and  of 
TNFa  mRNA  in  liver  later  during  infection,  were  found  in  susceptible  A/J  mice.  This 
suggests  that  TNFct  has  a  protective  role  during  a  P.  chabaudi  infection  when  it  is 
produced  in  the  spleen  and  the  liver  early  during  infection  and  has  a  deleterious  effect 
when  it  is  found  high  only  in  the  liver.  Jacobs  et  al.  (1996b)  suggested  that  the 
paradoxical  role  of  protection  (or  resistance)  versus  pathology  (or  susceptibility)  of 
TNFa  in  malaria  infection  may  be  dependent  on  the  amount  of  TNFct  released  and 
the  timing  and  site  of  its  expression.  The  way  in  which  orally  delivered  TNFa  exerts 
an  effect  on  resistance  to  P.  chabaudi  is  not  known.  S.  typhimurium  mutants  establish 
in  deep  organs  of  the  host  where,  after  a  limited  cycles  of  replication,  the  cytokine  is 
released  after  bacterial  death.  Therefore  oral  inoculation  of  S.  typhimurium/TNFa 
mutant  might  result  in  increased  levels  of  the  cytokine  in  organs  such  as  liver  and 
spleen  early  in  the  infection  and  might  be  responsible  for  a  better  control  of  malaria 
infection.  Although  TNFa  has  no  direct  parasiticidal  effect  in  vitro  (Taverne  et  al., 
1987),  its  production  in  the  spleen  leads  to  production  of  NO  which  has  been  shown 
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to  protect  the  host  against  oxygen  radical-mediated  tissue  damage  during  blood-stage 
malaria  (Jacobs  et  at,  1995;  Jacobs  et  al.,  1996a).  However,  it  has  been  found  that 
expression  of  TNFct  in  the  liver  of  resistant  C57BL/6  mice  does  not  increase  NO 
production  and  therefore  other  mechanisms  may  be  responsible  for  the  enhanced 
control  of  infection  in  these  strains  of  mice  (Jacobs  et  at,  1996a).  TNFa  in  the  liver 
may  induce  the  production  of  acute-phase  reactants  (Urquhart,  1994),  which  have 
been  found  to  increase  during  acute  P.  falciparum  infection  (Graninger  et  at,  1994) 
In  conclusion,  S.  typhimurium  delivered  TNFa  had  an  effect  on  the  course  of  P. 
chabaudi  infection  in  A/J  mice  which  is  comparable  with  the  results  obtained  by 
injection  of  recombinant  TNFa,  indicating  that  this  murine  model  is  suitable  for  the 
study  of  the  effects  of  TNFa  on  a  malaria  infection. 
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EFFECT  OF  TRANSFORMING  GROWTH  FACTOR-BETA  ON  THE 
COURSE  OF  Plasmodium  chabaudi  INFECTION EFFECT  OF  TGF/3 
5.1.  Introduction 
Transforming  growth  factor-ß  (TGFj)  belongs  to  the  transforming  growth  factor 
superfamily.  Members  of  this  family  are  a  group  of  structurally  related  proteins  which 
are  among  the  most  versatile  carriers  of  growth  and  differentiation  signals  (reviewed 
by  Wahl  et  al.,  1994).  They  participate  in  setting  up  the  basic  body  plan  during 
embryogenesis  in  mammals,  frogs  and  flies  by  controlling  formation  of  the  neural 
tube,  limbs,  cartilage,  bone  and  sexual  organs;  suppress  epithelial  cell  growth; 
promote  wound  repair  and  influence  immune  and  endocrine  functions.  This  family 
include  among  others  the  TGF0s,  activins,  inhibins,  bone  morphogenetic  proteins, 
müllerian  inhibiting  substance  (Shull  &  Doetschman,  1994).  TGFO  is  a  homodimeric 
protein  of  25kD  which  is  secreted  locally  from  platelet  stores  during  early  stages  of 
inflammation  and  then  is  generated  by  inflammatory  cells  themselves  (reviewed  by 
Wahl,  1994).  Also  macrophages  and  lymphocytes  produce  TGFO  as  part  of  a 
cytokine  network  (reviewed  by  Wahl,  1994).  Initially,  the  cytokine  mediates  the 
egress  of  undifferentiated  leukocytes  and,  subsequently,  promotes  tissue  repair  and 
resolution  of  inflammation  (Wahl,  1992;  McCartney-Francis  &  Wahl,  1994).  TGFb 
has  the  capability  of  inducing  human  peripheral  blood  monocytes  to  express  the  type 
III  receptor  for  the  FC  portion  of  IgG  (FcyRIII/CD  16)  (Welch  et  al.,  1990),  promote 
their  chemotaxis  (Wahl  et  al.,  1987),  and  increase  their  synthesis  of  IL-1  and  TNFct 
(Wahl,  1992).  In  addition,  the  cytokine  down-regulates  activation  and  the  production 
of  free  oxygen  radicals  (Tsunawaki  et  al.,  1988)  and  NO  (Ding  et  al.,  1990;  Nelson  et 
al.,  1991;  James,  1995)  by  macrophages.  This  inhibition  of  NO  has  also  been 
observed  in  mice  and  rat  hepatocytes,  although  it  was  not  demonstrated  in  humans 
(Nussler  et  al.,  1995).  However,  TGFO  can  promote  immuno-suppression  as  recent 
evidence  suggests  that  systemic  TGFO  targets  endothelial  cells,  where  it  inhibits  E- 
selectin  expression  to  block  adhesion  and  targeting  of  leukocytes  to  the  site  of 
infection  (Gamble  et  al.,  1993).  As  part  of  this  immuno-suppressive  role,  TGFf3 
inhibits  IL-1  dependent  thymocyte  proliferation,  (Kehrl  et  al.,  1986a)  IL-2-dependent 
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T-cell  proliferation  (Kehrl  et  al.,  1986a;  Wahl  et  al.,  1988),  B-cell  proliferation  and 
immunoglobulin  secretion  (Kehrl  et  al.,  1986b),  and  IFNa  enhancement  of  NK  cell 
activity  (Rook  et  al.,  1986). 
In  malaria,  the  precise  role  of  TGFß  in  immunity  and  pathology  has  still  to  be 
elucidated  and  research  on  the  role  of  the  cytokine  is  very  limited.  V  gamma  9+  T 
cells  of  malaria  non-exposed  donors  produce  TGFß,  along  with  IFNy,  TNFa,  TNF(3 
and  IL-8,  when  exposed  to  P.  falciparum  schizont  antigens  (Goodier  et  al.,  1995) 
Mice  susceptible  to  malaria  have  been  found  to  have  reduced  expression  of  TGFß, 
while  resistance  to  cerebral  malaria  was  associated  with  high  expression  of  TGFß  (de 
Kossodo  &  Grau,  1993).  More  recently,  humans  infected  with  P.  falciparum  have 
been  found  to  have  decreased  levels  of  TGFß  in  their  serum  which  correlated 
inversely  with  serum  TNFa  levels.  These  patients  showed  background  TGFß 
production  after  treatment  with  antimalarials  (Wenisch  et  al.,  1995).  TGFß 
delivered  by  a  S.  typhimurium  mutant  administered  orally  has  been  shown  to  reduce 
inflammation  following  administration  of  carrageenin  in  the  footpad  of  mice  (Ianaro 
et  al.,  1995).  This  was  accompanied  by  suppression  of  an  ongoing  THI-like  response, 
characterised  by  the  production  of  IL-2  and  IFNy,  while  IL-10  production  was 
enhanced  . 
The  results  of  the  inoculation  of  the  same  mutant  and  the  effect  of  the 
cytokine  on  the  course  of  P.  chabaudi  infection,  are  presented  in  this  chapter.  The 
bacteria  were  inoculated  into  two  strains  of  mice:  A/J  and  NIH,  which  were  selected 
on  the  basis  of  the  different  effects  observed  in  the  two  inbred  strains  after  inoculation 
with  the  S.  typhimurium/TNFa  mutant  (see  Chapter  4). 
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5.2.  Results 
5.2.2.  Effect  of  S.  typhimurium  delivered  TGFf  on  the  course  of  a  malaria 
infection  in  NIH  mice 
A  group  of  6  mice  was  inoculated  with  2x  109S.  typhimurium/TGFO  bacteria  and  4 
days  later  were  infected  with  1x  105  pRBC.  Two  control  groups  were  set  up:  one 
was  inoculated  with  the  S.  typhimurium  mutant  control  and  the  parasite,  and  the 
other  was  only  infected  with  the  parasite.  Mice  from  the  experimental  group  had  a 
primary  patent  parasitaemia  from  day  3  p.  i.  to  day  17  p.  i..  The  parasitaemia  had  a 
mean  peak,  at  day  8  p.  i.,  of  33.56%  (±  4.51)  in  the  experimental  group  and  was  not 
different  from  controls.  All  groups  showed  a  recrudescent  parasitaemia  between  days 
20  p.  i.  and  30  p.  i.,  with  no  significant  differences  among  them  (Figure  16  ). 
In  a  second  experiment,  six  mice  were  inoculated  with  the  TGFI  mutant  and  7  days 
later  were  infected  with  1x  105  pRBC,.  They  developed  a  primary  patent 
parasitaemia  from  day  5  p.  i.  to  day  15  p.  i.,  with  a  peak  of  on  day  8  of  25.79%  ±4.88). 
This  peak  parasitaemia  was  not  different  from  controls.  A  recrudescent  parasitaemia 
was  observed  in  the  experimental  mice  from  day  28  p.  i.  to  34  p.  i,  with  a  mean  peak  of 
parasitaemia  at  day  31  p.  i.  of  (0.18%  ±0.93).  A  recrudescent  parasitaemia  was  also 
observed  in  control  groups  between  days  29  p.  i.  and  36  p.  i..  No  significant  differences 
were  observed  in  the  course  of  infection  in  the  experimental  mice  when  compared 
with  controls  (Figure  17) 
5.2.3.  Effect  of  S.  typhimurium  delivered  TGFJ  on  the  course  of  a  malaria 
infection  in  A/J  mice 
One  experiment  evaluating  the  effects  of  S.  typhimurium/TGF(3  was  performed  in  A/J 
mice.  In  this,  a  group  of  six  mice  were  inoculated  orally  with  the  TGFß  construct  and 
3  days  later  they  were  infected  with  1x  105  pRBC.  Two  control  groups  were  set  up: 
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one  was  given  the  S.  typhimurium  control  bacteria  and  3  days  later  was  infected  with 
P.  chabaudi,  another  was  only  infected  with  malaria. 
The  experimental  mice  showed  a  patent  parasitaemia  from  day  3  p.  i.  to  18  p.  i.,  with  a 
mean  peak  parasitaemia  of  33.77%  ±12.2),  at  day  7  p.  i..  Control  mice  inoculated  with 
the  S.  typhimurium  mutant  had  a  similar  onset  of  infection,  with  a  mean  peak  of 
parasitaemia  of  30.17%  ±4.9  at  day  8  p.  i..  In  the  malaria  control  group  mean  peak 
parasitaemia  was  42.88%  ±11.03.  The  S.  typhimurium  inoculated  mice  showed  a 
better  control  of  the  infection  in  comparison  with  the  malaria  control  group.  The 
parasitaemia  of  the  two  control  groups  became  subpatent  by  day  18  p.  i.  (Figure  18, 
Table  9). 
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Figure  16.  Course  of  P.  chabaudi  infection  in  NIH  mice  inoculated 
with  S.  typhimuriundTGFt  4  days  before  malaria 
infection. 
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Figure  17.  Course  of  P.  chabaudi  infection  in  NIH  mice  inoculated 
with  S.  typhimurium/TGFl  7  days  before  malaria 
infection. EFFECT  OF  TGFJJ 
7'GF1i  mutant 
n=6 
Control  inutant 
n=6 
P.  chahcrudi 
control 
n=G 
Day  post- 
infection 
'%U 
mean  parasitaemia  (S.  D.  ) 
3  0,07  (0,04)  0,02  (0,02)  0,14  (0,04) 
4  0,71  (0,4)  0,42  (0,08)  0,99  (0,43) 
5  0,52  (1,86)  2,88  (1,16)  3,68  (3,11) 
6  20,66  (4,48)  9,2(1,6)  23,4  (5,46) 
7  33,77  (12,2)  30,08  (4,28)  45,16  (7,3  1) 
8  20,97  (6,58)  30,17  (4,9)  42,88  (1  1,03) 
9  12,76  (4,19)  28,54  (10,77)  22,1  1  (9,17) 
10  4,56  (2,77)  10,74  (7,56)  2,36  (1,33) 
11  0,27  (0,22)  1,17  (0,47)  0,14  (0,  II) 
12  0,15  (0,1)  0,21  (0,11)  0,14  (0,064) 
13  0,22  (0,27)  0,06  (0,06)  (),  1  I  (0,05) 
14  0,22  (0,17)  0,04  (0,03)  0,28  (0,23) 
15  0,34  (0,21)  0,13  (0,14)  0,15  (0,15) 
16  0,17  (0,13)  0,03  (0,03)  0,3  (0,31  1) 
17  0,17  (0,24)  0,01  (0,13)  0 
18  0,002  (0,006)  0 
19  0  0  0 
Table  9.  Mean  value  (%)  and  standard  error  of  parasitaemias  in  A/J  mice 
inoculated  orally  with  S.  1yphin,  ur-ium/TGF(3  ('I'GF(l  mutant)  3  days 
before  malaria  infection.  Parasitaemia  of  mice  inoculated  with  S. 
lyphinnnrinm/control  (control  mutant)  and  P.  chahanc/i  only  (1'. 
chahaudi  control)  are  also  presented. 
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Figure  18.  Course  of  P.  chabaudi  infection  in  A/J  mice  inoculated 
with  S.  typhimurium/TGFI  3  days  before  malaria 
infection. EFFECT  OF  TGFß 
5.3.  Discussion 
TGFß  has  shown  to  suppress  immune  responses  in  a  number  of  different  parasitic 
infections.  Resistant  mice  infected  with  Trypanosoma  cruzi  became  susceptible  to 
infection  after  injection  of  TGFß,  while  similar  treatment  of  susceptible  mice  resulted 
in  an  exacerbation  of  infection  (Silva  et  al.,  1991).  In  human  onchocerciasis,  parasite- 
specific  anergy  has  been  demonstrated  to  be  under  TGFß  control  (King  et  al.,  1993). 
Infection  of  mice  with  Leishmania  major  induced  TGFß  production  which  blocked 
IFNy-induced  production  of  NO,  and  thereby  favours  parasite  survival  (Green  et  al., 
1994).  However,  an  immuno-suppressive  effect  of  TGFß  was  not  evident  in  the 
experiments  presented  in  this  chapter  since  the  course  of  parasitaemia  in  resistant 
NIH  and  susceptible  A/J  ty  in  vivo  in  BALB/c  mice  after  oral  inoculation  with  the 
bacteria.  Therefore  it  is  to  be  expected  in  the  present  study,  that  the  TGFß  construct 
would  reach  similar  levels  of  colonisation  and  stability  in  vivo  in  NIH  and  A/J  mice. 
When  studying  the  effect  of  TGFP  in  vivo,  its  localisation  appears  to  be  important 
(reviewed  by  Wahl,  1994).  The  first  reports  of  a  dichotomy  between  local  and 
systemic  increase  of  TGFß  were  made  in  a  model  of  experimental  arthritis  in  which 
local  increase  of  the  cytokine  was  found  to  drive  the  inflammatory  response  whereas 
a  high  systemic  concentration  was  inhibitory  (Allen  et  al.,  1990;  Wahl  et  al.,  1993). 
The  mechanisms  involved  in  the  local  anti-inflammatory  effect  of  TGFß  include 
leukocyte  recruitment  to  the  site  of  inflammation  with  increased  adhesion  and 
fibroblast  accumulation  (reviewed  by  Wahl.,  1994).  On  the  other  hand,  systemic 
TGFß  inhibits  leukocyte  recruitment  to  the  site  of  infection.  Thus,  the  route  of 
injection  and  the  resultant  local  or  systemic  levels  of  TGFß,  could  be  crucial  when 
studying  its  role  on  malaria  infection. 
As  an  immunomodulatory  agent,  TGFß  has  been  found  to  inhibit  IL-2-dependent  T 
cell  proliferation  (Kehrl  et  al.,  1986  a&b,  Wahl  et  al.,  1988),  IL-1-dependent  murine 
thymocyte  proliferation  (Kehrl  et  al.,  1986  a),  IFNy  enhancement  of  NK  cell  activity 
(Rook  et  al.,  1986),  and  B-cell  proliferation  and  immunoglobulin  secretion  (Kehrl  et 
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al.,  1986  b).  TGFß  has  been  reported  to  inhibit  reactive  oxygen  and  nitrogen 
intermediates  production  by  macrophages  (Tsunawaki  et  al.,  1988;  Vodovotz  et  al., 
1993). 
lanaro  et  al.  (1995)  have  demonstrated  that  oral  inoculation  of  mice  with  S. 
typhimurium/TGFß  did  not  increase  systemic  levels  of  the  cytokine.  If  the  same 
occurred  in  the  S.  typhimurium/TGF(3-P.  chabaudi  model,  then  an 
immunomodulatory  effect  might  have  been  exerted  locally  in  organs  such  as  spleen 
and  liver.  Accordingly  with  the  model  of  inflammation  discussed  above,  a  localised 
increase  of  TGFß  might  result  in  a  better  control  of  the  parasite  since  the  sequestered 
parasite  would  be  in  contact  with  activated  macrophages  and  its  products.  However, 
the  fact  that  important  macrophage  effector  mechanisms  for  parasite  killing  (i.  e. 
oxygen  and  nitrogen  intermediates)  can  be  inhibited  by  the  cytokine,  may  make 
changes  in  parasitaemia  not  obvious.  To  better  assess  the  effect  of  TGFß  in  the 
immune  response  against  P.  chabaudi  infection,  further  experiments  exploring 
variables  such  as  systemic  and  localised  (at  least  in  liver  and  spleen)  TGFß  and  NO 
production  should  be  performed.  Moreover,  since  pRBCs  adhere  to  E-selectin 
(Ockenhouse  et  al.,  1992)  and  TGFß  inhibit  its  expression  by  endothelial  cells,  it 
would  be  interesting  to  evaluate  changes  in  sequestration  of  P.  chabaudi. 
Finally,  it  is  evident  from  experiments  performed  with  other  constructs  (See  3.2  & 
4.2),  that  timing  between  the  construct  inoculation  and  parasite  infection  is  crucial  in 
order  to  observe  a  protective  response.  Ianaro  et  al.,  (1995),  demonstrated  that  an 
ongoing  TH1-like  response  could  be  suppressed  if  the  bacteria  were  inoculated  6  days 
before  induction  of  oedema.  In  the  experiments  presented  here,  NIH  mice  were  given 
the  bacteria  4  and  7  days  before  malaria  infection,  while  in  A/J  it  was  done  3  days 
before  P.  chabaudi  infection  and  no  changes  in  the  course  of  parasitaemia  were 
observed.  Further  experiments  with  changes  in  the  timing  between  the  S. 
typhimurium/TGF(3  construct  inoculation  and  the  P.  chabaudi  infection  should  be 
performed  before  any  effect  of  the  cytokine  on  malaria  infection  is  ruled  out. 
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INFECTION EFFECT  OF  IL-4 
6.1.  Introduction 
Interleukin  4  (IL-4)  was  originally  characterised  in  1985  (Oliver  et  al.  ),  by  its  ability 
to  stimulate  differentiation  of  resting  B  lymphocytes.  This  cytokine  is  a  growth  factor 
for  activated  T  lymphocytes,  thymocytes,  NK  cells  (Spits  et  al.,  1987  ;  Defrance  et 
al.,  1987;  Mosmann  et  al.,  1986)  and  mast  cells  (Mosmann  et  al.,  1986;  Lee  et  al., 
1988)  Furthermore,  it  induces  maturation  of  monocytes  on  which  it  can  exert  an 
stimulatory  effect  by  increasing  MHC  II  expression  and  antigen  presenting  ability 
(Zlotnik  et  al.,  1987).  On  the  other  hand,  IL-4  appears  to  inhibit  some  parameters  of 
monocyte  activation  including  superoxide  production  (Abramson  &  Gallin,  1990)  and 
inhibition  of  release  of  prostaglandin  E2 
, 
IL-10  (Hart  et  al.,  1989),  IL-6  (Yanagawa 
et  al.,  1991),  IL-8  (Standiford  et  al.,  1990),  and  TNFa  (Essner  et  al.,  1989). 
THO  CD4+  cells  produce  mainly  IL-2  in  response  to  primary  stimulation.  Persistent 
stimulation  results  in  differentiation  into  TH1  cells,  which  mainly  produce  IFNy,  and 
TH2  cells,  which  mainly  produce  IL-4.  TH2  cells  secrete  other  cytokines  including 
IL-5,  IL-6,  IL-9,  IL-10  and  IL-13  (reviewed  by  Kopf  et  al.,  1995).  Mast  cells  and 
eosinophils  can  also  secrete  these  TH2  cytokines. 
Parasitic  infections  tend  to  result  in  a  polarised  TH1  or  TH2  response  (reviewed  by 
Sher  &  Coffman,  1992).  In  general,  'protozoa  such  as  L.  major  (Wang  et  al.,  1994) 
and  T.  gondii  (Gazzinelli  et  al.,  1994)  trigger  a  dominant  TH1  response.  In  murine 
malaria,  acquisition  of  immunity  against  P.  vinckei  after  two  drug  treated  infections 
has  been  associated  with  a  TH1  response.  While  mice  infected  with  P.  chabaudi 
exhibited  characteristics  of  a  TH1  response  early  during  infection,  a  TH2  response 
became  predominant  after  two  weeks  of  infection  (reviewed  by  von  der  Weid  & 
Langhorne,  1993b;  Taylor-Robinson  et  al.,  1993). 
In  order  to  study  the  role  of  IL-4  on  a  P.  chabaudi  AS  strain  infection  further, 
susceptible  A/J  mice  and  resistant  NIH  mice  were  inoculated  with  a  S.  typhimurium 
carrying  the  murine  IL-4  gene  and  the  course  of  the  malaria  infection  was  followed. 
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6.2.  Results 
6.2.2.  Effect  of  S.  typhimurium  delivered  IL-4  on  the  course  of  a  malaria 
infection  in  NIH  mice 
In  the  first  experiment  with  the  S.  typhimurium/lL-4  construct,  the  bacteria  were 
given  to  a  group  of  6  NIH  mice  and  4  days  later  they  were  infected  with  1x  105 
pRBC.  Control  groups  were  set  up  as  follows:  (i)  6  mice  were  given  the  S. 
typhimurium  control  bacteria  and  4  days  later  they  were  infected  with  P.  chabaudi, 
and  (ii)  6  mice  were  only  infected  with  P.  chabaudi.  All  mice  had  a  primary 
parasitaemia  from  day  3  pi  to  day  16  pi  which  peaked  at  day  8  p.  i..  In  the 
experimental  group  the  mean  peak  parasitaemia  was  (34.42%  ±4.35),  which  was  not 
different  from  the  mean  peak  parasitaemia  of  controls  (41.9%  in  the  S.  typhimurium 
control  group,  and  38.4%  in  the  malaria  control  group)  and  became  subpatent  at  day 
16  p.  i..  All  groups  had  a  recrudescent  parasitaemia  between  days  20  p.  i.  and  32  p.  i., 
with  no  significant  differences  between  them  (Figure  19). 
In  a  second  experiment,  six  mice  were  mice  given  the  S.  typhimurium/IL-4  mutant  7 
days  before  injection  with  1x  105  pRBC.  These  mice  showed  a  primary  patent 
parasitaemia  from  day  3  p.  i.  to  day  13  p.  i.,  with  a  mean  peak  parasitaemia,  at  day  8, 
of  23.45%  ±6.78.  This  peak  parasitaemia  was  not  different  from  controls.  A 
recrudescent  parasitaemia  was  observed  in  the  experimental  mice  from  day  27  pi  to 
37  p.  i,  with  a  mean  peak  of  parasitaemia  at  day  32  pi  of  0.94%  (±0.92).  The  control 
groups  had  a  recrudescent  parasitaemia  between  days  29  p.  i.  and  36  p.  i..  No 
differences  were  observed  in  the  course  of  infection  in  the  experimental  mice  when 
compared  with  controls. 
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6.2.3.  Effect  of  S.  typhimurium  delivered  IL-4  on  the  course  of  a  malaria 
infection  in  A/J  mice 
A  single  experiment  was  carried  out  to  evaluate  the  effects  of  S.  typhimurium/IL-4  in 
the  course  of  P.  chabaudi  infection  in  'susceptible'  A/J  mice.  In  this,  six  mice  were 
inoculated  orally  with  the  S.  typhimurium/IL-4  construct  and  3  days  later  they  were 
infected  with  1x  105  pRBC.  Two  control  groups  were  set  up:  one  was  given  the  S. 
typhimurium  control  bacteria  and  3  days  later  was  infected  with  P.  chabaudi,  while 
another  was  only  infected  with  malaria. 
The  experimental  mice  had  a  patent  parasitaemia  from  day  3  p.  i.  to  17  p.  i.,  with  a 
mean  peak  parasitaemia  of  35.33%  (±  7.52),  at  day  7  p.  i..  Control  mice  inoculated 
with  the  S.  typhimurium  mutant  had  a  similar  onset  of  infection,  with  a  mean  peak  of 
parasitaemia  of  30.17%  (±  4.9)  at  day  8  p.  i..  The  malaria  control  groups  had  a  mean 
peak  parasitaemia  of  42.88  ±11.03).  Between  the  two  control  groups  there  were 
differences,  the  S.  typhimurium  inoculated  mice  showing  a  better  control  of  the 
infection  in  comparison  with  the  malaria  control  group.  The  parasitaemia  of  the  two 
control  groups  became  subpatent  by  day  18  p.  i.  (Figure  20,  Table  10).  No 
recrudescences  were  observed  in  any  of  the  groups  and  all  mice  survived  the  infection 
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with  S.  typhimurium/IL-4  4  days  before  malaria 
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IL-4  mutant 
n=6 
control  mutant 
n=6 
I  el  uhuucli  control 
u=6 
Day  post- 
infection 
lyo  mean  parasitaemia  (S.  D.  ) 
3  0,1  (0,07)  0,02  (0,02)  0,14  (0,04) 
4  0,45  (0,3)  0,42  (0,08)  0,99  (0,43) 
5  3,33  (0,96)  2,88  (1,16)  3,68  (3,11) 
6  12,38  (4,58)  9,2  (1,6)  23,4  (5,46) 
7  35,33  (7,52)  30,08  (4,28)  45,16  (7,3  1) 
8  25,9  (7,34)  30,17  (4,9)  42,88  (11,0-3) 
9  21,33  (5,07)  28,54  (10,77)  22,11  (9,17) 
10  6,61  (3,09)  10,74  (7,56)  2,36  (1,33) 
11  0,21  (0,07)  1,17  (0,47)  0,14  (0,1  1) 
12  0,16  (0,1)  0,21  (0,11)  0,14  (0,064) 
13  0,1  (0,08)  0,06  (0,06)  0,1  1  (0,05) 
14  0,15  (0,  I)  0,04  (0,03)  0,28  (0,2-3) 
15  0,12  (0,07)  0,13  (0,14)  0,15  (0,15) 
16  0,08  (0,09)  0,03  (0,03)  0,3  (0,3  1) 
17  0,04  (0,05)  0,01  (0,13)  0 
18  0  0  0 
Table  10.  Mean  value  (%)  and  standard  error  of  parasitaemias  in  A/.  I  mice 
inoculated  orally  with  S.  i  phinn"irun/II,  -4  (11.  -4  mutant)  ;  days 
before  malaria  infection.  Parasitaemia  of  mice  inoculated  with  S. 
iyphimru-inm/control  (control  mutant)  and  P.  chuhuuc/i  only  (P. 
chahaucli  control)  are  also  presented. 
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Figure  20.  Course  of  P.  chabaudi  infection  in  A/J  mice  inoculated 
with  S.  typhimurium/IL-4  4  days  before  malaria 
infection. EFFECT  OFIL-4 
6.3.  Discussion 
The  important  role  of  TH1  CD4+  T  cells  in  the  control  of  an  acute  malaria  infection 
with  P.  chabaudi  has  been  confirmed  in  NIH  mice.  Moreover,  a  TH2  type  immune 
response  has  been  demonstrated  to  follow  this  TH1  activation  (reviewed  by  Phillips  et 
al.,  1994).  In  vitro  production  of  IL-4  by  splenic  CD4  T  cells  of  NIH  mice  infected 
with  P.  chabaudi  has  been  found  significantly  increased  after  2  weeks  post-infection 
(Taylor-Robinson  &  Phillips,  1994b  &  1996).  A  predominant  THI  response  has  also 
been  demonstrated  in  resistant  C57BL/6  mice  infected  with  P.  chabaudi  and  early 
infection  has  been  associated  by  an  increase  of  IFNy  and  TNFa  as  well  as  inducible 
nitric  oxide  synthase  mRNA  expression  (Stevenson  &  Tam,  1993;  Stevenson  et  al., 
1995). 
In  the  experiments  presented  in  this  chapter,  NIH  mice  inoculated  with  the  S. 
typhimurium/IL-4  construct  4  or  7  days  before  P.  chabaudi  infection  showed  it  to 
have  no  apparent  effect  on  the  course  of  infection.  Accordingly,  others  have  failed  to 
demonstrate  a  major  role  for  IL-4  during  clearance  of  blood  stage  P.  chabaudi  adami 
infection  in  experiments  using  IL-4  deficient  mice  (van  der  Heyde  et  al.,  1997).  These 
mice  cleared  a  primary  infection  with  P.  c.  adami  in  a  similar  way  to  controls  and  did 
not  develop  a  persistent  malaria  indicating  that  IL-4  is  not  required  to  activate  the 
antibody  mediated  immunity  that  ultimately  sterilises  infection. 
In  contrast  to  the  findings  when  studying  resistant  C57BL/6  mice,  susceptible  A/J 
mice  that  develop  a  higher  peak  parasitaemia  and  succumb  to  infection,  showed  high 
production,  in  vivo  and  in  vitro,  of  IL-5  (a  TH2  cell  marker)  early  in  the  P.  chabaudi 
infection  (Stevenson  &  Tam,  1993),  suggesting  that  an  early  TH2  response  may  lead 
to  a  severe  and  lethal  course  of  malaria.  However,  when  treated  with  anti-IL-4 
monoclonal  antibodies,  peak  parasitaemia  was  not  affected  when  compared  with 
untreated  controls  (Jacobs  et  al.,  1996a).  This  later  finding  is  in  agreement  with  the 
results  obtained  when  A/J  mice  were  inoculated  with  the  IL-4  construct  and  infected 
with  P.  chabaudi  three  days  later.  These  and  the  control  mice,  which  were  given  S. 
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typhimurium  control  had  a  similar  course  of  parasitaemia,  and  both  of  them  were 
significantly  lower  when  compared  with  the  malaria  only  controls.  The  better  control 
of  the  malaria  infection  in  the  mice  which  were  given  any  of  the  bacteria,  could  be 
secondary  to  mediation  of  non-specific  mechanisms  by  the  bacteria  itself.  A  period  of 
non-specific  immunity  occurs  as  the  initial  replication  of  the  attenuated  organisms 
reaches  a  plateau,  during  which  resistance  to  infection  with  Listeria  monocytogenes, 
as  well  as  to  virulent  Salmonella,  has  been  reported  (Hormaeche  et  al.,  1991).  This 
non-specific  protection  is  mediated  primarily  by  activated  macrophages  and  NK  cells 
(Schafer  &  Eisenstein,  1992),  and  can  be  inhibited  by  anti-IFNy  monoclonal 
antibodies  (Motile  &  Make,  1993). 
Taylor-Robinson  &  Phillips  (1993)  have  demonstrated  that  transfer  of  TH2  cell  lines 
from  P.  chabaudi  AS  reinfected  mice  were  able  to  protect  naive  mice  but  transfer  of 
B  cells  was  also  required  to  be  fully  protective  in  immunocompromised  hosts.  In  line 
with  this,  mice  depleted  from  birth  of  B  cells  by  treatment  with  anti-g  antibodies  can 
control  but  not  clear  P.  chabaudi  AS  infections  (Meding  &  Langhorne,  1991;  von  der 
Weid  &  Langhorne,  1993a).  Recently,  a  lack  of  clearance  of  P.  chabaudi  AS 
infection  has  been  also  confirmed  in  gene-targeted  mice  lacking  B  cells  (von  der  Weid 
et  al.,  1996).  These  findings  suggest  the  presence  of  B  cells  may  be  required  for  the 
effective  clearance  of  the  parasite  at  the  later  stages  of  infection.  IL-4  might  have 
some  role  in  the  control  of  P.  chabaudi  AS  infection,  not  only  through  activation  of 
B  cells  to  produce  specific  antibodies,  but  also  by  inhibiting  TH1  differentiation  which 
contributes  to  the  TH1-TH2  CD4+  cells  switch  observed  in  resistant  mice. 
In  the  experiments  presented  in  this  Chapter,  S.  typhimurium  delivered  IL-4  had  no 
appreciable  effect  on  the  course  of  infection  with  P.  chabaudi  in  NIH  and  A/J  mice. 
Furthermore,  although  preliminary,  the  results  obtained  from  the  experiments  with  the 
A/J  mice  suggest  that  the  establishment  of  a  TH2  cells  pattern  early  during  P. 
chabaudi  infection  does  not  affect  the  outcome  of  the  infection.  Further  experiments 
using  the  construct  at  different  time  points  of  the  malaria  infection,  in  both  resistant 
and  susceptible  mice,  should  be  carried  out  in  order  to  better  assess  the  role  of  IL-4 
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on  P.  chabaudi  infection.  These  experiments  should  also  evaluate  TH1  and  TH2 
cytokines  production,  proliferative  responses  against  malarial  antigen  and  humoral 
responses. 
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ROLE  OF  NITRIC  OXIDE  IN  THE  CONTROL  OF  A  Plasmodium  chabaudi 
INFECTION ROLE  OF  NITRIC  OXIDE 
7.1.  Introduction 
Nitric  Oxide  (or  nitrogen  monoxide)  (NO),  is  a  gaseous  free  radical  that  exhibits 
multiple  biological  properties.  The  molecule  was  first  shown  in  1987  to  be  produced 
by  living  cells  and  was  confirmed  to  be  identical  to  the  endothelium-derived  relaxing 
factor  (Ignarro  et  al.,  1987;  Palmer  et  al.,  1987). 
Nitric  oxide  is  generated  in  conjunction  with  L-citrulline  from  the  guanidino  nitrogen 
of  L-arginine,  this  process  being  catalysed  by  the  enzyme  NO  synthase  (NOS)  (Figure 
21).  Several  isoforms  of  NOS  have  been  isolated  (reviewed  by  Schmidt  et  al.,  1992). 
The  NOS  which  is  always  present  in  cells,  is  a  constitutive  (cNOS)  low-output  form 
which  results  in  production  of  low  amounts  of  NO  for  short  periods  (reviewed  by 
James,  1995).  cNOS  activity  is  dependent  on  intracellular  concentrations  of  calcium 
and  the  enzyme  is  activated  after  the  binding  of  a  calcium-calmodulin  complex  (Bredt 
&  Snyder,  1990;  Lowenstein  et  al.,  1992).  At  least  two  isoforms  of  cNOS  have  been 
described,  one  restricted  to  neurones  and  the  other  to  endothelial  cells  (reviewed  by 
James,  1995). 
The  calcium-independent  NOS  can  be  induced  in  a  number  of  cells  including 
macrophages,  neutrophils,  hepatocytes,  muscle  cells  and  endothelial  cells.  Enhanced 
transcription  of  the  gene  for  these  inducible  NOS  (iNOS)  is  observed  in  response  to 
stimulation  with  LPS  and  cytokines  such  as  IFNy  and  TNFa  (Drapier  et  al.,  1988; 
Ding  et  al.,  1988).  The  enzyme  is  down-regulated  by  other  cytokines  including  IL-4, 
IL-5,  IL-8  and  IL-10,  and  by  some  growth  factors  and  glucocorticoids  (reviewed  by 
Cox  &  Liew,  1992).  Production  of  iNOS  results  in  a  much  higher  concentration  of 
NO  (reviewed  by  Clark  &  Rockett,  1996). 
NO  has  been  shown  to  be  important  in  hypertension  associated  with  kidney  failure 
and  pregnancy,  hypotension  of  septic  shock,  control  of  sphincters  in  the 
gastrointestinal  and  genito-urinary  tracts.  It  has  also  contributed  to  explain  the 
mechanisms  involved  in  immunosuppression,  insulin  production,  growth  factor  action, 
platelet  adhesion  and  aggregation,  childhood-onset  diabetes,  and  killing  of  bacteria 
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and  protozoa  by  host  defences  (reviewed  by  Clark  &  Rockett,  1996).  Indeed, 
microbicidal  activity  of  the  molecule  has  been  demonstrated  in  Schistosoma  mansoni, 
L.  major,  T.  gondii,  T  cruzi  and  E.  histolytica,  among  other  (reviewed  by  James, 
1995).  In  blood  stage  malaria  (Taylor-Robinson  et  al.,  1993;  Jacobs  et  al.,  1996a) 
increased  levels  of  NO  have  been  associated  with  acute  infection  but  the  precise 
mechanisms  of  parasite  killing  mediated  by  the  molecule  remain  unclear. 
High  levels  of  nitrate,  an  oxidised  form  of  NO,  have  been  observed  in  P.  chabaudi 
infected  mice.  These  developed  a  primary  parasitaemia  and  a  sharp  peak  of  nitrate 
production  which  was  associated  with  the  peak  of  infection  (Taylor-Robinson  et  al., 
1993).  Others  have  demonstrated  increased  levels  of  nitrate  in  plasma  of  individuals 
infected  with  P.  falciparum  or  P.  vivax  (Cot  et  al.,  1994;  Nüssler  et  al.,  1994). 
Furthermore,  it  has  been  suggested  that  NO  may  have  a  protective  effect  in  patients 
with  cerebral  malaria  as  affected  children  with  relatively  higher  levels  of  nitrate  in 
plasma  had  a  shorter  duration  of  coma  (Cot  et  al.,  1994). 
To  assess  further  the  role  of  NO  in  a  model  of  P.  chabaudi  infection,  mice  lacking 
iNOS  were  infected  and  the  course  of  parasitaemia  followed.  Other  immunological 
parameters  assessing  humoral  and  cellular  responses  were  studied. 
Mice  homozygous  for  the  iNOS  mutation  have  previously  been  shown  to  be 
susceptible  to  L.  major  infection  in  contrast  to  wild  type  and  heterozygous  mice  (Wei 
et  al.,  1995).  The  experiments  presented  in  this  chapter  were  performed  in 
homozygous  mice  lacking  iNOS  and  heterozygous  mice  were  used  as  controls. 
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7.2.  Results 
7.2.1.  Course  of  P.  chabaudi  infection  in  iNOS  depleted  mice 
For  the  first  experiment  6  iNOS  depleted  mice  and  8  control  mice  were  infected  i.  v. 
with  1x  105  P.  chabaudi  pRBC.  The  experimental  group  had  a  patent  primary 
parasitaemia  from  day  3  p.  i.  to  day  18  p.  i..  A  peak  of  infection  was  observed  at  day  8 
p.  i.  (mean  17.66%  ±8.1).  Control  mice  had  a  similar  onset  and  resolution  in  their 
primary  parasitaemia  and,  although  the  peak  of  infection  occurred  2  days  later  in 
experimental  mice.  A  recrudescence  was  observed  in  both  groups  between  days  28 
p.  i.  and  32  p.  i..  No  differences  were  observed  between  the  groups  during  the  peak  of 
this  recrudescent  parasitaemia  which  occurred  at  day  30  p.  i.. 
In  the  second  experiment  11  iNOS  depleted  mice  were  infected  i.  v.  with  1x  105 
pRBC.  The  mice  showed  a  primary  parasitaemia  from  day  3  p.  i.  which  peaked  at  day 
10  p.  i.  (mean  31.68%  ±8.98).  This  peak  parasitaemia  was  significantly  higher 
(p<0.01)  when  compared  with  controls  (mean  17.85%  ±12.24).  Both  groups  became 
subpatent  at  day  14  p.  i..  A  low  level  parasitaemia  was  noted  in  some  mice  from  both 
groups  from  day  16  p.  i.  until  day  30  p.  i.,  after  which  all  mice  controlled  the  infection 
(Figure  22,  Table  11). 
The  third  experiment  was  performed  in  27  iNOS  mice  infected  with  1x  105  P. 
chabaudi  pRBC.  The  course  of  parasitaemia  was  followed  only  in  6  mice  of  each 
group.  They  had  a  patent  parasitaemia  from  day  3  p.  i.  to  14  p.  i.  The  peak  of  infection 
occurred  at  day  9  p.  i.  (mean  21.8%  ±23.11)  and  was  not  different  from  control  mice  ( 
mean  19.18%  ±13.6).  Results  of  other  variables  studied  in  this  experiment  are 
presented  below  (Figure  23,  Table  12). 
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7.2.2.  Sequestration  of  P.  chabaudi  at  peak  parasitaemia 
Possible  differences  in  sequestration  of  the  parasite  in  deep  organs,  such  as  liver  and 
spleen,  were  evaluated  in  the  third  experiment.  For  this  27  iNOS  depleted  mice  were 
infected  with  1x  105  pRBC,  and  a  control  group  of  27  mice  was  included.  The 
parasitaemia  of  6  malaria  infected  mice  was  followed  every  six  hours  between  days  8 
p.  i.  and  10  p.  i..  The  peak  of  infection  in  these  mice  occurred  at  day  9  p.  i.. 
At  day  8  p.  i.  a  maximum  of  sequestration  (mean  parasitaemia  10.03%  ±6.76)  was 
observed  at  00:  00  hr  in  the  experimental  mice,  which  was  not  different  from  controls 
(mean  parasitaemia  9.61%  ±8.74)  (Figure  24).  Six  hours  later  (06:  00  hr)  a  mean  peak 
parasitaemia  of  19.18  %  (±13.6)  was  observed  in  the  experimental  group,  while  in  the 
control  group  it  was  21.81%  (±23.11).  The  proportion  of  parasites  in  circulation 
dropped  gradually  in  both  groups  during  day  9  p.  i.  reaching  the  lowest  point  (mean 
6.1%  ±5.48  in  experimental  mice,  mean  8.92%  ±7.52  in  control  mice)  at  00.00  hr. 
No  differences  were  observed  in  the  pattern  of  sequestration  among  the  two  groups 
(Figure  24). 
7.2.3.  Haematology 
Comparisons  of  the  haematological  parameters  such  as  anaemia  and  reticulocytaemia 
between  the  iNOS  depleted  mice  and  controls  infected  with  malaria,  were  made  in  the 
mice  from  the  second  experiment. 
In  order  to  assess  the  degree  of  anaemia,  samples  of  blood  were  taken  from  the  tail 
and  the  haematocrit  measured.  Two  mice  were  bled  from  each  group  before  malaria 
infection  and  on  days  6,11,19,23,28,33  and  41  p.  i. 
The  basal  haematocrit  of  iNOS  depleted  mice  was  not  different  from  that  of  controls. 
Peak  parasitaemia  occurred  at  day  10  p.  i.  and  was  higher  in  the  iNOS  depleted  mice  . 
In  addition,  their  haematocrit  was  slightly  lower  when  compared  with  controls.  This 
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pattern  persisted  until  day  23  p.  i.,  after  which  both  groups  had  recovered  from 
anaemia  and  their  haematocrit  returned  to  pre-infection  levels  (Figure  25). 
Thin  smears  were  made  from  two  mice  at  days  0,6,11,15  and  19  p.  i.,  and  they  were 
stained  to  evaluate  the  proportion  of  reticulocytes  (see  2.8.2.  ).  Both  groups  showed 
an  increase  of  reticulocytaemia  simultaneously  with  peak  infection.  This  peak  of 
reticulocytes  in  circulation  was  higher  in  iNOS  depleted  mice  (Figure  25.  ). 
7.2.4.  Antibody  production 
In  the  second  experiment  using  iNOS  depleted  mice  (See  7.2.1.  )  humoral  responses 
were  studied  by  assessing  total  specific  IgG  production  during  P.  chabaudi  infection. 
Samples  of  serum  were  taken  from  the  same  two  mice  before  malaria  infection  and  6, 
11,15,19  days  p.  i.. 
The  mice  had  a  peak  of  infection  at  day  10  p.  i.  and  this  was  higher  in  the  iNOS 
depleted  mice  (see  7.2.1.,  second  experiment).  IgG  was  detected  from  day  I1  in  all 
groups  with  no  significant  differences  among  them.  Maximum  IgG  titres  were 
reached  at  day  15  p.  i.  in  iNOS  mice  and  these  were  not  different  from  those  observed 
in  control  mice. 
7.2.5.  Serum  levels  of  nitric  oxide 
Serum  nitrate  levels  were  evaluated  as  a  measure  of  NO  levels.  Nitrogen  oxidation  of 
L-arginine  results  in  the  release  of  the  highly  reactive  intermediate  NO,  which  has  a 
half-life  of  milliseconds  before  udergoing  further  oxidisation  to  nitrite  (NO2-)  and 
nitrate  (NO3-).  Both  NO2-  and  NO3-  are  more  stable  forms  and  can  be  detected  in 
serum  as  a  result  of  NO  production  (reviewed  by  Green  et  al.,  1990).  Samples  from 
at  least  two  mice  were  taken  before  malaria  infection  and  from  day  5  to  12  p.  i. 
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iNOS  depleted  mice  showed  background  levels  of  NO  during  the  period  of 
evaluation.  On  the  other  hand  control  mice  showed  an  increase  of  NO  levels  at  day  9 
and  10  p.  i.  (Figure  26).  These  findings  were  confirmed  in  two  separate  experiments. 
7.2.6.  Proliferative  response  of  spleen  cells 
Spleen  cells  from  three  P.  chabaudi  infected  iNOS  depleted  mice  were  taken  at 
different  time  points  during  infection.  They  were  incubated  with  fresh  P.  chabaudi 
antigen  (see  2.18)  or  ConA  and  two  controls  were  included:  non-infected  RBC  and 
medium.  After  72  hours  of  incubation,  the  cells  were  pulsed  for  18  hours,  then 
harvested  and  incorporation  of  [3H-methyl]  thymidine  was  measured. 
In  all  the  assays  performed,  spleen  cells  failed  to  proliferate  with  the  fresh  P. 
chabaudi  antigen.  However,  proliferation  was  observed  in  response  to  ConA  (Figure 
27).  Spleen  cells  from  iNOS  depleted  mice  obtained  at  day  0  of  malaria  infection 
proliferate  in  response  to  ConA  to  a  similar  degree  as  controls.  However,  six  days 
after  infection,  cells  from  the  experimental  group  had  a  higher  mean  rate  of 
proliferation  than  cells  from  control  mice.  A  marked  reduction  of  proliferation  in 
response  to  ConA  was  observed  at  day  10  p.  i.  in  coincidence  with  peak  parasitaemia 
in  both  groups.  By  day  14  p.  i.  spleen  cells  from  both  experimental  and  control  mice 
recovered  the  ability  to  proliferate  when  stimulated  with  ConA  and  no  differences 
were  observed  in  the  proliferative  rate  between  the  cells  from  groups.  Similarly,  at 
day  18  p.  i.  cells  from  experimental  and  control  mice  showed  similar  rates  of 
proliferation  in  response  to  Con  A  (Figure  27). 
7.2.7.  IL-4  and  IFNy  production  by  spleen  cells 
Supernatants  of  ConA  stimulated  spleen  cells  from  two  malaria  infected  mice  from 
each,  were  collected  24,48  and  72  hours  after  incubation. 
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At  day  6  p.  i.,  IFNy  production  by  cells  from  iNOS  depleted  mice  was  higher  (381 
µg/m1)  in  comparison  with  the  two  controls  (70.8  µg/ml  and  113  µg/ml).  In  both 
groups,  cells  taken  from  mice  after  10  days  of  infection,  did  not  show  production  of 
the  cytokine.  However,  at  day  14  p.  i.  cells  from  experimental  mice  produced  higher 
levels  of  IFNy  (582  tg/ml  &  476  µg/ml)  than  cells  from  control  mice  (143  pg/ml  & 
71  µg/ml).  By  day  18  p.  i.  IFNy  production  was  similar  in  both  groups  (Figure  28.  a.  ). 
IL-4  was  detected  at  day  18  p.  i.  in  both  groups  in  supernatants  collected  24  hours 
after  incubation  (Figure  28.  b.  ).  The  level  of  IL-4  production  in  the  iNOS  depleted 
mice  and  in  the  controls  was  similar  (between  13  and  17  µg/ml). 
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iNOS  deficient 
n=11 
Controls 
n=12 
Day  post-infection  `Yo  mean  parasitaeniia  (S.  D.  ) 
3  0,02  (0,02)  0,01  (0,03) 
4  0,06  (0,5)  0,18  (0,39) 
5  0,43  (0,19)  0,42  (0,49) 
6  1,21  (0,42)  1,65  (1,72) 
7  6,14  (2,84)  3,77  (2,58) 
8  18,16  (6,12)  9,79  (3,92) 
9  30,15  (10,44)  15,82  (5,8) 
10  3  1,68  (8,98)  17,85  (12,24) 
11  11,86  (6,87)  3,37  (2,85) 
12  1,32  (1,51)  0,24  (0,19) 
13  0,15  (0,18)  0,1  (0,2) 
14  0,002  (0,007)  0,06  (0,08) 
15  0  0,02  (0,07) 
16  0  0 
Table  11.  Mean  value  (%)  and  standard  error  of  parasitaemias  in  iNOS 
depleted  mice  and  control  mice. 
147 40, 
35  -ý 
10  15 
Days  after  malaria  infection 
NOS  mice 
20 
Figure  22-Course  of  P.  chabaudi  infection  in  iNOS  depleted  mice. 
Each  point  represents  the  average  parasitaemia  of  11  mice. RULE  OF  NITRIC  OXIDE 
iNOS  deficient 
n=6 
Controls 
n-6 
Day  post-infection  `%  mean  parasitaemia  (S.  D.  ) 
0,04  (0,03)  0,12  (0,23) 
4  0,17  (0,4)  0,35  (0,19) 
5  0,6  (0,47)  1,39  (0,97) 
6  3,45  (2,4)  5,49  (3,37) 
7  9,03  (6,35)  10,26  (5,73) 
8  12,37  (7,86)  13,6  (9,36) 
9  21,81  (23,11)  19,18  (13,6) 
10  5,7  (4,34)  8,77  (6,97) 
11  1,34  (1,81)  1,37  (1,69) 
12  0,4  (0,8)  0,02  (0,075 
13  0,001  (0,01)  0,001  (0,0  I) 
14  0 
15  0  0 
Table  12.  Mean  value  (%)  and  standard  error  of  parasitaemias  in  iNO  S 
depleted  and  control  mice. 
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7.3.  Discussion 
Both  iNOS  depleted  mice  and  control  mice  develop  a  parasitaemia  after  injection  with 
blood  forms  of  P.  chabaudi.  A  primary  parasitaemia  was  observed  from  day  3  p.  i. 
with  a  peak  of  infection  around  day  10  p.  i..  After  two  weeks  of  infection,  the 
parasitaemia  had  become  sub-patent  and  was  resolved  from  around  4  weeks  p.  i.. 
In  studies  carried  out  in  NIH  mice,  injection  of  the  NOS  inhibitor  L-Ny- 
monomethylarginine  (L-NMMA)  5  and  10  days  p.  i.  with  P.  chabaudi,  prevented  NO 
production  and  extended  the  primary  peak  parasitaemia  (Taylor-Robinson  et  al., 
1993).  In  addition,  transfer  of  TH1  cell  clones  from  immune  donors  into  CD4+T  cell- 
depleted  recipients,  has  a  protective  effect  which  was  reduced  after  L-NMMA 
treatment  suggesting  that  the  protection  was  partially  NO-dependent  (Taylor- 
Robinson  &  Phillips,  1994a). 
Peak  parasitaemia  was  significantly  higher  in  iNOS  depleted  mice  when  compared 
with  controls  suggesting  that  NO  has  some  role  in  the  control  of  the  parasite  around 
peak  of  infection.  This  confirms  previous  observations  in  NIH  mice  infected  with  P. 
chabaudi  AS  or  CB  strains,  in  which  a  very  sharp  increase  in  NO  production 
(measured  as  nitrate)  has  been  observed  1-2  days  before  peak  parasitaemia,  reaching 
a  maximum  with  the  peak  of  infection  and  rapidly  declining  to  background  levels  after 
this  (Taylor-Robinson  et  al.,  1993;  Mathers,  1994).  This  same  pattern  of  NO  rise 
around  peak  parasitaemia  was  observed  in  the  control  mice,  while  iNOS  depleted 
mice  evidence  basal  levels  of  NO  all  the  time  during  the  course  of  infection.  Phillips  et 
al.,  (review,  1994),  postulated  that  the  extracellular  merozoite  released  from  the 
sequestered  erythrocyte  could  be  the  stage  most  vulnerable  to  NO.  Since  P.  chabaudi 
sequesters  in  the  liver  where  NO  would  be  expected  to  be  produced  by  Kupffer  cells 
and  hepatocytes,  sequestered  parasites  may  be  exposed  to  relatively  high  local 
concentrations  of  NO.  This  would  not  be  the  case  in  iNOS  depleted  mice,  and, 
therefore,  an  impairment  of  the  control  of  the  parasite  can  be  expected. 
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A  lower  haematocrit  and  higher  proportion  of  reticulocytes  in  the  peripheral  blood  of 
iNOS  depleted  mice  could  be  explained  by  the  higher  parasitaemia  they  suffered  in 
comparison  with  controls. 
Vasodilatory  effects  of  NO  may  result  in  changes  in  the  pattern  of  sequestration  in 
mice  with  impaired  production  of  the  molecule.  Cytosolic  guanylate  cyclase  is 
activated  when  nitric  oxide  displaces  the  iron  from  the  porphyrin  ring  plane.  This 
results  in  generation  of  a  cyclic  guanosine  monophosphate  (reviewed  by  Ignarro, 
1992;  Clark  &  Rockett,  1996).  Through  this  mechanism  NO  is  a  major  controller  of 
vascular  tone.  Therefore,  NO  produced  around  the  peak  of  malaria  infection  would 
be  expected  to  produce  vasodilatation  of  deep  tissue  capillaries  and  post-capillary 
venules  which  would  make  conditions  for  parasite  sequestration  less  favourable. 
However,  assessment  of  sequestration  by  following  changes  in  peripheral 
parasitaemia  showed  no  differences  between  the  experimental  mice  and  controls. 
Several  factors  can  explain  this  result.  First,  the  changes  in  the  parasitaemia  may  be 
subtle  and  the  assay  used  is  not  sensitive  enough  to  detect  them.  Second,  several 
other  factors,  different  from  NO,  are  known  to  be  involved  in  sequestration  and  the 
role  of  the  molecule  might  only  be  accessory.  Third,  a  vasodilatory  effect  secondary 
to  NO  production  has  been  demonstrated  in  the  brain  and  has  been  associated  with 
cerebral  malaria  (Clark  et  al.,  1991),  but  a  generalised  vasodilatory  effect  is  not  yet 
proven. 
Six  days  after  P.  chabaudi  infection,  iNOS  depleted  mice  exhibited  a  significantly 
higher  level  of  proliferation  of  their  spleen  cells  in  comparison  with  controls  and 
under  stimulation  with  ConA.  This  confirms  previous  observations  in  L.  major 
infection,  where  spleen  cells  from  infected  iNOS  mice  had  a  higher  index  of 
stimulation  when  cultured  with  specific  and  non-specific  antigens  (Wei  et  al.,  1995). 
During  the  peak  of  malaria  infection,  spleen  cells  from  iNOS  depleted  mice  and  from 
the  control  group  showed  suppression  of  in  vitro  proliferation  . 
Immuno-suppression 
during  acute  malaria  infection  has  been  documented  by  several  authors.  A  failure  of 
lymphocyte  proliferation  in  response  to  asexual  blood  stage  malarial  antigens  has  been 
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associated  with  acute  P.  falciparum  malaria  (Ballet  et  at,  1981;  Brasseur  et  at, 
1983;  Troye-Blomberg  et  at,  1983).  Evaluation  of  spleen  cells  supernatants  for  in 
vitro  production  of  IFNy  showed  that  production  by  cells  from  iNOS  depleted  mice 
was  significantly  increased  in  response  to  ConA  stimulation  at  days  6  and  14  p.  i.. 
Cells  from  both  groups  of  mice  recovered  on  day  10  p.  i.  did  not  produce  IFNy.  By 
day  18  p.  i.,  IFNy  production  was  significantly  reduced  in  the  iNOS  depleted  mice  and 
was  not  significantly  different  from  that  of  the  controls.  High  production  of  IFNy  by 
spleen  cells  of  iNOS  depleted  mice  has  also  been  reported  in  L.  major  infection  in 
response  to  leishmanial  antigen  (Wei  et  at,  1995).  In  the  Leishmania  model,  IL-4 
production  has  been  found  to  be  reduced  when  compared  with  controls.  However, 
when  infected  with  P.  chabaudi,  production  of  IL-4  was  only  detected  at  day  18  p.  i. 
in  both  experimental  and  control  groups.  This  confirms  previous  observations 
suggesting  that  a  sequential  activation  of  TH1  and  TH2  cells  subsets  are  involved  in 
the  control  of  P.  chabaudi  infection  (reviewed  by  Phillips  et  at,  1994).  Taylor- 
Robinson  et  at,  (1994),  demonstrated  that  expansion  of  malarial-specific  THI  clones, 
but  not  TH2,  were  inhibited  by  NO,  and  suggested  that  the  molecule  may  down 
regulate  TH1  cells  and  precede  the  development  of  a  TH2  specific  response.  This  has 
been  confirmed  by  the  experiments  presented  in  this  chapter,  in  which  in  iNOS 
depleted  mice  infected  with  P.  chabaudi,  the  absence  of  NO  resulted  in  higher  peak 
parasitaemia  and  was  associated  with  high  in  vitro  production  of  IFNy  but  did  not 
affect  IL-4  production. 
The  results  presented  in  this  chapter  confirm  that  mice  deficient  in  NOS  provide  an 
important  tool  which  could  help  to  understand  the  involvement  of  NO  in  immunity 
against  P.  chabaudi  malaria.  However,  the  mechanisms  mediated  by  NO  which 
contribute  to  parasite  killing  remain  unclear.  Further  work  with  this  model  of  P. 
chabaudi  AS  infection  should  include  study  of  in  vitro  proliferative  responses  against 
P.  chabaudi  antigen,  as  well  as  in  vitro  cytokine  production  at  different  stages  of 
infection,  since  specific  responses  against  malarial  antigens  may  differ  from  those 
observed  in  response  to  ConA.  Expression  of  TH1  and  TH2  cytokines  and  NO 
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should  be  assessed  in  samples  from  liver  and  spleen  and  compared  with  levels  of  the 
molecules  in  the  circulation.  Finally,  changes  in  sequestration  in  this  model  of 
infection  should  be  further  explored  and  histological  samples,  in  addition  to  blood 
smears,  should  illustrate  them  better. 
159 CHAPTER  EIGHT 
GENERAL  DISCUSSION GENERAL  DISCUSSION 
8.  General  Discussion 
Resistance  to  blood  stages  of  P.  chabaudi  chabaudi  AS  is  largely  CD4+  T 
lymphocyte  dependent.  Both  TH1  and  TH2  cell  subsets  produce  soluble  mediators 
that  have  been  associated  with  protection.  The  aim  of  the  work  reported  in  this  thesis 
was  to  contribute  to  the  understanding  of  the  role  of  these  T  cells  in  the  acquisition 
of  immunity  against  the  murine  infection  with  asexual  blood  stages  of  P.  c.  chabaudi 
AS.  To  this  end  the  murine  cytokines  IFNy,  TNFa,  TGF(3  and  IL-4  were  delivered 
in  vivo  using  a  S.  typhimurium  expression  system  and  their  effects  on  the  malaria 
infection  were  studied.  The  contribution  of  NO  in  the  development  of  protective 
immunity  against  malaria  was  further  assessed  by  studying  the  course  of  the  infection 
in  iNOS  deficient  mice. 
The  level  of  resistance  to  blood-stage  infection  with  P.  chabaudi  varies  among  inbred 
strains  of  mice  and  is  dependent  on  the  strain  of  the  parasite.  Host  protective 
mechanisms  appear  to  be  different  in  resistant  and  susceptible  hosts.  Resistant  NIH 
mice  infected  with  P.  chabaudi  AS  strain  experience  a  primary  patent  parasitaemia 
and  one  or  two  recrudescences  before  the  infection  is  eliminated.  TH1  cells  seem  to 
be  dominant  in  the  control  of  the  primary  parasitaemia,  while  mainly  TH2  appear  to 
mediate  the  control  of  recrudescences  and  challenge  infections  (  Von  Der  Weid  & 
Langhorne,  1993  a;  Taylor-Robinson  &  Phillips,  1994).  In  contrast,  susceptible  A/J 
had  an  enhanced  TH2  type  response  early  during  P.  chabaudi  malaria  infection, 
which  led  to  severe  malaria  disease  and  death  (Stevenson&  Gadhirian 
, 
1989;  Jacobs 
et  at,  1996a  &  b). 
The  immune  effector  mechanisms  which  may  contribute  to  the  better  control  of 
malaria  infection  in  resistant  mice  start  with  the  rising  parasitaemia  (Figure  29). 
Initially,  antigens  are  taken  up  by  monocytes/macrophages  and  are  processed  and 
presented  to  T  cells.  An  equally  important  role  of  macrophages  during  early  stages  of 
malaria  infection  is  to  produce  IL-12.  This  cytokine  has  pleiotropic  effects  on  both 
NK  and  T  cells  (Kobayashi  et  at,  1989).  IL-12  induces  IFNy  and  TNFa 
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production  by  these  cells,  enhances  their  cytotoxic  activity  and  stimulates  their 
proliferation  (when  in  the  presence  of  IL-2).  Additionally,  IL-12  promotes  the 
differentiation  of  CD4  T  cells  into  Till  cells  in  vitro,  through  induction  of  IFNy 
production  (Hsieh  et  al.,  1993,  Manetti  et  al.,  1993;  Seder  et  al.,  1993).  In  P. 
chabaudi  AS  infection,  a  protective  effect  on  giving  additional  IL-12  has  been 
demonstrated  in  susceptible  A/J  mice  (Stevenson  et  al.,  1995),  but  a  toxic  effect  was 
observed  in  givinglL-12  to  resistant  C57BL/6  mice.  The  deleterious  effect  of  IL-12 
on  mice  with  acute  malaria  was  associated  with  induction  of  high  levels  of  TNFa 
production,  which  resulted  in  toxic  shock  and  death  (Stevenson  et  al.,  1995). 
However,  the  protective  effect  observed  in  susceptible  mice  was  associated  with 
expression  of  high  levels  of  IFNy  in  the  spleen  of  IL-12  treated  mice  and  high  serum 
levels  of  TNFa,  IFNy  and  NO  (Stevenson  et  al.,  1995). 
IFNy,  a  mainly  TH1  cell  cytokine,  peaks  in  resistant  mice  2-3  days  before  the  peak  of 
infection  with  P.  chabaudi  AS  (Slade  &  Langhorne,  1989)  (Figure  30),  and  in  vitro 
production  of  the  cytokine  by  spleen  cells  stimulated  with  ConA,  has  been  observed 
1-2  days  before  peak  parasitaemia  (Stevenson  et  al.,  1990a,  Taylor-Robinson  & 
Phillips,  1994a).  Neutralisation  of  IFNy  in  vivo  results  in  exacerbation  of  infection 
and  injection  of  rIFNy  depress  parasitaemia  (Stevenson  et  al.,  1990a).  This  protective 
effect  of  IFNy  in  P.  chabaudi  infection  in  resistant  mice  is  confirmed  in  the  work 
presented  in  Chapter  3,  in  which  administration  of  IFNy  using  a  S.  typhimurium 
expression  system  resulted  in  a  better  control  of  the  primary  parasitaemia.  The 
protective  effect  of  IFNy  is  predominant  during  early  stages  of  the  infection 
(Stevenson  et  al.,  1990a),  as  has  been  confirmed  in  the  experiments  with  S. 
typhimurium  delivered  IFNy,  which  had  an  appreciable  effect  on  the  course  of 
parasitaemia.  Tsuji  et  at  (1995)  have  reported  a  slight  delay  (2-3  days)  in  the 
clearance  of  a  blood  infection  with  P.  chabaudi  adami  in  IFNy-  receptor  ß-chain 
deficient  mice  in  comparison  with  controls.  Furthermore,  the  results  reported  by  van 
der  Heyde  et  at,  (1997)  suggest  that  the  role  for  IFNy  on  the  control  of  a  malaria 
infection  might  extends  up  to  the  third  week  post-infection.  In  this,  infection  of 
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IFNy-deficient  mice  with  blood  forms  of  P.  chabaudi  adami,  resulted  in  a  higher 
peak  parasitaemia  and  prolonged  infection  when  compared  with  controls. 
TH1  cells  and  IFNy  activated  macrophages  produce  reactive  nitrogen  intermediates, 
of  which  NO  has  been  implicated  in  the  control  of  infectious  agents  (James  &  Hibbs, 
1990).  In  malaria,  NO  may  be  effective  in  controlling  blood  forms  of  P.  chabaudi 
AS  and  P.  chabaudi  CB  infection  in  NIH  mice.  A  very  sharp  increase  of  NO 
production  which  rises  from  1-2  days  before  the  peak  of  infection,  reaches  a 
maximum  simultaneously  with  peak  parasitaemia  and  decreases  rapidly  afterwards 
(Taylor-Robinson  et  al.,  1993;  Mathers,  1994).  Moreover,  inhibition  of  NO  synthase 
by  L-NMMA  has  resulted  in  higher  and  extended  primary  parasitaemias  compared 
with  controls  (Taylor-Robinson  et  al.,  1993).  The  way  NO  contributes  to  the  control 
of  blood  forms  of  malaria  is  not  completely  understood.  A  direct  cytotoxic  effect  of 
NO  has  been  observed  on  asexual  erythrocytic  stages  of  P.  falciparum  treated  with 
NO  derivatives  in  vitro  (Rockett  et  al.,  1991).  In  addition,  a  cytostatic  effect  on 
P.  falciparum  blood  forms  has  been  observed  in  vitro  when  cultures  were  treated 
with  SNAP  (an  NO  producer)  in  order  to  reach  physiological  concentrations  of  NO 
(Balmer  et  al.,  1995).  Mice  inoculated  with  the  S.  typhimurium/IFNy  construct 
controlled  a  P.  chabaudi  AS  infection  better  than  controls,  although  no  significant 
increase  in  NO  production  could  be  detected  in  their  serum  during  the  primary 
parasitaemia.  Therefore  it  can  be  speculated  that  IFNy  is  responsible  for  the  better 
control  of  the  infection  through  mediation  of  NO  independent  mechanisms  (see 
Figure  30).  Alternatively  NO  production  during  malaria  infection  may  depend  on 
some  threshold  levels  of  antigen  loading.  This  has  been  also  suggested  in  an  NIL!  -  P. 
chabaudi  CB  model  of  infection,  in  which  treatment  with  chloroquine  1-2  days 
before  peak  parasitaemia  resulted  in  lower  parasitaemias  and  basal  serum  NO  during 
the  infection  (unless  chloroquine  itself  inhibits  NO  production)  (Phillips  el  al.,  1994). 
Therefore  increased  NO  production  during  acute  malaria  infection  may  have  a 
protective  role,  but  might  not  be  necessary  if  the  parasitaemia  is  not  high  enough  to 
compromise  the  survival  of  the  host.  Such  a  protective  action  of  NO  has  been 
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demonstrated  in  murine  infection  with  P.  vinckei,  in  which  the  molecule  was 
protective  either  by  directly  inactivating  tissue-damaging  oxygen  radicals  or  by 
preventing  hypoxic  tissue  damage  by  inhibiting  leukocyte  adhesion  to  endothelium 
and/or  increasing  vasodilatation  (Kremsner  et  at,  1993). 
In  addition  to  confirming  that  NO  is  important  in  the  prevention  of  high 
parasitaemias,  one  experiment  with  iNOS  mice  supports  the  theory  that  the  control 
of  acute  malaria  infections  is  not  solely  dependent  on  the  actions  of  the  molecule.  In 
this  model  of  P.  chabaudi  AS  infection,  a  significantly  higher  primary  parasitaemia 
was  observed  in  iNOS  deficient  mice  than  in  controls,  but  no  differences  were 
observed  in  the  clearance  of  infection.  Supernatants  of  spleen  cells  from  iNOS 
depleted  mice  obtained  at  days  6,10  and  14  p.  i,  produced  high  amount  of  IFNy  (and 
no  IL-4)  when  stimulated  with  ConA.  However,  at  day  18  p.  i.,  IL-4  was  high  and 
IFNy  was  not  detected.  This  pattern  of  IFNy/IL-4  production  by  spleen  cells  was  also 
observed  in  controls  and  may  be  an  indication  of  a  switch  from  TH1  to  TH2 
phenotype.  This  normal  TH1-TH2  switch  in  iNOS  deficient  mice  suggests  that  in  this 
model  of  infection,  NO  has  no  apparent  regulatory  role  on  CD4  T  cell  populations. 
However,  one  should  be  careful  in  the  interpretation  of  these  results,  since  congenital 
deficiencies  of  one  immune  factor  could  be  compensated  by  overproduction  of 
other(s).  In  the  case  of  iNOS  depleted  mice,  the  observation  of  higher  levels  of  IFNy 
during  early  stages  of  infection  when  compared  with  controls,  could  be  explained  not 
only  as  a  consequence  of  absence  of  the  down-regulatory  effect  of  NO  on  IFNy 
production,  but  can  also  be  the  result  of  an  exaggerated  compensatory  immune 
response.  Future  work  into  the  role  of  NO  in  malaria  infection  using  NOS  mice, 
should  include  the  study  of  differences  in  sequestration  between  the  iNOS  depleted 
mice  and  controls  which  produced  NO  normally.  NO  due  to  its  vasodilatory  effect 
might  be  responsible  for  a  reduced  sequestering  of  mature  blood  forms  of  the 
parasite,  and  therefore  increased  clearance  of  the  parasite  as  it  circulates  through  the 
spleen.  In  addition  to  peripheral  thin  blood  smears,  histological  techniques  might 
prove  useful  in  assessing  sequestration.  Since  the  significance  of  the  differences 
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observed  in  the  course  of  parasitaemia  are  affected  by  the  number  of  mice  evaluated 
(see  chapter  7),  all  studies  should  be  performed  in  groups  of  more  than  six  mice. 
Evaluation  of  proliferative  responses  of  spleen  cells  stimulated  with  malarial  antigens, 
which  was  tried  unsuccessfully,  would  be  a  better  parameter  of  specific  immunity, 
therefore  a  P.  chabaudi  antigen  should  be  standardised  to  be  used  in  this  assays.  This 
would  also  aid  in  elucidating  if  any  difference  in  cytokine  production  exists  between 
the  malaria  infected  iNOS  depleted  mice  and  controls.  In  addition,  in  vitro  cytokine 
production  should  be  correlated  with  serum  levels  of  cytokines  during  the  infection. 
Evaluation  of  cytokine  expression  in  situ  in  the  liver  and  the  spleen  might  contribute 
to  the  understanding  of  the  phenomena  responsible  for  the  better  control  of  infection 
in  NO  producing  mice,  as  it  would  provide  a  better  picture  of  in  cytokine  production 
between  iNOS  depleted  mice  and  controls.  For  this,  samples  of  these  organs  taken  at 
different  time  points  of  the  malaria  infection  are  stored  in  N2  (-196_C)  have  been 
preserved  and  training  in  PCR  techniques  has  started.  Finally,  other  models  of  NO 
depleted  mice  have  been  reported  and  it  would  be  interesting  to  compare  the  course 
of  P.  chabaudi  infection  observed  in  them  with  the  one  reported  here. 
TNFa  is  an  important  cytokine  produced  by  macrophages  during  infection.  Its 
important  role  in  mediation  of  immunity  against  malaria  has  been  illustrated  in 
experiments  where  susceptible  A/J  mice  were  treated  with  rTNFa.  They  survived  P. 
chabaudi  AS  infection  and  had  a  significant  decrease  in  the  peak  parasitaemia  when 
compared  with  untreated  mice,  which  died  after  developing  high  parasitaemias 
(Stevenson  &  Ghadirian,  1989).  In  the  same  study,  treatment  of  C57BL/6  resistant 
mice  with  rTNFa  had  no  effect  on  the  course  of  the  parasitaemia.  A/J  mice  given  the 
S.  typhimurium/TNFa  construct  had  a  significantly  decreased  patent  parasitaemia, 
while  in  resistant  NIH  mice  this  treatment  had  no  effect  on  the  course  of  infection. 
The  first  conclusion  that  can  be  drawn  from  these  results  is  the  confirmation  that  the 
TNFoc  construct  is  expressed  and  active  in  vivo  (McSorley,  personal 
communication)  as  it  has  a  significant  effect  on  reducing  the  peak  of  parasitaemia  in 
A/J  mice.  Secondly,  the  differences  in  the  role  of  TNFct  among  the  different  strains  of 
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mice  observed  by  other  researchers,  can  be  reproduced  using  this  delivery  system. 
Jacobs  et  al.  (1995)  have  attributed  the  differences  in  the  response  to  TNFa  treatment 
between  the  different  strains  of  mice,  to  early  changes  in  the  pattern  of  the  cytokine 
production  during  acute  P.  chabaudi  AS  infection.  Mice  with  high  levels  of  TNFa 
mRNA  expression  in  the  liver  and  increased  levels  of  serum  TNFa  during  late  stages 
of  infection  showed  susceptibility  to  malaria.  On  the  other  hand,  resistance  to 
infection  has  been  observed  in  mice  with  high  TNFa  mRNA  expression  in  the  spleen 
during  early  stages  of  infection.  Administration  of  TNFa  using  a  S.  typhimurium 
delivery  system  might  result  in  an  early  increase  of  TNFa  production  in  the  spleen  of 
A/J  mice  compared  with  control  mice,  thereby  increasing  resistance  to  infection. 
Since  TNFa  might  already  been  produced  in  the  spleen  of  NIH  during  early  stages  of 
the  infection,  administration  of  the  construct  did  not  change  the  pattern  of  production 
of  the  cytokine  and  therefore  had  no  effect  in  the  course  of  infection.  Moreover,  it 
could  be  expected  that  excessive  production  of  TNFa  might  result  in  toxic  shock 
(and  possible  death).  This  was  the  case  in  the  experiments  using  rTNFa  at  very  high 
doses  and  reported  above.  However,  mice  inoculated  with  the  TNFa  construct 
showed  no  evidence  of  more  severe  illness  nor  did  they  die.  A  possible  explanation,  is 
that  the  increased  systemic  levels  of  TNFa  which  are  associated  with  severe  disease, 
were  not  achieved  after  inoculation  with  the  construct.  Previously,  Ianaro  et  al. 
(1995)  have  demonstrated  that  in  a  similar  cytokine  delivery  system  (S. 
typhimurium/TGFI3),  oral  administration  of  a  S.  typhimurium  construct  did  not 
result  in  an  increase  of  serum  basal  levels  of  the  cytokine. 
TNFa  production  has  been  inversely  correlated  with  TGF3  levels  in  human  malaria. 
P.  falciparum  infected  individuals  who  have  high  TNFa  serum  levels,  showed  a 
decreased  TGFß  production  which  can  be  restored  after  antimalarial  treatment 
(Wenisch  et  al.,  1995).  That  study  it  was  suggested  that  TGF(3  might  have  a 
protective  effect  against  malarial  disease  through  down  regulation  of  TNFa. 
However  TGFß  production  can  have  a  immunosupressive  effect  due  to  down 
regulation  of  macrophage  activation  and  inhibition  of  production  of  oxygen  free 
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radicals  (Tsunawaki  et  al.,  1988)  and  NO  (Ding  et  al.,  1990;  Nelson  et  al.,  1991). 
Knowledge  of  the  role  TGFß  in  the  acquisition  of  immunity  against  malaria  remained 
limited.  The  experiments  reported  in  Chapter  5  are  preliminary  and  indicate  that 
administration  of  TGFß  using  a  S.  typhimurium  as  a  delivery  vehicle  has  no  effect  in 
the  course  of  parasitaemia  in  both  susceptible  A/J  or  resistant  NIH  mice. 
Nevertheless,  the  importance  of  TGFß  in  down  regulation  of  TH1-like  immune 
responses  (lanaro  et  al.,  1995)  should  be  further  explored  and  the  S.  typhimurium 
might  be  an  useful  instrument.  Since  it  constitutes  an  affordable  and  easy  way  to 
deliver  TGFß  in  vivo  in  malaria  infected  mice. 
As  mentioned  above,  during  a  P.  chabaudi  AS  infection  in  NIH  mice,  a  sequential 
activation  of  TH1  and  TH2  cells  appear  to  be  involved  in  the  control  of  the  infection. 
As  the  primary  parasitaemia  goes  into  remission,  a  dominant  TH2  response  is 
initiated.  In  susceptible  A/J  mice  however,  high  levels  of  TH2  cytokines  (IL-4,  IL-5 
and  IL-10)  are  produced  by  spleen  cells  of  mice  during  the  first  week  of  infection 
(Stevenson  &  Tam,  1993).  These  latter  results  suggest  that  an  early  TH2  cell 
activation  might  lead  to  severe  disease  and  death.  In  the  experiments  where  resistant 
NIH  mice  were  given  the  S.  typhimurium/IL4  construct,  no  differences  were 
observed  in  the  course  of  infection  and  the  mice  did  not  become  more  susceptible  to 
the  parasite.  Thus,  IL-4  administered  in  this  way  might  not  have  any  effect  on  a 
strong  TH1  type  response.  However,  as  occurred  with  the  S.  typhimurium/TGF  3 
construct,  the  experiments  with  the  IL-4  construct  were  very  limited  and  preliminary 
and  further  experiments  evaluating  its  effect  on  the  immune  response  against  P. 
chabaudi  AS  should  be  performed.  An  important  parameter  which  must  be  evaluated 
in  the  future  when  working  with  this  IL-4  construct  is  its  effect  on  B  cells  and 
antibody  production  during  malaria  infection. 
During  the  experiments  carried  out  with  the  S.  typhimurium  mutants,  it  was  observed 
that  the  control  mutant  provided  some  degree  of  protection  against  the  malaria 
infection.  Although  inconsistent,  this  protection  was  in  most  cases  evident  as  a  lower 
peak  parasitaemia  in  comparison  with  P.  chabaudi  controls.  S.  typhimurium  BDR509 
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has  been  shown  to  induce  TH1  and  TH2-type  cytokines  in  the  gut  associated 
lymphoid  tissue  (GALT),  after  oral  administration  (Karem  et  al.,  1996).  Moreover, 
TH1-type  responses  are  seen  in  organs  such  as  spleen,  following  oral  immunisation 
with  S.  typhimurium  mutants  (Klimpel  et  al.,  1995).  These  results  suggest  that  the 
potential  for  a  TH1  or  TH2  polarised  immune  response  after  oral  administration  of 
the  bacteria  does  exist,  and  that  upon  stimulation  with  P.  chabaudi  antigens  an 
enhanced  THI  may  be  dominant  and  help  with  the  control  of  the  infection  during 
early  stages. 
The  results  presented  in  this  thesis  showed  that  S.  typhimurium  mutants  expressing 
cytokine  genes  are  useful  in  modulating  the  immune  response  against  blood  forms  of 
P.  chabaudi  AS  when  administered  orally.  However  the  mechanism(s)  involved  in 
this  modulation  need  to  be  explored  further.  S.  typhimurium/IFNy  had  an  important 
effect  in  the  control  of  the  parasite  during  the  primary  parasitaemia  in  NIH  mice,  but 
no  clear  mechanism  of  action  could  be  elucidated.  NO  does  not  seem  to  be  involved 
in  the  process.  However  iNOS  expression  in  liver  and  spleen  should  be  evaluated 
since  serum  NO  does  not  reflect  increased  in  situ  production  of  the  molecule.  For 
this,  tissue  samples  from  liver  and  spleen  of  NIH  mice  inoculated  with  S. 
typhimurium/IFNy  8  days  before  malaria  infection,  were  collected  from  different  time 
points  after  malaria  infection.  The  samples  will  also  be  valuable  for  obtaining 
information  of  the  type  of  cytokines  produced,  initially  to  confirm  the  in  vivo 
expression  of  IFNy  by  S.  typhimurium,  and  later  to  establish  a  dominant  pattern  of 
cytokine  expression  which  might  explain  the  differences  observed  between 
experimental  and  controls  groups.  Tissue  samples  from  spleen  and  liver  were  also 
fixed  for  evaluation  with  conventional  histopathological  techniques.  No 
histopathological  differences  were  observed  after  evaluation  of  hematoxylin-eosin 
stained  sections  of  liver  and  spleen  (data  not  shown).  Samples  were  also  cryo- 
preserved  and  a  technique  for  detection  of  a-naphthyl  acetate  esterase  has  been 
standardised  for  the  detection  of  macrophages.  Once  performed  it  would  allow 
evaluation  of  differences  in  macrophage  migration  in  the  different  groups. 
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The  important  observation  that  TNFa  delivered  by  a  S.  typhimurium  vector 
contributed  significantly  to  the  control  of  the  parasite  in  A/J  mice  during  acute 
infection,  also  requires  further  investigation.  When  using  this  construct  in  malaria 
infection,  assessment  of  the  pattern  of  cytokine  production  in  liver  and  spleen  is 
essential  in  understanding  the  immune  mechanisms  evoked  by  the  cytokine,  since 
others  have  demonstrated  that  increased  levels  of  TNFa  expression  in  spleen  are 
protective  against  severe  P.  chabaudi  infection  (Jacobs  et  al.,  1996b).  Furthermore, 
research  into  the  iNOS  expression  in  liver  of  resistant  and  susceptible  mice  would 
confirm  previous  observations  made  by  others,  which  indicate  that  NO  is  involved  in 
TNFa-dependent  protection  (Jacobs  et  al.,  1996a). 
The  work  carried  out  with  the  TGF(3  and.  IL-4  S.  typhimurium  constructs  was 
preliminary.  Further  exploration  on  their  effects  in  the  course  of  infection  in  resistant 
and  susceptible  models  of  P.  chabaudi  infection  should  be  performed  by  changing  the 
timing  between  the  S.  typhimurium  administration  and  the  malaria  infection.  This  in 
order  to  identify  first  the  optimal  time  for  the  cytokines  to  have  any  effect  on  the 
course  of  the  malaria  infection. 
Taken  together  the  experiments  presented  in  this  thesis  demonstrate  that  the  outcome 
of  a  P.  chabaudi  AS  blood-stage  infection  involves  a  complex  interaction  of  cells  and 
factors  (i.  e.  cytokines,  NO,  ROI)  of  the  immune  system.  In  addition,  the  S. 
typhimurium  mutants  provide  an  excellent  tool  for  the  delivery  of  cytokines  and  for 
the  study  of  their  effects  in  the  development  of  immunity  against  P.  chabaudi  AS  in 
resistant  and  susceptible  mice.  S.  typhimurium  has  shown  to  be  useful  for  the 
delivery,  in  vivo,  of  murine  cytokines  in  malaria  infected  mice.  This  would  prove 
valuable  in  the  research  of  malaria  vaccines  either  by  the  use  of  S.  typhimurium  to 
coexpress  cytokines  and  malarial  antigens  or  by  inoculating  S.  typhimurium 
expressing  cytokine  genes  into  immunised  individuals.  Finally,  the  iNOS  depleted 
model  of  P.  chabaudi  AS  infection  can  also  contribute  in  further  understanding  the 
role  of  the  molecule  in  the  control  the  infection. 
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GIEMSA'S  BUFFER 
3.0  g  NA2HP4 
0.6  g  KH2PO4 
Made  up  to  11  with  distilled  water  and  adjusted  to  pH  7.4. 
GREISS  REAGENT 
The  Greiss  reagent  is  obtained  by  mixing  in  equal  volumes,  the  two  following 
solutions: 
(a)  0.1%  alpha-naphtyl-amine  (Sigma)  in  distilled  water. 
(b)  1%  sulphanilamide  (Sigma)  in  phosphoric  acid. 
Store  both  solutions  in  the  dark.  Prepare  fresh  Greiss  reagent  every  time. 
NITRATE  CONVERSION  BUFFER 
Stock  reagents 
NADPH  (Sigma)  5  mg/ml  in  pBS  or  distilled  water,  stored  at  -20_C. 
FAD  (Sigma)  41.5  mg/ml  in  PBS  or  distilled  water,  stored  at  -20_C. 
Nitrate  reductase  (Sigma)  34  mg/ml  -  lyophilised  powder  diluted  in  distilled 
water.  Aliquots  of  50  tl  stored  at  -70_C. 
KH2PO4  (anhydrous)  0.5  M,  pH  7.5 
Buffer 
For  50  samples  and  standards  in  duplicate: 
500  µl  NADPH 
500  µl  FAD 
500  µl  KH2PO4 
500  µl  distilled  water 
50  µl  nitrate  reductase  freshly  diluted  in  450  µl  distilled  water. 
PHOSPHATE  BUFFERED  SALINE  (PBS) 
Stock  solution 
60.0  g  Na2HP04.12H20 
13.6  g  Na2HPO4.2H20 
8.5  g  NaCI 
Made  up  to  11  with  distilled  water. 
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Buffer 
40  ml  stock,  made  up  to  11  with  0.9  %  saline  and  adjusted  to  pH  7.2. 
RPMI 
Malaria  Stock  medium 
10.39  g  RPMI  powdered  medium  (with  L-glutamine)  (Gibco). 
5.94  g  (25mM)  N2-hydroxyethylpiperazine-N'-  ethane  sulphonic  acid 
(HEPES)  (Sigma). 
Made  up  to  960  ml  with  distilled  water  and  filter-sterilised  (Millipore/Gelman  filter 
size  0.22  p.  m). 
Malaria  incomplete 
Stock,  aliquoted  in  100  ml  volumes  to  which  the  following  supplements  are  added: 
4.2  ml  5%  w/v  NaHCO3 
0.25  ml  Gentamicin  (Sigma) 
Cell  culture  Stock  medium 
10.39  g  RPMI  powdered  medium  (with  L-glutamine)  (Gibco). 
5.94  g  (25mM)  N2-hydroxyethylpiperazine-N'-  ethane  sulphonic  acid 
(HEPES)  (Sigma). 
Made  up  to  960  ml  with  distilled  water  and  filter-sterilised  (Millipore/Gelman  filter 
size  0.22  µm),  pH  adjusted  to  7.2. 
Cell  culture  Incomplete 
Stock  supplemented  with  the  following: 
11  ml  L-glutamine  (Gibco) 
5.5  ml  NaHCO3  (3.5%) 
0.55  ml  2-Mercaptoethanol  (0.1  M) 
22  ml  Fungizone  (Gibco) 
2.2  ml  Gentamycin  (Sigma) 
Aliquots  of  85  ml  dispensed  into  100  ml  bottles. 
Both  complete  media  contained  10%  FCS  (Gibco) 
SORBITOL-GLYCEROL 
380  g  glycerol  (Sigma) 
39  g  sorbitol  (BDH) 
6.3  g  NaCI 
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TRIS-AMMONIUM  CHLORIDE 
0.17M  Tris(hydroxymethyl)aminomethane  (20.6  g/1) 
0.16M  ammonium  chloride  (8.3  g/1) 
10  ml  Tris  added  to  90  ml  ammonium  chloride  and  the  0.83%  stock  solution 
adjusted  to  pH  7.4. 
MOPS  GEL 
10  ml  1  OX  MOPS 
73  ml  RNAse  free  dH2O 
1.2  gm  agarose  (1.2%) 
Boil  for  about  5  min  or  until  agarose  is  completely  dissolved.  Cool  to  55°C.  In 
fumehood,  add  17  ml  formaldehide  (17%).  Mix  and  pour. 
lOX  MOPS 
0.2M.  Morpholinopropanesulphonic  acid 
0.05M  Sodium  acetate 
0.01M  EDTA  pH  7 
Make  up  to  400m1  with  RNAase  free  dH2O. 
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